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Immunoglobulins (Igs) represent an important part of the human immune system and 
can adapt to many different antigenic challenges. Structural variety of Igs is achieved by 
the expression of hypervariable regions which create the antigen binding site and define 
the antigen specificity and affinity. Moreover, various classes (i.e. IgM, IgD, IgG, IgA, 
IgE) and subclasses (e.g. IgG1-4) of immunoglobulins are present in humans, differing 
in temporal expression patterns as well as in function. IgG represents the most abundant 
antibody class in the human circulation, being present at a concentration of approximately 
10 mg/ml.1,2 Two major application fields for IgG glycosylation analysis have evolved, 
first IgGs in the human circulation as part of the humoral immune response, and second 
biotechnologically produced monoclonal antibodies for therapeutic purposes.
IgG consists of two heavy chains and two light chains. Parts of the heavy chains, 
together with the light chains, form two fragment antigen binding (Fab) moieties, whilst 
the remainders of the two heavy chains form the fragment crystallizable (Fc) moiety. 
Next to the enormous variety in the sequence of the antigen-binding region of plasma 
IgG, human IgGs vary in the N-glycosylation at the highly conserved N-glycosylation 
site asparagine 297 in the CH2 domain of each heavy polypeptide chain of the Fc part. 
As a general pattern, most IgG Fc N-glycans are biantennary complex-type structures, 
which often carry a core-fucose (Fuc) and vary in the number of antenna galactose (gal) 
residues (Figure 1A).3,4 Some of the glycans contain a bisecting N-acetylglucosamine 
(GlcNAc) and a small portion may carry a sialic acid (SA) residue attached to an antenna 
galactose. Notably, the largest variation has been reported regarding galactosylation: 
a varying portion of the IgG Fc N-glycoforms is truncated. The biantennary, core-
fucosylated IgG Fc N-glycoforms with no, one, or two galactoses are referred to as G0F, 
G1F, and G2F, respectively. The portion of IgG Fc N-glycoforms that carry no galactose is 
particularly large for rheumatoid arthritis (RA) patients, as has been described by Parekh 
et al. in 1985.3 This is demonstrated in Figure 1, which shows IgG Fc N-glycosylation 
profiles of a healthy control (B) and an RA patient (C). 
The second field of IgG glycosylation analysis has experienced a considerable 
growth in recent years. With the advent of therapeutic monoclonal IgGs, the 
engineering and analysis of IgG Fc N-glycosylation, Fab glycosylation as well as 
O-glycosylation, together with other posttranslational modifications, has become an 
important analytical challenge in the pharmaceutical industry. The number of licensed 
monoclonal antibodies (mAbs) is steadily increasing. There are over 30 approved 
therapeutic mAbs worldwide and hundreds in clinical trials or in development.5-7 
The glycosylation present on the mAbs must be consistent and human-like to prevent 
adverse effects.5 Therefore, monitoring of IgG glycosylation is essential in cell line and 
clone selection and during cell culture optimization, where a high number of samples 
are subjected to product quality analysis including glycosylation profiling, and where 
fast analysis is required.
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Figure 1. Fc glycosylation monitoring for human IgG at the level of tryptic glycopeptides. (A) 
The four human IgG subclasses show differences in the peptide sequence and a considerable 
variation (microheterogeneity) in the structure of the attached N-glycan. The glycosylation 
profiles of IgG1 and IgG2 tryptic glycopeptides were obtained from Protein A-purified human 
serum IgG of a control person (B) and a rheumatoid arthritis patient (C) and show pronounced 
differences in the relative intensities of G0F, G1F and G2F structures. Analyses were performed 
by MALDI-TOF-MS in the linear positive mode using 2,5-dihydroxybenzoic acid (DHB) as 
matrix substance.
IgG glycosylation in healthy human populations
Many descriptive data regarding the biological and clinical role of IgG Fc N-glycosylation 
have been accumulated over the past 30 years. For healthy donors the obtained IgG 
glycosylation data showed an association of certain IgG glycosylation features with age, 
sex, and pregnancy. A first publication on the age-dependency of IgG glycosylation was 
from Parekh et al. in 1988,8 who studied the degree of IgG N-glycan galactosylation for 
a group of 151 healthy individuals of both sexes varying in age from 1 to 70 years. The 
10
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1authors did not distinguish between Fc and Fab glycosylation and focused specifically on galactosylation. All heterogeneity in terms of attached sialic acids, N-acetylglucosamine 
and fucose was eliminated by performing corresponding exoglycosidase treatments prior 
to oligosaccharide analysis, leaving galactosylation as the only feature to be analyzed. This 
revealed that the mean incidence of N-glycans on IgG with both outer arms terminating 
in N-acetylglucosamine is higher than 30% on average at birth, reaching a minimum 
of approximately 20% for persons of 25 years of age and then increases continuously to 
reach approximately 40% by 70 years of age. The mean incidence of monogalactosylated 
N-glycans remains remarkably constant at approximately 40% over the whole age range, 
while the digalactosylated N-glycans shows a pattern which is complementary to the 
parabolic age-dependency curve of the non-galactosylated N-glycans. No sex-specific 
differences where found. Notably, much of the biological variation observed in this study 
could not be explained by sex and age heterogeneity.
Approximately 10 years later two IgG glycosylation studies in healthy individuals 
were published by Japanese research teams. Yamada et al. (1997) enzymatically 
released N-glycans from human serum IgG of 176 female and 227 male individuals 
ranging in age from 0 to 84 years.9 N-glycans were labeled with 2-aminopyridine, 
desialylated, and profiled by reverse phase high performance liquid chromatography 
(RP-HPLC) with fluorescence detection, allowing the registration of 12 different 
glycan structures. This study confirmed the age-dependency of galactosylation8 for 
both sexes. In addition, a difference in the degree of galactosylation was found between 
males and females at age of approximately 25 years. Women of this age showed on 
average lower levels of agalactosyl glycoforms than men. Moreover, the occurrence of 
bisecting N-acetylglucosamine showed an age-dependency. The incidence of bisecting 
N-acetylglucosamine in healthy individuals generally increased with age and seems to 
reach a plateau at the age of 50 years.
Corroborating the findings of Yamada et al.9 Shikita et al. (1998) released N-glycans 
by hydrazinolysis from human serum IgG of a small cohort consisting of 43 female and 
37 male individuals ranging in age from 18 to 73 years.10 N-glycans were labeled with 
p-aminobenzoic acid ethyl ester (ABEE) and analyzed for their degree of sialylation by 
anion exchange chromatography. Glycans were profiled by RP-HPLC with fluorescence 
detection after desialylation, allowing the registration of 12 glycan structures, 
demonstrating the age-dependency of galactosylation only for females. For the males 
a slight trend towards lower galactosylation at higher age was observed. However, this 
tendency was not found to be significant with the small number of males included 
in the study due to the considerable biological variability. The decreasing incidence 
of monosialylated N-glycans with age might be explained by the lower incidence of 
galactosylated antennae (acceptor structures) at higher life-time. The incidence of 
bisecting GlcNAc was found to increase with age for both sexes. 
Recently, the age and sex dependency of IgG galactosylation and bisecting GlcNAc 
were confirmed in two large scale clinical studies where glycosylation of affinity purified 
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IgG was studied either in 1821 individuals as released and 2-AA labeled N-glycans 
by HILIC coupled to fluorescence detection11 or in 1967 individuals as tryptic Fc 
N-glycopeptides by matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS).12
A first indication for a particularly high degree of IgG galactosylation during 
pregnancy was published by Pekelharing et al.13 In the following, Rook et al. showed 
for ten healthy women and 8 RA patients a low degree of IgG G0F during pregnancy.14 
This was recently confirmed in 148 pregnant RA patients and 32 healthy controls for 
two IgG subclasses (IgG1 and IgG2),15 and in a pregnant RA patient for three IgG 
subclasses (IgG1, IgG2 and IgG4).4 In addition, glycosylation of IgG from the fetal 
circulation was analyzed and compared to maternal IgG.16 Interestingly the incidence 
of IgG G0F was found to be approximately 25% higher in maternal serum as compared 
to fetal umbilical vein serum, which might indicate a glycosylation-sensitive transport 
of maternal IgG via the placenta to the fetal circulation with a selection for highly 
galactosylated glycoforms. Alternatively, this difference may be caused by the difference 
in the relative abundance of IgG subclasses in umbilical vein serum as compared to 
maternal serum.17 
In conclusion, glycosylation of IgG varies considerably between individuals of the 
same sex and age. The differences between sexes are minor compared to the influence 
of life-time. There is a clear age-dependency of IgG N-glycan galactosylation and 
decoration with bisecting GlcNAc. Galactosylation increases after birth up to age 25 
years and decreases again with higher life-time. This decrease in galactosylation seems 
to be accompanied by a decrease in sialylation. Moreover, pregnancy is associated with 
a temporal increase in IgG galactosylation. 
IgG glycosylation in diseases
In 1985, researchers from Oxford and Tokyo showed an increase in IgG G0F for patients 
with RA and osteoarthritis3 and many more reports have followed describing similar 
IgG glycosylation features for other autoimmune diseases, infectious diseases, and 
cancer. An overview of key publications on diseases with an elevated incidence of G0F 
on IgG is given in Table 1. Low galactosylation of IgG is clearly a common feature in 
various diseases. In RA, IgG G0F has been shown to correlate with clinical parameters 
like joint destruction and disease activity and may serve as an indicator for the disease 
course.18 Interestingly, remission of arthritis is often observed during pregnancy, which 
is associated with a decrease of IgG G0F.14 A pathogenic role of IgG G0F autoantibodies 
has been demonstrated by Rademacher et al. for murine collagen-induced arthritis,19 
where treatment of an autoantibody-containing IgG preparation with b-galactosidase 
to increase the level of IgG G0F glycoforms resulted in a more efficient induction of 
arthritis than the untreated IgG preparation. In the following, a role has been suggested 




20 However, to establish the mechanisms of pathogenicity of IgG G0F in RA and 
related diseases more research will be required.
The hitherto studied autoimmune diseases showing lowered IgG galactosylation 
are characterized by both cell-mediated and humoral autoimmunity. The study of 
IgG glycosylation in antibody-mediated autoimmune diseases such as Lambert-Eaton 
myasthenic syndrome (LEMS) and myasthenia gravis (MG) for which the role of 
Table 1. Diseases for which elevated IgG G0F and/or lowered IgG galactosylation have been 
reported
Disease Study cohort Analytical method Reference
rheumatoid arthritis (RA) 19 patients glycan release and chromatography 3
RA 127 patients lectin binding assay 18
RA 29 patients lectin binding assay 21
RA 232 patients glycan release and chromatography 22
RA 29 patients lectin binding assay 23
RA  85 patients glycopeptides and mass spectrometry 24
RA 148 patients glycopeptides and mass spectrometry 15
juvenile chronic arthritis 34 patients lectin binding assay 25
adult onset RA 53 patients glycan release and chromatography 26
juvenile onset RA 27 patients glycan release and chromatography 26
juvenile onset RA 9 patients lectin binding assay 21
Osteoarthritis 13 patients glycan release and chromatography 3
Osteoarthritis 13 patients lectin binding assay 21
Crohn’s disease 9 patients glycan release and chromatography 27
Crohn’s disease 17 patients lectin binding assay 21
systemic lupus erythematosus 
with Sjörgen’s syndrome 10 patients glycan release and chromatography 27
systemic lupus erythematosus 12 patients lectin binding assay 21,28
ankylosing spondylitis 12 patients lectin binding assay 21
ulcerative colitis 32 patients immunoassay with anti-GlcNAc mAb 29
ulcerative colitis 16 patients lectin binding assay 21
infective endocarditis 12 patients lectin binding assay 21
Tuberculosis 21 patients glycan release and chromatography 27
liver fibrosis and cirrhosis in 
hepatitis C infection ~200 patients
lectin binding assay (AAL; alauria aurantia 
lectin)1 30
HIV-infection 28 patients lectin binding assay; glycan release and mass spectrometry 31
ovarian cancer 3 patients glycan release and chromatography 32
Myositis 14 patients glycopeptides and mass spectrometry 33
1 specific analysis of anti-alpha-Gal antibodies.
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pathogenic antibodies against well known target antigens has been described in detail 
could provide valuable insights into the influence of IgG Fc N-glycosylation features 
on antibody pathogenicity.
A few reports have shown changes in IgG galactosylation during a humoral immune 
response. For example, Lastra et al. have shown in mice that during a humoral immune 
response IgGs with a low degree of galactosylation are produced, whereas, antibodies 
became more highly galactosylated when IgG titers were falling.34 Moreover, Kaneko et 
al. found a specific decrease of IgG sialylation during humoral immune response in a 
mouse nephropathy model.35 Future studies will hopefully shed light on the regulation 
and dynamics of IgG glycosylation in human humoral immune response.
Antibody-dependent cellular cytotoxicity
IgG Fc N-glycosylation is crucial for high-affinity interaction with Fcγ-receptors, 
which can be demonstrated by enzymatically removing parts of the glycan structures. 
After cleavage of the chitobiose core of the N-glycan by endoglycosidase Endo S from 
Streptococcus pyogenes (leaving a single N-acetylglucosamine on the Fc portion),36,37 
IgG binding to the Fcγ-receptor changes and the binding to activated monocytes 
decreases. Endo S was found to have a protective effect in a mouse model of idiopathic 
thrombocytopenic purpura and is a potential therapeutic agent against antibody-
mediated autoimmune diseases.38 Notably, Fc N-glycans influence the binding to 
Fcγ-receptors by determining the conformational structure of the Fc moiety. Fully 
galactosylated N-glycans are positioned between the Fc polypeptide chains, resulting 
in an open Fc conformation. Removal of N-glycans resulted in a closed conformation, 
which is unfavorable for most IgG Fcγ-receptor interactions.39
Next to the removal of most of the Fc N-glycans by Endo S treatment, more 
subtle changes in the IgG Fc glycosylation pattern, as achieved by choosing different 
expression systems40 and by modifying the glycosylation using exoglycosidases,41,42 
have likewise been shown to have a profound influence on the interaction of the IgG Fc 
portion with Fcγ-receptors. Many reports have shown that the presence or absence of 
core-fucose is the most important feature with respect to antibody-dependent cellular 
cytotoxicity (ADCC) of IgG1, while the degree of sialylation, antenna galactosylation, 
and the presence of bisecting N-acetylglucosamine do not seem to have a strong 
influence.41-44 The lack of core-fucoses on IgG1 Fc N-glycans has been shown to result 
in an enhanced binding to Fcγ-receptor IIIa expressed on macrophages leading to a 
drastic enhancement of ADCC.43,44 Enhanced ADCC activity of afucosylated IgG1 may 
have profound effects on the severity of antibody-mediated autoimmune diseases.43-45 
In in-vitro ADCC assays antibodies lacking core-fucosylation have shown enhanced 
efficacy.44,46 Glycosylation of therapeutic antibodies is, therefore, often engineered to 




Glycosylation of IgG has recently received much attention due to the findings of Ravetch 
and coworkers,35,47 who analyzed the protective effect of intravenous immunoglobulin 
(IVIg) in a mouse arthritis model and could demonstrate that only the Fc parts exhibit 
the immunosuppressive function. Moreover, using both neuraminidase treatment and 
enrichment of sialylated species by lectin affinity chromatography, they showed that 
sialylated IgGs as well as sialylated IgG Fc moieties are much more potent in preventing 
pathology.35 In a mouse model, the 2,6-sialylated N-glycan antennae on the Fc moieties 
were identified to be the motifs recognized by the C-type lectin SIGN R1 (an orthologue 
of the human Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin; DC-SIGN) expressed on murine macrophages in the splenic marginal 
zone, thereby inducing the expression of inhibitory IgG Fcγ-receptors on effector 
macrophages.47,48 In a humanized DC-SIGN mouse model the same group revealed 
that administration of 2,6-sialylated Fc moieties suppressed inflammation through 
a novel TH2 pathway via production of the cytokine IL-33.
49 Recently, Stadlmann et 
al.50 refined the study on anti-inflammatory properties of Sambucus nigra agglutinin 
(SNA) lectin enriched IVIg and argued that the anti-inflammatory properties of IVIg 
accounts from double sialylation of IgG.50,51 Contradictory results were obtained for the 
SNA fraction of IVIg by Guhr et al.52 who observed only enrichment of Fab sialylated 
IgG. Moreover, the SNA fraction was shown to have no effect on the platelet count in a 
murine model of passive immune thrombocytopenia, suggesting that SNA lectin is not 
a suitable method to enrich Fc sialylated IgG. 
Refinement of the receptor binding properties of IgG Fc moieties and derived 
recombinant drug candidates is expected to provide a way of efficient treatment of 
autoimmune disorders.47,53 Hitherto IVIg has been used on the basis of its anti-
inflammatory properties at high doses (above 1-2 g/kg) for the treatment of various 
autoimmune diseases such as RA, idiopathic thrombocytopenic purpura, systemic 
lupus erythematosus, and Guillain-Barré syndrome.54,55 
Regulation of IgG glycosylation
B-lymphocytes may produce distinct IgG Fc glycosylation profiles. For example, Fc 
N-glycans of antigen affinity purified IgG1 thought to be involved in the pathogenesis 
of rheumatoid arthritis have been shown to harbor different glycoforms compared with 
total sera IgG1.24,45,56 Furthermore, the glycosylation of IgG1 produced by B lymphocytes 
in-vitro has been shown to be influenced by environmental factors and factors known 
to stimulate the innate or adaptive immune system.57 In-vitro stimulation of B-cells 
with all-trans retinoic acid (environmental factor) resulted in the expression of IgG1 
with decreased galactosylation within a time-range of several days, while increased 
galactosylation and reduced bisecting GlcNAc have been observed after stimulation 
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with CpG oligodeoxynucleotide (stimulates the innate immune system) or interleukin 
21 (stimulates the adaptive immune system).57
IgG stability and half-life
The absence of Fc N-glycosylation on IgG does not affect antigen binding affinity,58,59 
but it has been demonstrated with monoclonal antibodies that the structure of the 
CH2 domain is altered resulting in decreased stability.
41,42,60-62 In a pharmacokinetics 
study in humans and cynomolgus monkeys, the N-glycan composition in the Fc 
domain of human recombinant p55 tumor necrosis factor receptor-immunoglobulin 
G1 fusion protein (Lenercept) was shown to be drastically changed during the first 
24 h after injection after which the glycosylation remained constant over 10 days.63 
In the rapid initial phase it was observed that therapeutic protein complexes carrying 
Fc N-glycans with terminal GlcNAc were rapidly cleared suggesting clearance by the 
mannose receptor. Similar reports have, however, not yet been presented for IgG. In the 
human circulation increased clearance has been shown for therapeutic IgGs containing 
high-mannose glycans.64 Although the quantitative effect on pharmacokinetic area 
under the curve was shown to be relatively minor it strongly emphasizes that the high 
mannose content may affect pharmacokinetic properties of therapeutic antibodies 
and should be considered an important product quality attribute. Likewise, Chen et 
al. observed a decrease of Fc N-mannosylation for IgG2 in a human pharmacokinetic 
study. Intriguingly, they found similar changes after in-vitro incubation of the antibody 
in serum, suggesting high mannose glycan cleavage instead of clearance.65 More studies 
are required to allow the elucidation of the effect of Fc N-glycan composition on the 
IgG clearance.
IgG purification
Parekh et al. (1985) were the first to analyze IgG glycosylation in great detail.3 To purify 
the IgGs, ammonium sulphate precipitation and anion-exchange chromatography 
was used, based on a protein fractionation protocol which is considerably older.66 
Adaptations of this method are still in use, primarily for the purification and subsequent 
glycan release of IgG from human serum or plasma.10,67-69 The most popular technique 
is, however, affinity-purification using immobilized Protein A (e.g.70-73) and Protein G 
(e.g.9,74-76). These bacterial proteins bind to IgGs of various species and are commercially 
available in immobilized form (e.g. Sepharose beads and magnetic beads). IgGs may 
be loaded at neutral pH and elution is achieved at low pH. Generally, Protein A and 
Protein G columns are reusable for many purification cycles. The use of Protein A 
and Protein G is particularly popular for the purification and subsequent glycosylation 
analysis of recombinant mAbs. For the purification of IgG from human serum, both 
Protein A and Protein G may be applied, with the important difference that Protein 
16
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1G will bind all 4 human IgG subclasses, while Protein A will only retain IgG1, IgG2, and IgG4, but not IgG3.4,77 Additional sample preparation steps like buffer exchange or 
desalting may be necessary to get the IgG samples purified for downstream analytical 
methods.78
An alternative approach for IgG purification from plasma or serum is the use of 
SDS-PAGE, followed by the in-gel N-glycan release or generation of glycopeptides.79 
Moreover, the simultaneous glycosylation analysis of major human serum 
glycoproteins after albumin depletion has been demonstrated by RP-HPLC-MS/MS at 
the glycopeptide level, covering the glycosylation profiles of 23 N-glycosylation sites of 
serum glycoproteins including the Fc part of the different IgG subclasses.80
Released N-glycans
Starting from purified IgG, glycans are released using either enzymatic (e.g. 
N-glycosidase F; PNGase-F)72,75,81,82 or chemical (e.g. hydrazinolysis)10,69,83,84 cleavage. 
PNGase-F releases all asparagine-linked oligosaccharides with high yields, unless they 
are α1-3 core-fucosylated (core-modification not observed in mammals, but common 
in plants). Hydrazinolysis allows the release of O-glycans in addition to N-glycans. 
However, hydrazinolysis is a rather harsh method leading to the loss of N-acetyl groups 
that are present on N-acetylglucosamine residues of the N-glycans thus requires re-
N-acetylation. Moreover, working with anhydrous hydrazine requires special safety 
precautions, and any contact with water has to be avoided.85 
Three major strategies are used for analyzing oligosaccharides from glycoproteins 
such as antibodies. A first approach includes labeling of the reducing end of released 
glycans (e.g. 2-aminobenzoic acid, 2-aminobenzamide)86-88  followed by liquid 
chromatography (e.g. reverse phase,89,90 hydrophilic interaction)11,32,75,91,92 or capillary 
electrophoresis.93-95 These separation techniques may be combined with fluorescence 
detection or mass spectrometry. Second, native reducing-end N-glycans may be 
analyzed by MALDI-TOF-MS,78,96 high-pH anion exchange chromatography with 
electrochemical detection,97 or by microfluidic chip LC-MS.98 Third, permethylation 
of all hydroxyl groups (stabilizes the sialic acids) may be performed, followed by 
mass spectrometric analysis using either MALDI or (microchip)LC-ESI-MS.77,99 With 
these methods, the composition of the glycans can be established. Even though mass 
spectrometric methods for the analysis of released native or labeled glycans comprise 
generally highly sensitive procedures, no information can be obtained regarding 
linkages, epimericity, and anomericity. In order to obtain this information, several 
studies have applied multiple exoglycosidases.78,83,93,96 Furthermore, unambiguous 
assignment of glycans to the Fc and Fab moieties can be achieved when antibody 
fragments are separation prior to N-glycan release.5,72,100,101
17
Glycopeptides
Various specific and nonspecific proteolytic enzymes are available for the digestion 
of glycoproteins, including trypsin,102,103 lysylendopeptidase (Lys-C),102 endoproteinase 
Glu-C (V8 protease)104 and pronase.103-105 In general, completeness of proteolytic 
cleavage is improved by the addition of denaturing agents, such as guanidine 
hydrochloride, urea and acetonitrile. In addition, reduction of cysteine disulfide 
bonds by reducing agents such as dithiothreitol (DTT) and β-mercaptoethanol further 
improves accessibility of proteolytic cleavage sites. Since not all proteolytic enzymes 
retain their full activity under reducing conditions, and in order to avoid reformation 
of disulfide bonds during (glyco-)peptide storage and analysis, sulfhydryl groups 
are often blocked with alkylating agents, such as iodoacetamide, iodoacetic acid 
and ethyleneimine. To ensure full activity of the proteolytic enzyme, the reduction/
alkylation buffer is usually diluted or replaced by a digestion buffer using dialysis and 
gel filtration which may be followed by lyophilization of the desalted sample.80,106,107 In 
order to simplify IgG analysis, heavy and light chains resulting from the reduction and 
alkylation can be separated by RP-HPLC or SDS-PAGE prior enzymatic digestion. This 
approach is often applied in studies characterizing recombinant monoclonal antibody 
glycosylation.96,108,109 It should be taken into account that peptides with a N-terminal 
glutamine residue or a carboxyamidomethylated cysteine (product after alkylation 
with iodoacetamide) often reveal additional (glyco)peptides with ammonium loss (-17 
Da) due to pyroglutamic acid or 5-oxothiomorpholine-3-carboxylic acid (cyclization 
of the carboxyamidomethylated cysteine) formation, respectively.110
An improvement of the sample-processing using proteolytic cleavage reactions is 
often achieved by the use of enzymes which are immobilized on beads, monoliths, or on 
capillary walls, offering the advantage of enzyme re-usability, automation and complete 
digestion in very short times with a resulting peptide mixture lacking contamination 
with protease and its auto-proteolysis fragments.111-115
Trypsin (serine protease) is by far the most widely applied proteolytic enzyme 
in proteomics and glycoproteomics, cleaving peptides at the carboxyl side of lysine 
and arginine, unless the following amino acid is a proline. IgG Fc glycopeptides 
resulting from tryptic digestion are often easy to ionize by ESI and MALDI. Trypsin 
digestion is typically performed overnight at 37ºC in a 10 to 100 mM reaction buffer 
(Tris-HCl or ammonium bicarbonate, pH~8) using a 1:100 to 1:20 protease:protein 
ratio.4,80,92,96,102,113,116-118 To improve trypsin digestion enzyme mixtures102 or denaturing 
agents such as guanidine-HCL or urea with concentrations up to 2 M are sometimes 
applied.96,113,119 Interestingly, addition of acetonitrile with concentrations up to 80% was 
shown to improve enzymatic activity and digestion efficiency for a protein standard 
mixture,120,121 though this has not been shown for IgG. 
Samples prepared by trypsin digestion have successfully been used for the 




4,79,80,117,123 Due to the occurrence of tryptic Fc glycopeptides with identical peptide 
moieties for the IgG2 and IgG3 subclasses, the analysis of a proteolytic digest of total 
serum IgG will not allow the specific assignment of glycopeptides to these subclasses.4 
Therefore, serum IgG was fractionated into a pool of IgG1, IgG2, and IgG4 by Protein 
A capturing, followed by the capturing of IgG3 from the flow-through using Protein 
G beads. Analysis of the trypsinized eluates by RP-HPLC allowed the unambiguous 
assignment of the observed tryptic glycopeptides to specific IgG subclasses.4,45,56
Mass spectrometry of glycopeptides
Mass spectrometric detection of glycopeptides offers the possibility to determine 
glycosylation profiles in a site-specific manner. Traditionally, glycopeptides were 
ionized by fast atom bombardment and laser desorption. Within the past two decades, 
the softer ionization techniques electrospray ionization (ESI) and MALDI came in 
place, providing a higher sensitivity and making intact ions of high-molecular mass 
compounds accessible.
MALDI of tryptic IgG glycopeptides typically results in singly charged [M+H]+ 
ions,92,96,102,116,117,119,124 while ESI often results in doubly charged [M+2H]2+ ions4,80,107,125 
and/or triply charged [M+3H]3+ ions.4,71,79 However, quadruply charged [M+4H]4+ 
ions due to one missed cleavage (see Figure 2C in79) and doubly charged sodiated 
[M+H+Na]2+ ions116 of tryptic IgG glycopeptides have also been reported with ESI. 
The ESI conditions markedly influence the charge state distribution, with harsher ion 
transfer conditions leading to lower charge states. 
Ionization of glycopeptides can be suppressed by highly abundant coexisting peptide 
ions. In addition, salts present in the original sample or introduced during reduction, 
alkylation and enzymatic cleavage can suppress glycopeptide ionization, especially with 
ESI. Finally, overlapping isotope clusters from coexisting peptides or missed cleavages 
can complicate glycopeptide mass determination and identification. Therefore, proper 
sample pretreatment (enrichment, efficient enzymatic cleavage, desalting) prior to 
ionization is important. Sample purification and pre-separation of (glyco)peptides can 
be achieved using hyphenated techniques such as LC-ESI-MS. Alternatively, samples 
can be fractionated and desalted by preparative LC or SPE, followed by MALDI-MS.
RP-HPLC-ESI-MS
One of the most widely applied analytical techniques for glycopeptide analysis involves 
direct analysis of proteolytic digests by RP-HPLC coupled to ESI-MS. RP-HPLC 
separation of proteolytic IgG digests is mostly performed on C18 analytical columns of 
various dimensions. As an alternative to RP-HPLC, graphitized carbon chromatography 
can be applied.126 In general, a water/acetonitrile gradient with increasing acetonitrile 
concentrations, typically containing approximately 0.1% acidic mobile phase additive 
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such as trifluoroacetic acid (TFA) or formic acid (FA) is used in RP-HPLC-MS.4,80,106,107,127 
TFA is a commonly used mobile phase additive due to its positive effect on analyte 
retention and peak concentration.128 However, TFA can form gas-phase ion-pairs 
with positively charged analyte ions potentially increasing ESI suppression.128,129 For 
IgG glycosylation analysis, FA is therefore applied more often as acidic mobile phase 
additive. In addition, to ensure method stability in terms of separation, ionization and 
detection, most studies have applied micro-LC107,127,130 or capillary-LC79,80,106,109 coupled 
to ESI-MS, while nanoLC is less frequently used.4,45,56,71,125,131
ESI-MS/MS spectra of LC separated glycopeptides can be high-lighted on the basis 
of glycan specific oxonium ions of m/z 204 [HexNAc+H]+, 366 [Hex1HexNAc1+H]
+, 
528 [Hex2HexNAc1+H]
+, and 657 [Hex1HexNAc1NANA1+H]
+ (Hex, hexose; HexNAc, 
N-acetylhexosamine; NANA, N-acetylneuraminic acid) obtained on collision induced 
dissociation (CID) or by scanning for specific neutral losses of terminal monosaccharides 
such as fucose, N-acetylglucosamine , and sialic acid.80,116,132 Moreover, multiply charged 
IgG glycopeptide ions as generated by ESI allow the performance of CID and electron 
transfer dissociation (ETD) experiments, with the latter resulting in peptide sequence 
information.4 Glycopeptides with a common peptide moiety generally elute close to 
each other. Interestingly, some RP-HPLC columns show an enhanced retention of 
sialylated glycopeptides when compared to glycopeptides with neutral glycan chains,4 
while other RP-HPLC columns do not exhibit this pronounced difference in retention 
times.79 To ensure the measurement of intact glycopeptides, in source decay, which 
often results in the loss of sialic acid or the cleavage of the GlcNAcb1-2Man linkage, 
has to be ruled out by choosing the ion transfer voltages carefully.79 This allows the 
acquisition of Fc glycosylation profiles by RP-HPLC-ESI-MS,79,80,133,134
Mass spectrometry of glycopeptides allows the determination of glycan structure 
and attachment site in a single experiment. For example, analysis of lysyl endopeptidase-
digested mouse antidansyl mAb IgG2b (RCM-IgG2b) by an automated LC-MS(/MS) 
mode, allowed assignment of twelve different types of O-linked oligosaccharides to 
the heavy chain threonine 221 in the hinge region.106 Moreover, three major types of 
N-linked oligosaccharides could be assigned to the heavy chain asparagine 297 from 
endoproteinase Glu-C digested RCM-IgG2b (see Figure 5C in106).
Accurate MS measurement of glycopeptide amounts in complex samples is 
complicated by ionization variability. UV-detection, by contrast, often allows proper 
quantification in peptide mapping by RP-HPLC.108 Due to the unspecific nature of UV 
detection, quantification is only possible when compounds are at least partially resolved 
into individual LC peaks. Monitoring LC separations with in-line UV followed by 
ESI-MS characterization and identification combines the quantitative strength of UV 
with the profiling strength of MS. Additionally, an extra quality control step is offered 
to determine digestion completeness, separation quality and sample identity.
As for IgG glycosylation, quantification of non-glycosylated, deglycosylated and 




135 Non-glycosylated and deglycosylated peptides were separated into 
individual LC peaks. The total N-glycosylated species were determined by the analysis 
of the tryptic digests before and after PNGase-A treatment. Additionally, IgG1 purified 
from human polyclonal IgG was analyzed, showing the presence of a peptide co-eluting 
with the deglycosylated peptides. This contamination prevented proper quantification 
on the basis of UV only, pointing out the necessity of combination with the more 
tedious and time-consuming MS detection. 
HILIC-ESI-MS
HILIC coupled to ESI-MS is another powerful technique for the separation and analysis 
of glycopeptides. While retention in RP-HPLC is primarily mediated by hydrophobic 
interactions of the peptide moiety, retention in HILIC is mainly achieved via hydrophilic 
interactions between the stationary phase and the glycan moieties of the glycopeptides, 
which results in the (partial) separation of glycopeptides from peptides.92,136-140 
Retention will generally increase with the size of the glycan moiety. Therefore, 
separation of glycopeptides can be achieved according to the degree of sialylation.140-142 
ZIC-HILIC separation of tryptic IgG1 and IgG2 glycopeptides containing the same 
glycan moiety showed that the presence of more hydrophilic amino acids in the peptide 
chain affects glycopeptide retention.92 Tryptic IgG1 Fc glycopeptides which contain 
two tyrosine residues showed more retention than tryptic IgG2 Fc glycopeptides which 
instead contain two phenylalanine residues, thus structurally only differing by two 
aromatic hydroxyl groups. Moreover, with ZIC-HILIC it was possible to separate IgG 
glycopeptides with identical peptide moieties containing isomeric glycan structures. 
For example, G1F glycopeptides of both IgG1 and IgG2 containing an upper antenna 
galactose were efficiently separated from those containing a lower antenna galactose.92 
Similar separation of upper and lower antenna galactosylation was recently shown for 
a monoclonal IgG1 using an ACQUITY BEH HILIC column.136
Detailed glycan structural information can be obtained by sequential exoglycosidase 
treatments of antibody glycopeptides followed by LC-MS. For example, sequential 
exoglycosidase treatments of endoproteinase Lys-C digested humanized anti-Aβ IgG1 
monoclonal antibody showed that the major N-linked oligosaccharide structures 
in the Fv region were core-fucosylated biantennary oligosaccharides with no or 
one β-linked N-acetylgalactosamine, zero or one α-linked galactose and one or two 
N-glycolylneuraminic acid residues.134 In addition, typical core-fucosylated, biantennary 
N-glycans with one or two galactose residues were observed in the Fc region. 
MALDI-MS
IgG glycosylation is often studied by MALDI-MS. Generally, MALDI is less sensitive to 
ion suppression than ESI. Nevertheless, direct glycopeptide analysis from proteolytic 
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digests is often prohibited by the presence of non-volatile salts, detergents and 
non-glycosylated peptides. In addition, occurrence of overlapping isotope clusters 
from coexisting peptides or missed cleavages can further complicate glycopeptide 
identification and mass determination. Therefore, IgG glycopeptides are often enriched 
and desalted by RP-HPLC fractionation,96,117,119,124 HILIC affinity chromatography,102,119,143 
or lectin-based affinity chromatography.119 MALDI sources are most often coupled to 
time-of-flight (TOF) MS, but also to ion trap-MS, FTICR-MS, and Orbitrap MS. 
MALDI-TOF-MS analysis of tryptic IgG glycopeptides overlaid, mixed or sandwiched 
with 2,5-dihydroxybenzoic acid (DHB) and/or α-cyano-4-hydroxycinnamic acid 
(CHCA) can be performed in linear positive, linear negative, reflectron positive, and/
or reflectron negative mode. Due to the soft nature of MALDI ionization most IgG 
glycopeptide ions remain intact. Sialylated glycopeptides, however, when analyzed by 
positive-ion or negative-ion MALDI-TOF-MS with delayed extraction in the reflectron 
mode, often show massive desialylation due to in-source decay and metastable decay 
caused by laser-induced decomposition and/or collisional fragmentation during ion 
acceleration. By contrast, detection of sialylated glycopeptides can be achieved by 
MALDI-TOF-MS in the linear mode,102,119 since the lack of an extraction delay strongly 
reduces in-source decay of the sialylated glycopeptides. Moreover, any metastable 
decay products formed after ion acceleration are not separated from their precursor 
ions in linear mode.
Large transfer voltages as applied in TOF instruments require MALDI to be 
performed under high vacuum. By contrast, trapped-ion mass spectrometers allow 
the use of high pressure MALDI sources which demonstrated the ability to cool the 
internal vibrational energy of ions and allowed registration of intact labile molecules 
such as sialylated gangliosides.144
Additional structural information can be obtained by CID if MALDI is coupled 
to tandem mass spectrometers, such as QIT/TOF, QTOF, and TOF/TOF mass 
spectrometers. For example, CID of [M+H]+ glycopeptide ions by MALDI-QIT/
TOF allowed glycan identification and sequencing.102 In addition, fragment ions 
corresponding to the peptide with attached N-acetylglucosamine were formed, 
which could be isolated and subjected to CID providing peptide sequence and glycan 
attachment site information in MS3. Notably, MALDI-TOF/TOF-MS as well as MALDI-
QTOF-MS analyses of glycopeptides often directly provide detailed peptide sequence 
information. In contrast, product ion spectra obtained by automatic LC-MS, LC-MS/




In the pharmaceutical industry the detailed characterization of the glycans on 
biopharmaceuticals (e.g. therapeutic monoclonal antibodies) is of outmost importance 
to prevent detrimental side effects and ensure product quality. Detailed characterization 
of polyclonal IgG glycosylation changes as part of humoral immune responses could 
provide valuable information on the regulatory mechanisms involved. Two potential 
strategies to determine IgG Fc N-glycosylation are the analysis of released N-glycans or 
glycopeptides by mass spectrometry. While valuable information regarding N-glycan 
heterogeneity is provided with both strategies, only IgG glycopeptide analysis allows 
discrimination between different IgG subclasses and provides N-glycan profiles that 
are Fc specific. The scope of this thesis was to develop miniaturized (high-throughput) 
sample preparation and analysis strategies for the more detailed characterization of 
IgG Fc N-glycosylation by mass spectrometry. The methods should be applicable to 
characterize the glycosylation of therapeutic monoclonal antibodies as well as human 
polyclonal IgG and had to be applied for clinical cohorts to gain insights into the 
mechanisms regulating IgG Fc glycosylation. In clinical glycomics high-throughput 
analysis with low sample amounts is often mandatory, as large cohorts result in a high 
statistical power and biological material is precious.
In Chapter 2 the development of a fast and robust nanoLC-MS method for the analysis 
of human polyclonal IgG Fc N-glycopeptides is presented. A thorough method validation 
and evaluation of pregnancy related IgG Fc N-glycosylation changes are included. 
Chapter 3 describes the development of cotton HILIC SPE microtips for micro-
scale purification and enrichment of glycopeptides and released glycans. Furthermore, 
the potential of the microtips for analyzing neutral and sialylated glycoconjugates as 
well as the capacity of the cotton stationary phase is shown.
In Chapter 4 the development of a high-throughput IgG Fc N-glycopeptide 
profiling method by MALDI-FTICR-MS is described. Moreover, the potential of the 
developed method for clinical applications is shown with samples from presumably 
healthy individuals.
In Chapter 5 the rationally designed 4-chloro-α-cyanocinnamic acid (Cl-CCA) 
matrix is evaluated for MALDI-TOF-MS analysis of sialylated glycoconjugates. The 
performance of the matrix is shown for glycopeptides and released glycans from 
various proteins in positive and negative-ion mode.
Chapter 6 describes the application of the developed fast and robust nanoLC-MS 
method for the evaluation of IgG Fc N-glycosylation changes in Caucasian adults and 
African children upon vaccination. IgG glycosylation changes in total plasma IgG as 
well as antigen-specific purified IgG are evaluated. 
Chapter 7 describes the application of the developed high-throughput MALDI-FTICR-
MS IgG Fc N-glycopeptide profiling method for the evaluation of Fc N-glycosylation 
changes in Lambert-Eaton Myasthenic Syndrome and myasthenia gravis. 
Finally, a general discussion is given in Chapter 8.
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Abstract
Biological activities of immunoglobulin G such as effector functions via Fcγ-receptor 
interactions are influenced by Fc linked N-glycans. Here we describe a fast, robust 
and sensitive nanoLC-ESI-MS method for detailed subclass-specific analysis of IgG 
Fc N-glycosylation. High capacity extraction and fast separation of tryptic (glyco)
peptides from affinity chromatography purified human polyclonal plasma/serum 
IgG was achieved by combining a porous particle C18 trap column with a fused 
core particle C18 nanoLC column. A sheath-flow ESI sprayer was used as a sensitive 
zero dead volume plug-and-play interface for online MS coupling, generating a 
very constant spray and ionization over the entire LC gradient. The propionic acid 
containing sheath-liquid effectively suppressed TFA gas-phase ion-pairing, enabling 
the use of TFA containing mobile phases. The fixed position of the sheath-flow ESI 
sprayer, far away from the glass capillary inlet, reduced MS contamination as compared 
to conventional nano-ESI. The method was found to be suitable for fast and detailed 
subclass-specific IgG Fc N-glycosylation profiling in human plasma. The obtained 
subclass-specific IgG Fc N-glycosylation profiles were processed automatically using in 
house developed software tools. For each of the IgG subclasses the 8 major glycoforms 
showed an interday analytical variation below 5%. The method was used to profile the 
IgG Fc N-glycosylation of 26 women at several time points during pregnancy and after 
delivery, revealing pregnancy-associated changes in IgG galactosylation, sialylation 
and incidence of bisecting N-acetylglucosamine.
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Introduction
In human blood IgG represents the most abundant antibody class (approximately 10 
mg/ml serum).1,2 IgGs occur in four subclasses (i.e. IgG1-4)4 and consist of two heavy 
and two light polypeptide chains each having a variable and a constant region. The 
two light chains and parts of the two heavy chains form the fragment antigen binding 
(Fab) moieties, while the remainder of the two heavy chains forms the fragment 
crystallizable (Fc) moiety. A biantennary complex type N-glycan is present on each of 
the heavy polypeptide chains at asparagine 297 in the CH2 domain of the Fc moiety. 
This N-glycan is often core-fucosylated and varies in the number of antenna galactose 
residues resulting in the prominent glycoforms G0F (no galactose), G1F (1 galactose), 
and G2F (2 galactoses). A small part of the Fc N-glycans may carry a bisecting 
N-acetylglucosamine (GlcNAc). In addition, these glycans may contain a sialic acid 
residue attached to an antenna galactose.
Fc N-glycans influence the biological activity of IgG by modulating Fcγ-receptor 
binding.19,35,38,39,43,44,146 For example, cleavage of the chitobiose core with endoglycosidase 
from Streptococcus pyogenes (Endo S) results in a closed Fc conformation which strongly 
decreases binding to activated monocytes.38,39 Even small changes in the Fc N-glycan 
structure may have profound effects on the Fcγ-receptor binding. The absence of a 
core-fucose on IgG1 Fc N-glycans was found to promote binding to Fcγ-receptor 
IIIa expressed on macrophages and resulted in a drastic enhancement of antibody-
dependent cellular cytotoxicity (ADCC).43,44 Bioengineered antibodies lacking a core-
fucose may, therefore, represent a potent new generation of anti-cancer therapeutics.44,46 
In a mouse arthritis model it has been shown that the anti-inflammatory properties of 
intravenous immunoglobulin depend on α2,6-linked sialic acid on IgG Fc N-glycans 
which lead to Fc mediates signaling via the C-type lectin SIGN R1 (an orthologue 
of the human DC-SIGN) expressed on murine macrophages in the splenic marginal 
zone.35,47,48 Moreover, decreased levels of IgG Fc sialylation have been observed in 
a murine nephritis model suggesting that the decrease in sialylation may provide a 
switch from the steady state innate anti-inflammatory activity to an adaptive pro-
inflammatory response.35 For a variety of autoimmune diseases, infectious diseases 
and cancer lowered IgG Fc galactosylation has been observed.3,32,147 Moreover, changes 
in IgG Fc N-glycans of healthy individuals have been associated with age, gender and 
pregnancy.8-10
Accurate analysis of IgG Fc N-glycosylation is essential for e.g. the characterization 
of biotechnologically produced therapeutic monoclonal antibodies and obviously is of 
benefit for the analysis of glycosylation changes of polyclonal IgGs as part of humoral 
immune responses. Fc N-glycosylation of IgGs can be determined by mass spectrometry 
(MS) after enzymatically releasing the N-glycans or after preparation of (glyco)peptides. 
With released N-glycans subclass-specific Fc N-glycosylation profiling is only allowed 
when IgG subclasses are separated prior to N-glycan release. By contrast, analysis 
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of IgG Fc N-glycopeptides allows discrimination between subclasses on the basis of 
the peptide moieties and masses. Analysis of IgG glycopeptide microheterogeneity 
can be achieved by MALDI-MS77,102,119,148 or LC-MS.4,50,79,140 MALDI-MS is very well 
suited for high-throughput analysis and has been shown to allow subclass-specific 
Fc N-glycopeptide profiling of human polyclonal IgG.148 However, the presence of 
isomeric glycopeptides prevents proper determination of IgG2 fucosylation and 
IgG4 glycosylation.148 By performing an LC separation prior to MS detection detailed 
characterization of IgG subclass-specific Fc N-glycosylation can be achieved in a single 
analysis.4,79
To allow direct coupling of the chromatographic separation with the mass 
spectrometer, formic acid (FA) is often applied as acidic mobile phase additive.45,71,125 
Analyte retention and peak shapes can be improved by using trifluoroacetic acid (TFA) 
in stead of FA.128 Moreover, ionic interactions of basic analytes with residual silanol 
groups on silica based RP stationary phases are strongly reduced with TFA.129 However, 
TFA is known to form gas-phase ion-pairs with positively charged analyte ions resulting 
in ESI ion suppression. By applying a mixture of isopropanol (IPA) and propionic acid 
(PA) or acetic acid (TFA fix) prior to ESI this effect can be substantially reduced.149-151
Interfacing of TFA containing separations to MS is predominantly performed with 
analytical to capillary scale LC separations as conventional nano-ESI sources often lack 
robustness, even when run by qualified operators. Here we present a fast and robust 
nano-reversed phase-LC-MS method for IgG subclass-specific Fc N-glycopeptide 
profiling, using TFA containing mobile phases and a sheath-flow ESI sprayer for 
HPLC-MS interfacing. Fast separation is achieved on fused core particles at high 
flow rates. The sheath-flow ESI sprayer provides a plug-and-play zero dead volume 
interfacing and allows successful in-spray mixing of the LC gradient with TFA fix with 
minimal sample dilution. Moreover, MS contamination was found to be significantly 
reduced compared to standard nanoLC-MS interfacing. The robustness, sensitivity and 
reproducibility of the nanoLC-MS setup were evaluated with tryptic IgG digests. The 
method was applied to study pregnancy-associated IgG Fc glycosylation changes in a 
cohort of 26 women.
Experimental section
IgG purification and enzymatic cleavage. IgGs were affinity captured from total human 
serum or plasma and digested by trypsin as described previously.148 Briefly, human 
polyclonal IgGs were captured from 2 µl plasma or serum by affinity chromatography 
with Protein A-SepharoseTM Fast Flow beads (GE Healthcare, Uppsala, Sweden), and 
cleaved overnight at 37˚C with 200 ng sequencing grade trypsin (Promega, Madison, 
WI). The entire sample preparation was performed in 96-well plate format. Monoclonal 
antibody samples (provided by Hoffmann la Roche, Penzberg, Germany) were diluted 
in PBS and subjected to trypsin cleavage.
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Fast nano-reversed phase-LC-ESI-MS. Separation was achieved on a Ultimate 3000 
HPLC system (Dionex Corporation, Sunnyvale, CA), consisting of a degasser unit, 
binary loading pump, dual binary gradient pump, a temperature controlled autosampler 
maintained at 5ºC and two column oven compartments maintained at 30ºC. The Ultimate 
3000 autosampler was fitted with a 10 μl PEEK sample loop. Samples were centrifuged at 
4000 rpm for 5 min and 250-5000 nl were applied to a Dionex Acclaim PepMap100 C18 
(5 mm x 300 μm i.d.) solid phase extraction (SPE) trap column conditioned with 0.1% 
TFA (Fluka, Steinheim, Germany; mobile phase A). In an alternative set up samples 
were applied to a 330 nl HALO C18 StemTrap SPE trap column (Optimize Technologies, 
Oregon City, USA) conditioned with mobile phase A. Sample loading was performed on 
the SPE trap column with mobile phase A at 25 µl/min for 1 min, followed by switching 
the SPE in-line with the gradient and separation column for 8 min. After 8 min the SPE 
was washed off-line by three full loop injections containing 5 µl 5% IPA + 0.1% FA and 
5 µl 50% IPA + 0.1% FA. Separation was achieved on an Ascentis Express C18 nanoLC 
column (50 mm x 75 μm i.d., 2.7 μm HALO fused core particles; Supelco, Bellefonte, 
USA) conditioned at 900 nl/min with mobile phase A after which the following 
gradient of mobile phase A and 95% acetonitrile (ACN; Biosolve BV, Valkenswaard, 
the Netherlands; mobile phase B) was applied: 0 min 3% B, 2 min 5% B, 5 min 20% B, 
6 min 30% B, 8 min 30% B, 9 min 0% B, and 14 min 0% B. The analytical column was 
protected for particulates coming from the sample injection by a stainless steel frit (2 µm 
pore size) mounted between the autosampler transfer tubing and the trap column. The 
HPLC system was coupled to a Dionex Ultimate UV detector (recording absorbance 
at 214 nm) equipped with a 3 nl flow cell. The HPLC was interfaced to a quadrupole-
TOF-MS mass spectrometer (micrOTOF-Q; Bruker Daltonics, Bremen, Germany) 
with a standard ESI source (Bruker Daltonics) and a sheath-flow ESI sprayer (Figure 
1; capillary electrophoresis ESI-MS sprayer; Agilent Technologies, Santa Clara, USA) 
applying the UV outlet tubing (20 µm i.d., 360 µm o.d.) as sprayer needle. To reduce the 
gas-phase TFA ion-pairing and assist with ESI spray formation a 2 μl/min sheath-flow 
of 50% IPA, 20% PA and 30% water was applied by one of the binary gradient pumps. To 
improve mobile phase evaporation a nitrogen stream was applied as dry gas at 4 l/min 
with a nebulizer pressure of 0.4 bars. Alternatively the LC-MS interfacing was achieved 
with a nano-ESI source (Bruker Daltonics) equipped with a metal nano-ESI needle (30 
µm i.d.; Proxeon Biosystems, Odense M, Denmark). Scan spectra were recorded from 
300 to 2000 dalton with 2 average scans at a frequency of 1 Hz. Quadrupole ion energy 
and collision energy of the MS were set at 2 and 4 eV, respectively. The total analysis time 
per sample was 16 min. The Ultimate 3000 HPLC system and the Bruker micrOTOF-Q 
were operated under Chromeleon Client version 6.8 and micrOTOF control version 2.3 
software, respectively. 
Data processing. Liquid chromatography-mass spectrometry datasets were calibrated 
internally using a list of known glycopeptides and were exported to the open mzXML 
format by Bruker DataAnalysis 4.0 in batch mode.152 Each dataset was then aligned to 
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a master dataset of a typical sample (containing many of the (glyco-)peptide species 
shared between multiple samples) using msalign2153 and a simple warping script in 
AWK.154 A list of 402 pre-defined features, defined as peak maximum (applied in this 
study) or peak area in specific mass and retention time windows, i.e. an accurate mass 
and time tag,155 were then extracted from each dataset using the in-house developed 
software “Xtractor2D” and merged to a complete data matrix. As input, Xtractor2D 
takes one dataset in the mzXML format aligned to the master dataset and a reference 
list with pre-defined features with m/z windows and retention times in seconds. The 
retention times are on the chromatographic time scale of the master dataset used for the 
alignment and m/z values are calculated. The software and ancillary scripts are freely 
available at www.ms-utils.org/Xtractor2D. The complete sample-data matrix was finally 
evaluated using Microsoft Excel. Structural assignment of the detected glycoforms was 
performed on the basis of literature knowledge of IgG N-glycosylation.3,4,9,10,79,148 Relative 
intensities of the glycopeptide species (Table 1) derived from IgG1 (18 glycoforms), 
IgG4 (10 glycoforms), and IgG2 (18 glycoforms) were obtained by integrating and 
summing three isotopic peaks followed by normalization to the total IgG subclass-
specific glycopeptide intensities. 
On the basis of the normalized intensities the level of galactosylation, sialylation, 
bisecting N-acetylglucosamine, fucosylation, and the number of sialic acid moieties 
present on the galactose moieties (SA/Gal)  were calculated according to the following 
formulas: Galactosylation = (G1F + G1FN + G1FS + G1FNS + G1 + G1N + G1S) * 0.5 
+ G2F + G2FN + G2FS + G2FNS + G2 + G2N + G2S for IgG1 and IgG2, and (G1F + 
G1FN + G1FS + G1FNS) * 0.5 + G2F + G2FN + G2FS + G2FNS for IgG4. Sialylation = 
G1FS + G2FS + G1FNS + G2FNS + G1S + G2S for IgG1 and IgG2, and G1FS + G2FS 
+ G1FNS + G2FNS for IgG4. Bisecting GlcNAc = G0FN + G1FN + G2FN + G1FNS + 
G2FNS + G0N + G1N + G2N for IgG1 and IgG2, and G0FN + G1FN + G2FN + G1FNS 
+ G2FNS for IgG4. Fucosylation IgG1 and IgG2 = G0F + G1F + G2F + G0FN + G1FN 
+ G2FN + G1FS + G2FS. No fucosylation level was determined for the IgG4 subclass as 
the non-fucosylated species remained below the limit of detection. The number SA/Gal is 
calculated by dividing the prevalence of IgG sialylation by 2 * the level of galactosylation. 
Glycopeptide profiling of a pregnancy cohort. Serum from 26 healthy pregnant 
Caucasian women without adverse obstetric history ranging in age between 24 and 
40 years was obtained at three time points during pregnancy (1st, 2nd, 3rd trimester) 





Figure 1. Schematic representation of the sheath-flow ESI sprayer.
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IgGs were purified with Protein G-SepharoseTM Fast Flow beads (GE Healthcare), 
digested overnight with trypsin and the resulting glycopeptides were analyzed by fast 
nano-reversed phase-LC-ESI-MS. Liquid chromatography-mass spectrometry datasets 
were processed automatically. Differences during pregnancy were evaluated using the 
Repeated Measures analysis (ANOVA) and differences between the 3rd pregnancy 
trimester and the last time point (28 to 52 weeks after delivery) were evaluated 
with the Paired-Samples T-test. p-Values were adjusted for multiple comparisons by 
Bonferroni correction, and p-values ≤ 0.013 were considered statistically significant. 
Data evaluation and statistical analysis were performed with Microsoft Excel and SPSS 
16.0, respectively.
Table 1. Theoretical m/z values of human IgG Fc glycopeptides detected by nanoLC-ESI-MS.
Glycan species
IgG1 P01857b IgG2 P01859b IgG4 P01861b
[M+2H]2+  [M+3H]3+ [M+2H]2+  [M+3H]3+ [M+2H]2+  [M+3H]3+
No glycan 595.260 397.176 579.265 386.513 587.262 391.844
G0Fc 1317.527 878.687 1301.532 868.024 1309.529 873.356a1
G1F 1398.553 932.705 1382.558 922.042 1390.556 927.373a2
G2F 1479.580 986.722 1463.585 976.059 1471.582 981.391
G0FN 1419.067 946.380 1403.072 935.717 1411.069 941.049a3
G1FN 1500.093 1000.398 1484.098 989.735 1492.096 995.066a4
G2FN 1581.119 1054.416 1565.124 1043.752 1573.122 1049.084
G1FS 1544.101 1029.737 1528.106 1019.073 1536.104 1024.405a5
G2FS 1625.127 1083.754 1609.132 1073.091 1617.130 1078.423
G1FNS 1645.641 1097.430 1629.646 1086.766 1637.643 1092.098
G2FNS 1726.667 1151.447 1710.672 1140.784 1718.670 1146.116
G0 1244.498 830.001 1228.503 819.338 - -
G1 1325.524 884.019 1309.529 873.356a1 - -
G2 1406.551 938.036 1390.556 927.373a2 - -
G0N 1346.038 897.694 1330.043 887.031 - -
G1N 1427.064 951.712 1411.069 941.049a3 - -
G2N 1508.090 1005.730 1492.096 995.066a4 - -
G1S 1471.072 981.051 1455.077 970.387 - -
G2S 1552.098 1035.068 1536.104 1024.405a5 - -
a1 – a5isomeric glycopeptide species of IgG4 and IgG2.
bSwissProt entry number
cglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
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Results
Nano-reversed phase-LC-ESI-MS. In a first setup of the method, a tryptic IgG 
(glyco-)peptide pool prepared from plasma of a healthy donor by protein A affinity 
chromatography148 was analyzed by direct injection of 250 nl onto the Ascentis Express 
C18 column. Separation was achieved at 500 nl/min using an ACN gradient with 
formic acid (FA) as acidic mobile phase additive to allow direct coupling with the mass 
spectrometer. The LC separation was interfaced to the mass spectrometer by a 30 μm 
i.d. metal nanoLC-ESI-MS sprayer. Good separation of IgG Fc N-glycopeptides from 
different human IgG subclasses was obtained within a window of 15 min (Figure 2A). 
Sialylated IgG Fc N-glycopeptides of each specific subclass eluted later than the non-
sialylated counterparts showing almost baseline separation.
To simplify LC-MS coupling and improve system robustness we interfaced the 
nanoLC separation to the mass spectrometer by a Agilent sheath-flow ESI sprayer 
(Figure 1) mounted in the standard ESI source at the default, fixed position. The UV 
outlet tubing (20 μm i.d., 360 μm o.d.) is applied directly as sprayer tip coupling the LC 
separation to the MS with zero dead volume. To assist with the electrospray formation 
a sheath-flow of 50% IPA in water with 2% PA was applied at 2 µl/min. Furthermore, a 
nitrogen stream was applied as dry gas at 4 l/min with a nebulizer pressure of 0.4 bars 
to improve mobile phase evaporation.
The MS intensities of tryptic IgG Fc N-glycopeptides obtained with the sheath-
flow sprayer (Figure 2B) were compared to those obtained with the metal nanoLC-ESI 
sprayer interface (Figure 2A). While IgG1 and IgG4 glycopeptides revealed similar 
intensities with both sprayers, the metal nanoLC-ESI sprayer provided higher IgG2 
glycopeptide signals. In contrast to the metal nano-ESI sprayer the sheath-flow ESI 
sprayer provided a constant spray current which was independent of the LC gradient. 
This resulted in a more stable spray which performed equally well over the entire LC 
gradient. Moreover, the larger distance between the sheath-flow sprayer tip and the 
MS inlet resulted in a strong contamination reduction of the MS glass capillary as 
compared to the metal nanoLC-ESI sprayer.
To improve the separation and reduce the observed higher retention of sialylated 
glycopeptides FA was substituted for TFA. This resulted in sharper peaks and co-elution 
of sialylated IgG Fc N-glycopeptides with their non-sialylated counterparts (Figure 
3). However, lower IgG glycopeptide signals were obtained (Figure 3A), which could 
be restored by increasing the PA concentration in the sheath-liquid to 20% (Figure 
3B). Potential sample dilution and band broadening during ESI as a result of mixing 
with the sheath-liquid was evaluated by varying the sheath-flow rate from 1 to 10 µl/
min. Best results in terms of MS signal intensities were obtained at 2 µl/min sheath-
flow. Moreover, all sheath-flows revealed peaks of similar widths indicating that band 
broadening upon mixing is negligible. In addition to IPA, acetone, ACN and ethanol 
were evaluated as sheath-liquid additives at different flow rates but proved to be less 
effective than IPA in reducing/eliminating TFA gas-phase ion paring.
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Figure 2. Comparison of the 
different sprayers for IgG Fc 
N-glycopeptide ionization. Extracted 
ion chromatograms obtained with 
a metal nano-ESI sprayer (A) and a 
sheath-flow ESI sprayer (B). Figures 
are represented with the same 
scaling. IgG Fc N-glycopeptides 
were separated at 500 nl/min using 
an ACN gradient with FA as mobile 
phase additive. The sheath-flow 
sprayer was applied with a 2 μl/min 
sheath-flow of 50% IPA containing 




















Figure 3. Effect of the PA 
concentration in the sheath-
liquid on reduction of the TFA 
signal suppression. Extracted ion 
chromatograms of IgG glycopeptides 
with a 2 μl/min sheath-flow of 50% 
IPA containing 2% (A) or 20% (B) 
PA. Figures are represented with the 
same scaling. IgG Fc N-glycopeptides 
were separated at 500 nl/min using 
an ACN gradient with TFA as mobile 
phase additive. Glycan code as in 
Figure 1 of Chapter 1.
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To shorten the total analysis time (TAT) we increased the mobile phase flow rate 
to 900 nl/min and implemented a 330 nl HALO C18 StemTrap trap column for fast 
on-line analyte extraction and purification of large sample volumes. Extraction and 
separation were evaluated at three different temperatures (30, 40 and 60ºC) showing 
low recoveries for all analytes with peak tailing (data not shown). Moreover, very 
broad IgG1 glycopeptide peaks were observed at 40ºC, and peak splitting occurred 
at 60ºC. In an effort to improve the analyte recoveries we replaced the StemTrap with 
a Dionex PepMap trap column and reevaluated the separations at the three different 
temperatures. While analyte recoveries were significantly improved, broad peaks 
were observed for separations at 40 and 60ºC. Separation at 30ºC provided sharp and 
symmetrical peaks for all subclass-specific IgG Fc glycopeptides. Moreover, separation 
could be achieved within 7 to 10 min using a short steep ACN gradient allowing a TAT 
of 16 min from sample to sample (Figure 4).
IgG Fc N-glycopeptides already eluted from the trap column within the first 8 min 
of the gradient. For efficient washing of the trap column and in order to minimize 
carryover, we switched the trap column off-line at 8 min and performed full loop 
injections (10 µl) onto the trap column with various IPA dilutions. With three full 
loop injections filling the loop with 5 µl 50% IPA containing 0.1% FA and 5 µl 5% IPA 











Figure 4. Fast nanoLC-ESI-MS of a tryptic 
IgG digest employing a sheath-flow sprayer. 
Base peak chromatogram of m/z 700-1700 
(A); Extracted ion chromatogram of IgG1 (B), 
IgG4 (C), and IgG2 (D) Fc N-glycopeptides. 
Figures are represented with the same scaling. 
Separation was performed at 900 nl/min using 
an ACN gradient with TFA as mobile phase 
additive.  
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Optimization of mass spectrometry settings. In addition to the subclass-specific 
glycoforms (Table 1), using the standard (proteomics) MS settings IgG1, IgG4 and 
IgG2 glycopeptide decay products were observed as doubly charged fragment ions 
at m/z 1215.983, 1207.986 and 1199.988 Da, respectively. To minimize these decay 
products we evaluated various MS transfer parameters including capillary exit voltage, 
funnel voltages, quadrupole ion energy and collision energy. In the sheath-flow ESI 
setup, the capillary exit and funnel voltages hardly influenced the level of these decay 
products. By contrast, significant less decay products were observed when lowering the 
quadrupole ion energy (5 eV) and collision energy (10 eV) to 2 and 4 eV, respectively. 
While decreasing these energies resulted in lower total MS intensities, the signal to noise 
ratios remained unaffected. Tryptic IgG Fc N-glycopeptide ions were predominantly 
observed as [M+3H]3+ and [M+2H]2+ with low amounts of [M+2H+Na]3+ (Figure 
5). A total of 38 glycopeptide species derived from IgG1 (14 glycoforms), IgG4 (10 
glycoforms), and IgG2 (9 glycoforms) were registered in both doubly charged and triply 
charged form for the healthy donor serum sample (Table 1) which is in accordance 
with previous reports on IgG Fc glycosylation profiling by LC-MS.4,79
Repeatability. To evaluate the repeatability of the nanoLC-MS analysis a tryptic IgG Fc 
glycopeptide pool was analyzed eight times on three different days. Compound spectra 
were processed automatically which involved internal calibration, LC alignment and 
peak picking, revealing a good intra- and interday repeatability with lower than 5% 
relative standard deviation (RSD) of the normalized peak heights for the 8 major 
glycoforms of IgG1, IgG4 and IgG2 (data not shown). The robustness and repeatability 
of the entire analytical method including sample preparation (protein A affinity 
purification and trytpic cleavage) and mass spectrometric detection was assessed by 
performing three independent experiments comprising eight replicates each. The 
intraday variability for IgG1 (Figure 6A), IgG4 (Figure 6B), and IgG2 (Figure 6C) was 
determined within the three experiments and the interday repeatability was determined 
by comparing the results of the three experiments (Figure 6). For the 8 major IgG1, 
IgG4 and IgG2 glycoforms the RSDs for the intra- and interday repeatability were 
below 5% of the normalized peak heights, indicating that the variability of the sample 
preparation was below the variability of the nanoLC-MS analysis.
Limit of detection. To evaluate the limit of detection (LOD) of the reverse phase 
nanoLC-ESI-MS setup we prepared a dilution series with tryptic digests of two 
monoclonal antibodies ranging from 0.024 to 100 ng/µl and analyzed 1 µl of each 
dilution. In the Fc portion of each antibody two N-glycans are located, which may vary 
in glycan composition. Upon analysis of the lowest measurable concentration three 
different glycoforms were observed. The LOD was estimated thereof to be 870 amol 
and was calculated by:
Lowest measurable antibody concentration (0.195 ng/µl) * Number of Fc N-glycans (2)

























































































Figure 5. Tryptic glycopeptide mass spectra of IgG1 (A), IgG4 (B), and IgG2 (C) analyzed by 
fast nanoLC-ESI-MS with the sheath-flow ESI sprayer interface. Glycan code as in Figure 1 of 
Chapter 1.
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Figure 6. Repeatability of the sample preparation (protein A capturing, trypsin digestion) 
and analysis (fast nanoLC-ESI-MS with sheath-flow ESI sprayer interface) of IgG1 (A), IgG4 
(B) and IgG2 (C). Relative intensities and standard deviations (STD) were determined from 
three independent experiments comprising eight replicates each. Glycan code as in Figure 1 of 
Chapter 1.
Pregnancy related IgG Fc N-glycosylation changes. The developed nano-reversed 
phase-LC-ESI-MS setup was applied to profile the IgG Fc N-glycosylation of 26 
pregnant women at several time points during and after pregnancy. The obtained 
data revealed that the level of galactosylation, sialylation, and the number of SA/Gal 
increased significantly from the 1st to the 2nd pregnancy trimester for IgG1 (p-values < 
0.005), IgG2/IgG3 (p-values < 0.010), and IgG4 (p-values < 0.015), while no significant 
increase was observed from 2nd to the 3rd pregnancy trimester (Table 2, Figure 7). 
During pregnancy no changes were observed for the level of fucosylation and bisecting 
N-acetylglucosamine of IgG1, IgG2/IgG3 and IgG4. The most prominent glycosylation 
changes between two consecutive time points were observed for the 3rd pregnancy 
trimester (time point 3) and 6 weeks post partem (time point 4; Table 2): all of the 
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analyzed glycosylation features, i.e., galactosylation, sialylation, SA/Gal, bisecting 
GlcNAc, and fucosylation showed significant changes (p-values < 0.001; Table 2). While 
galactosylation, sialylation, and SA/Gal were found to be decreased after delivery, the 
incidence of bisecting GlcNAc as well as fucosylation were increased for IgG1, IgG2/
IgG3, and IgG4 (Table 2, Figure 7). 
In order to identify pregnancy-associated glycosylation changes which are 
supposed to be reversed 28-52 weeks after delivery, IgG glycosylation was compared 
between the 3rd pregnancy trimester (time point 3) and time point 6. Again, the levels 
of galactosylation, sialylation, and the number of SA/Gal for IgG1, IgG2/IgG3, and 
IgG4 were significantly higher in the 3rd pregnancy trimester compared to 28-52 weeks 
after pregnancy (p-values < 0.001). By contrast, significantly higher levels of bisecting 
GlcNAc and fucosylation were observed for IgG1 and IgG2/IgG3 28-52 weeks after 
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Pregnancy time point Pregnancy time point Pregnancy time point Pregnancy time point
A B C D
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I J K L
Figure 7Figure 7. Pregnancy-associated IgG Fc N-glycosylation changes in 26 Caucasian women. For 
IgG1 (A-D), IgG2/IgG3 (E-H), and IgG4 (I-L) the level of galactosylation (A, E, I), sialylation 
(B, F, J), the incidence of SA/Gal (C, G, K) and the incidence of bisecting GlcNAc (D, H, L) are 
given for time point 1 (1st trimester), 2 (2nd trimester), 3 (3rd trimester), 4 (6 weeks after delivery), 
5 (12 weeks after delivery), and 6 (28 to 52 weeks after delivery). Mean values are indicated by 
horizontal bars.
38
Robust nano-reversed phase LC-ESI-MS
2




Mean (%) p-value* Mean (%) p-value* Mean (%) p-value*
Galactosylation
1 68.34 59.02 53.24
2 70.16 < 0.001 61.35 0.009 55.06 0.012
3 70.68 0.453 63.23 0.036 54.67 0.515
4 63.13 < 0.001 54.68 < 0.001 47.55 < 0.001
5 61.21 < 0.001 51.65 < 0.001 46.02 0.006
6 61.92 0.140 52.07 0.338 46.44 0.469
Sialylation
1 22.98 22.76 24.72
2 24.22 < 0.001 24.55 < 0.001 26.46 < 0.001
3 24.47 0.449 25.65 0.020 26.35 0.728
4 19.83 < 0.001 20.61 < 0.001 21.08 < 0.001
5 18.74 0.001 18.56 < 0.001 19.85 < 0.001
6 19.44 0.023 18.73 0.544 19.96 0.768
SA/Gal
1 16.66 19.18 23.07
2 17.10 0.001 19.89 < 0.001 23.86 < 0.001
3 17.14 0.734 20.18 0.019 23.92 0.578
4 15.56 < 0.001 18.76 < 0.001 21.96 < 0.001
5 15.16 0.017 17.86 < 0.001 21.37 < 0.001
6 15.57 0.031 17.87 0.967 21.36 0.927
Bisecting GlcNAc
1 12.44 10.37 12.41
2 11.98 0.148 10.10 0.167 12.37 0.937
3 12.35 0.232 10.28 0.329 13.22 0.108
4 13.79 < 0.001 10.98 < 0.001 14.03 < 0.001
5 13.81 0.921 11.16 0.092 13.91 0.605
6 13.80 0.956 11.21 0.534 13.54 0.041
Fucosylation
1 92.24 97.28 n.d. n.d.
2 92.24 0.966 97.19 0.134 n.d. n.d.
3 92.03 0.362 97.00 0.003 n.d. n.d.
4 92.90 < 0.001 97.34 < 0.001 n.d. n.d.
5 93.15 0.071 97.42 0.253 n.d. n.d.
6 92.86 0.111 97.40 0.816 n.d. n.d.
*Repeated Measures analysis p-values < 0.013 are considered to be significant and are highlighted in bold. 




Here we describe a fast nanoLC-MS method for detailed Fc N-glycosylation profiling of 
human IgG subclasses in a single analysis. Human polyclonal IgGs were purified from 
plasma by protein A (captures IgG1, IgG2, and IgG4) or protein G (captures IgG1-4) 
affinity chromatography and digested overnight with trypsin in 96-well plate format. 
Aliquots of the samples containing IgG (glyco)peptides were loaded onto a C18 trap 
column and separated on a fused core C18 nanoLC column. In a first version of the 
setup, samples were injected directly onto the nanoLC column. The LC was interfaced 
to the MS by a metal nano-ESI sprayer and separation was performed with a gradient 
of ACN (mobile phase B) and FA (mobile phase A). No acid was added to the ACN 
to avoid potential acid-catalyzed hydrolysis of ACN to acetic acid and ammonia156-158 
which might result in the formation of ammonium adducts. The metal nano-ESI sprayer 
was set close to the glass capillary inlet and the position was optimized manually to 
obtain the best ESI current.
During the LC gradient the increase in the ACN content of the mobile phase resulted 
in an increase of the total ion current and higher MS intensities later in the gradient. 
On reverse phase LC columns IgG glycopeptides elute at a relative low percentage of 
ACN and thus experience less favorable ESI spray conditions with standard nano-ESI 
sources. By replacing the nano-ESI source and sprayer with a conventional ESI 
source and a sheath-flow ESI sprayer we obtained a plug-and-play zero dead volume 
nanoLC-MS interface. Compared with regular nano-ESI sprayers, the sheath-flow ESI 
sprayer is positioned considerably further away from the glass capillary inlet. This 
reduced contamination of the MS and allowed many sequential injections without 
intensity loss. The volatile sheath-liquid required for proper spraying with the sheath-
flow sprayer provided a very constant spray and ionization over the entire gradient 
with MS intensities early in the gradient being similar to those observed with a metal 
nano-ESI sprayer. The sheath-liquid composition was optimized to enhance analyte 
signal intensities,159 and reduce TFA gas-phase ion-pairing with basic analytes by 
introducing TFA fix149,151 during spray formation without excessive sample dilution. 
We expect that the sheath-flow ESI sprayer will find acceptance for other applications 
which require robust and sensitive coupling of nanoLC to mass spectrometry.
With standard porous particle nanoLC columns separation is achieved with mobile 
phase flow rates between 100-300 nl/min generating pressures up to 200 bars. Current 
fused core particle columns offer higher efficiency due to the combination of a smaller 
longitudinal diffusion coefficient and lower eddy diffusion160 and can be applied at 
higher mobile phase flow rates resulting in efficient separation without requiring ultra-
high pressures.161 Moreover, similar resolving power (plate height) has been reported for 
both low and high mobile phase flow rates. We, therefore, increased the mobile phase 
flow rate 1.8 times which effectively reduced the TAT to 16 min. Separation at 30ºC of 
StemTrap extracted analytes showed peak tailing for all IgG Fc N-glycopeptides which 
could not be eliminated by diluting the sample or lowering the injection volume. Tailing 
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with HALO stationary phases has been reported for separations of basic peptides at 
lower temperatures which disappeared when the temperature was increased to 60ºC.162 
We, therefore, explored this possibility by increasing the separation temperature up 
to 60ºC. While recoveries were comparable at the three temperatures, tailing of the 
analyte peaks increased at higher temperatures with even peak splitting at 60ºC, which 
suggests that the tailing was a result of the relatively low loading capacity of the fused 
core trap column (surface area ~150 m2/g). To improve analyte recoveries and eliminate 
peak tailing we, therefore, replaced the fused core trap column by a porous particle 
trap column (surface area ~300 m2/g). Both porous particle trap column and fused core 
particle analytical column revealed similar retention for the IgG Fc N-glycopeptides 
providing a system with high capacity sample extraction and fast analyte separation. 
The soft nature of ESI allows analysis of intact glycopeptides including sialylated 
glycopeptides. However, at standard (proteomics) MS settings glycopeptides are prone 
to show in-source decay and/or fragmentation during ion-transfer.137,139 We observed 
doubly charged IgG glycopeptide ions which only occur when the linkage between one 
of the antenna GlcNAc residues and the core mannose breaks. By lowering the default 
collision energy and quadrupole ion energy occurrence of these decay products could 
almost be reduced to noise levels. The funnel setup of the quadrupole-TOF-MS did 
not appear to influence the level of glycopeptide decay products observed, indicating a 
softer ion transfer compared to the setup with skimmer and lenses used in the TOF-MS 
(Bruker micrOTOFTM) where lowering the voltage difference between the capillary exit 
and lens 1 was required to reduce these decay products (data not shown).
Simultaneous glycosylation profiling of different IgG subclasses can be achieved 
by direct infusion-MS,137 MALDI-MS102,148 and LC-MS.4,79 Detailed glycosylation 
analysis of human polyclonal IgG by direct infusion-MS and MALDI-MS is limited 
by the presence of isomeric glycopeptide species.148 By contrast, LC-MS provides 
detailed glycosylation profiles of different IgG subclasses in a single analysis.4,79 The 
nanoLC-MS method described in this manuscript allows fast and detailed subclass 
specific analysis of IgG Fc N-glycosylation with a similar LOD but a substantially 
shorter TAT (16 min) compared to previously described methods.4,79 Due to the sheath-
flow ESI sprayer interface the system remains highly stable over a long period of time 
(more than 3 weeks) without the requirement of MS cleaning and maintenance (data 
not shown). The ionic interactions of sialylated glycopeptides with residual silanol 
groups on the silica based RP stationary phase is suppressed by the presence of TFA 
improving chromatographic resolution.129 Due to the predominantly peptide-based 
retention the complete IgG subclass specific glycopeptide profile is obtained in a 30 s 
separation window (Figure 4). The here developed robust, fast and sensitive method 
for IgG Fc glycosylation analysis will not only be suitable to analyze the glycosylation 
of clinical IgG samples but will also be applicable in a biotechnological setting for the 
characterization of recombinantly produced therapeutic IgGs.
41
For a variety of diseases lowered IgG galactosylation has been reported.147 In healthy 
individuals IgG Fc N-glycosylation is known to be influenced by age, gender and 
pregnancy.4,8-10,13,14 During pregnancy a decreased percentage of agalactosylated IgG has 
been reported which after delivery increased to values similar to before conception.14 
The here developed fast nano-reversed phase HPLC-MS method was successfully 
applied to profile IgG Fc N-glycosylation of 26 pregnant women, confirming the 
previous reported increase of IgG galactosylation during pregnancy.15 The applied 
technique additionally allowed sensitive and accurate determination of sialylated IgG 
glycopeptides, revealing increased levels of IgG1, IgG2/IgG3, and IgG4 sialylation 
during pregnancy. The pregnancy-associated increase in sialylation was found to be 
more pronounced than the increase in galactosylation. This is reflected by the fact that 
the ratio of SA/Gal is higher during pregnancy compared to after delivery (Figure 7C, 
G, and K). This finding indicates that IgG Fc galactosylation and sialylation, although 
they tend to show some correlation,15 are not fully concerted in terms of regulation.
Furthermore, we observed lower levels of IgG1 and IgG2/IgG3 bisecting GlcNAc 
and fucosylation during pregnancy than after delivery. Differences in IgG glycosylation 
are postulated to be a reflection of altered N-glycan biosynthesis in B-lymphocytes.12,57 
Thus the decreasing levels of bisecting GlcNAc and fucosylation with increasing levels of 
galactosylation and sialylation during pregnancy may indicate altered activities of GlcNAc 
transferase III (catalyzes the addition of a β-1,4-linked GlcNAc to the β-linked mannose 
of the trimannosyl core),163 α1,6-fucosyltransferase (catalyzes the addition of a fucose 
residue to the innermost GlcNAc of the chitobiose core),164 β4-galactosyltransferase(s) 
(catalyzes the addition of β1,4-linked galactoses to the GlcNAc residues),165 and α2,6/
α2,3-sialyltransferase (catalyzes the addition of α2,6 or α2,3-linked sialic acids to the 
antennae galactose residues).166,167 Future studies will hopefully elucidate the regulatory 
mechanisms involved in inducing pregnancy-associated glycosylation changes as well as 
the immunological role and implications of these alterations.
In conclusion, the here described nano-reversed phase HPLC-MS method allows 
sensitive, fast and reproducible analysis of subclass-specific IgG glycosylation and is 
combined with automated data processing. Moreover, the sheath-flow ESI sprayer 
provides a sensitive and robust plug-and-play interface that minimizes contamination 
of the mass spectrometer. The system is currently being applied to analyze large clinical 
cohorts, and no decrease in signal intensity has been observed after 2000 injections.
Acknowledgements 
The authors thank Carolin Huhn, Dietmar Reusch and Markus Haberger for fruitful 
discussions regarding zero dead volume sheath-flow interfacing of LC separations with 
mass spectrometry. The monoclonal antibodies used to determine the sensitivity of 
the reverse phase nanoLC-ESI-MS with sheath-flow interface were kindly provided by 




3Cotton HILIC SPE microtips for micro-scale purification and enrichment of glycans and glycopeptidesSelman, M.H.J.1¥; Hemayatkar, M.1,2¥; Deelder, A.M.1; Wuhrer, M.1 1Biomolecular Mass Spectrometry Unit, Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands, 2Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran¥These authors contributed equally to this workAnalytical Chemistry, 2011, 83, 2492-2499.
Abstract
Solid phase extraction microtips are important devices in modern bioanalytics, as 
they allow miniaturized sample preparation for mass spectrometric analysis. Here we 
introduce the use of cotton wool for the preparation of filter-free HILIC SPE microtips. 
To this end, pieces of cotton wool pads (approximately 500 µg) were packed into 10 
µl pipette tips. The performance of the tips was evaluated for micro-scale purification 
of tryptic IgG Fc N-glycopeptides. Cotton wool HILIC SPE microtips allowed the 
removal of salts, most non-glycosylated peptides, and detergents such as SDS from 
glycoconjugate samples. MALDI-TOF-MS glycopeptide profiles were very repeatable 
with different pristine tips as well as reused tips, and very similar profiles were obtained 
with different brands of cotton wool pads. In addition, we used cotton HILIC microtips 
to purify N-glycans after PNGase-F treatment of IgG and transferrin followed by 
MALDI-TOF-MS detection. In conclusion, we establish cotton wool microtips for 
glycan and glycopeptide purification with subsequent mass spectrometric detection.
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Introduction
Due to its speed, resolution and sensitivity, modern mass spectrometry provides great 
opportunities for detailed structural characterization of protein glycosylation including 
protein identification, determination of site-specific glycosylation profiles, and 
structural characterization of glycans at the level of glycopeptides and released glycans. 
For the efficient ionization and detection of glycopeptides and glycans, enrichment or 
purification steps are often required. Next to graphitized carbon solid phase extraction 
(SPE), hydrazine coupling, and lectin or antibody affinity chromatography, hydrophilic 
interaction liquid chromatography (HILIC) has been found to be very suitable for 
this purpose.168-170 While the specificity of lectins and antibodies often only allows the 
isolation of a subset of glycans or glycopeptides from a pool, HILIC and graphitized 
carbon SPE can be employed for isolation of a broad range of glycoconjugates, making 
these adsorption chromatography methods applicable in a wide range of glycomics and 
glycoproteomics studies.168-170
HILIC SPE has been found to be particularly useful for the enrichment of tryptic 
N-glycopeptides. For this purpose, ZIC-HILIC stationary phases have been applied in 
ion-pairing mode using trifluoroacetic acid as a mobile phase additive.138 Alternatively, 
carbohydrate-based stationary phases such as Sepharose and microcrystalline 
cellulose have been used for N-glycopeptide isolation.102,148 An important feature of 
these carbohydrate-based stationary phases is that they are non-ionic, and HILIC 
adsorption is, therefore, dominated by hydrogen bonding of the glycan moieties with 
the stationary phase, while non-glycosylated peptides, lipids, salts and detergents tend 
to show low retention.94,138,139 Retention of glycoconjugates is usually achieved with 
acetonitrile concentrations in the range of 80% while elution is performed with high 
water content.139 The required elution conditions make HILIC well compatible with 
mass spectrometry, both in online and off-line mode.92,138,139,171
Immunoglobulin G (IgG) Fc N-glycosylation profiles can be analyzed in a 
reproducible and robust manner by MALDI-MS after HILIC SPE with Sepharose as 
well as microcrystalline cellulose performed in batch mode or at the 96-well plate 
format.102,148 Here we introduce the use of cotton wool in microtips as versatile HILIC 
micro-SPE tool and demonstrate the reproducible application of these tips for isolation 
of tryptic IgG Fc N-glycopeptides from human plasma, followed by subclass-specific 
glycosylation profiling at the glycopeptide level. Moreover, the cotton wool microtips 
were successfully applied for the purification and enrichment of released N-glycans 
from detergent-containing glycoprotein samples treated with PNGase-F.
Experimental section
IgG purification. Polyclonal human IgGs were purified from plasma by affinity 
chromatography with immobilized protein A as described previously,4 with minor 
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modifications. Briefly, rProtein A-SepharoseTM beads (GE Healthcare, Eindhoven, The 
Netherlands) were washed three times with PBS. To each well of a 96-well OF1100 filter 
plate (Orochem Technologies Inc., Lombard, IL) 50 µl PBS, 50 µl of slurry containing 
ca. 5 µl of beads and 2 µl of human plasma (containing ca. 20 μg of IgG) were applied. 
The plate was covered with a lid and incubated at room temperature with gentle 
agitation for 1 h. After incubation, beads were washed with 3x 200 µl PBS and 3x 200 µl 
of water on a vacuum manifold. Captured human polyclonal IgGs were released from 
protein A by 5 minutes incubation with 40 µl of 100 mM formic acid (Fluka, Steinheim, 
Germany), eluted into a polypropylene 96-well V-bottom plate (V96 microwell; 
NUNC, Roskilde, Denmark) by centrifugation (1 min at 18 g). After centrifugation, the 
eluates were neutralized (final pH > 7) with 20 µl of 300 mM ammonium bicarbonate. 
Alternatively, the eluates were dried by vacuum centrifugation for 2 hours.
Trypsin digestion. Tosyl phenylalanyl chloromethyl ketone (TPCK) treated trypsin 
(Sigma-Aldrich, Steinheim, Germany) was dissolved in ice-cold 20 mM acetic acid 
(Merck, Darmstadt, Germany) to a final concentration of 0.05 µg trypsin per µl and 
stored in aliquots at -80°C until use. To each of the neutralized IgG samples 8 µl of 
the trypsin stock (400 ng in total) and 12 µl of water were added. The samples were 
shaken for 3 min and incubated overnight at 37°C. Tryptic IgG digests were stored at 
-20°C until Sepharose or cotton HILIC desalting and purification. Bovine fetuin (1 mg; 
Sigma-Aldrich) was dissolved in 200 µl 50 mM ammonium bicarbonate containing 10 
mM DTT and reduced at 60°C for 40 min. Cysteine alkylation was achieved by addition 
of 30 µl 100 mM iodoacetamide dissolved in 50 mM ammonium bicarbonate followed 
by 30 min incubation at room temperature in the dark. The alkylation reaction was 
stopped by putting the sample under a fluorescent lamp (gas discharge lamp) for 30 
min. Trypsin digestion was achieved overnight at 37°C with 20 µg sequencing grade 
modified trypsin (Promega, Madison, WI).
N-glycan release. N-glycans from protein A purified IgGs were released as described 
previously.94 Briefly, the dried IgG samples were denatured with 2 µl SDS (2%) at 60ºC 
for 10 min. Subsequently, 2 µl of a release mixture containing 2% NP-40, 2.5× PBS 
and 0.5 mU PNGase-F (Roche, Mannheim, Germany) was applied. The samples were 
incubated overnight at 37°C for N-glycan release. Human apo-transferrin (0.1 mg; 
Sigma-Aldrich) was dissolved in 21 µl 50 mM ammonium bicarbonate containing 10 
mM DTT and reduced at 60°C for 40 min. Cysteine alkylation was achieved by adding 
4 µl 200 mM iodoacetamide containing 50 mM ammonium bicarbonate followed by 30 
min incubation at room temperature in the dark. The alkylation was stopped by putting 
the sample under a fluorescent lamp (gas discharge lamp) for 30 min. To the sample 
6 mU PNGase-F was applied and incubated overnight at 37 °C for N-glycan release.
Sepharose HILIC SPE in 96-well plate format. Sepharose (45-165 µm; GE Healthcare, 
Uppsala, Sweden) HILIC SPE was performed as described previously.148
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Preparing cotton HILIC SPE microtips. Cotton wool pads of three different brands 
(Da, Dynaretail, Leusden, The Netherlands; Etos, Etos bv, Beverwijk, the Netherlands; 
Bella, Groupe Lemoine; Paris, France) were purchased in local stores and used for 
the preparation of HILIC SPE microtips. According to the manufacturers the cotton 
wool pads consist of 100% pure cotton. A small piece of cotton wool with a weight of 
approximately 500 μg was taken from a cotton wool pad and pushed into the end part 
of a 10 µl pipette tip (Rainin, Tiel, The Netherlands) using a blunt needle. Microtips 
were stored in a closed box until use.
Cotton HILIC micro-SPE of tryptic IgG glycopeptides and N-glycans. The cotton 
HILIC SPE microtip was washed with 5 times 10 μl of water and conditioned with 3 
times 83% of acetonitrile (Biosolve BV, Valkenswaard, The Netherlands) by aspirating 
and dispensing the solution. For less then 10% of the prepared tips the flow upon 
solvent aspiration was found to be slow and insufficient, and such tips were therefore 
discarded. For sample application to the cotton HILIC SPE microtip, 39 µl of acetonitrile 
was added to 8 μl of a tryptic IgG digest (corresponding to ca. 2 μg of IgG), a fetuin 
digest or an N-glycan release sample, and the mixture was pipetted up and down 20 
times to allow glycoconjugate adsorption. The adsorbed glycoconjugates were washed 
3 times with 10 µl of 83% acetonitrile containing 0.1% TFA and eluted directly onto a 
MALDI plate with 2 μl water. 
Capacity and recovery of cotton HILIC micro-SPE. To evaluate the capacity and 
recovery of cotton HILIC micro-SPE, maltoheptaose (Sigma-Aldrich) was labeled 
with 2-aminobenzoic acid (2-AA; Sigma-Aldrich) and analyzed by HILIC-HPLC with 
fluorescence detection (HPLC-Flu) as described previously.94 The labeled maltoheptaose 
stock was used to prepare a standard dilution series ranging from 0.98-1000 µg/ml. 
From each standard dilution 10 µl was diluted with 90 µl acetonitrile and applied to the 
cotton HILIC SPE microtip. The adsorbed maltoheptaose was washed 3 times with 10 
µl of 90% acetonitrile containing 0.1% TFA and eluted into a 96-well storage plate with 
10 μl water. The standard dilutions and cotton micro-SPE preparations were diluted 10 
times with water, brought to 75% acetonitrile, and analyzed by HPLC-Flu (injection of 
20 µl) in the order of increasing concentrations.
MALDI-TOF-MS. For IgG Fc N-glycopeptide profiling by reflectron positive mode 
MALDI-TOF-MS 2 μl of the Sepharose purified glycopeptides or glycopeptides 
eluted directly from cotton HILIC SPE microtips with 2 µl of water were spotted onto 
a polished stainless steel MALDI plate (Bruker Daltonics, Bremen, Germany) and 
allowed to air dry. Samples were overlaid with 2 μl α-cyano-4-hydroxycinnamic acid 
(CHCA, 5 mg/ml in 50% acetonitrile; Bruker Daltonics) and allowed to air dry. For 
glycosylation profiling in the linear positive mode, IgG glycopeptides were directly 
eluted onto an AnchorChip 600/384 MALDI plate (Bruker Daltonics) and allowed 
to air dry. Samples were overlaid with 1 µl dihydroxybenzoic acid (DHB, 5 mg/ml 
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in 50% acetonitrile with 0.1% TFA; Bruker Daltonics). The AnchorChip plate was 
covered with a pierced cap containing 5 holes of ca. 5 mm diameter, allowing the DHB 
matrix to air dry at room temperature in a controlled manner. Samples were analyzed 
on an Ultraflex II MALDI-TOF/TOF-MS (Bruker Daltonics), and mass spectra were 
processed with flexAnalysis software (Bruker Daltonics) as described previously.148 
Similarly, N-glycans were eluted from cotton HILIC SPE microtips, spotted directly 
onto an AnchorChip MALDI plate, allowed to air dry, and were overlaid with 1 µl 
DHB.
nanoLC-ESI-IT-MS(/MS) of fetuin. Tryptic fetuin digests (250 nl) were analyzed as 
described previously, with minor modifications.172 Briefly, separation was achieved on a 
Ultimate 3000 nanoLC system (Dionex, Amsterdam, The Netherlands) equipped with 
a reverse phase guard (C18 PepMap, 300 µm × 5 mm; Dionex) and analytical column 
(C18 PepMap, 3 μm; 75 μm × 100 mm; Dionex). The column was equilibrated at room 
temperature with eluent A (0.1% formic acid in water) at a flow rate of 300 nl/min. After 
injection of the samples, a gradient was applied to 25% eluent B (95% acetonitrile, 5% 
water) in 15 min and 70% eluent B at 25 min followed by an isocratic elution with 70% 
eluent B for 5 min. The separation was monitored by UV absorption at 215 nm. The LC 
system was interfaced to an Esquire HCTultra ESI-IT-MS (Bruker Daltonics, Bremen, 
Germany) by a metal nano-ESI sprayer (Proxeon Biosystems, Odense, Denmark). The 
MS was operated in the positive-ion mode at 1250 V. The solvent was evaporated at 
170°C with a nitrogen stream of 6 l/min. Ions from m/z 600-1600 were registered. 
Automatic fragment ion analysis was enabled, resulting in MS/MS spectra of the most 
abundant peaks. 
Results
IgG purification and tryptic cleavage. IgGs were affinity-captured from 2 µl of human 
plasma (containing ca. 20 µg IgG) in 96-well filter plates containing 5 µl of Protein 
A-Sepharose beads, followed by the elution of IgGs with 40 µl of 100 mM formic acid. 
While a previously described version of the protocol involves drying of the sample 
by vacuum centrifugation,4,148 this procedure was replaced in the current protocol 
by a neutralization step with ammonium bicarbonate. Tryptic cleavage of IgGs was 
performed by an overnight incubation at 37°C either with 200 ng sequencing grade 
modified trypsin or 400 ng TPCK-treated trypsin. IgG glycopeptides were purified 
by Sepharose HILIC SPE in 96-well plate format148 and analyzed by MALDI-TOF-
MS in the reflectron positive mode. The IgG Fc N-glycopeptide profiles obtained for 
the neutralization procedure were very similar to those observed with the previously 
described vacuum centrifugation procedure148 independent of the trypsin used (data 
not shown).
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Glycopeptide purification using cotton HILIC microtips. Cotton was evaluated for 
its potential as a stationary phase in HILIC SPE of IgG glycopeptides. To this end, a 
small piece of a cotton wool pad (approximately 500 µg) was packed into the end of 
a pipette tip (Figure 1). MALDI-TOF-MS profiles obtained from blank elutions using 
cotton HILIC SPE microtips were evaluated and found to be virtually identical to 
matrix controls (only matrix spotted). Moreover, no cotton wool-related contaminant 
peaks were detected in the MALDI-TOF-MS profiles (data not shown).
Next, the obtained SPE microtips were tested for HILIC mode enrichment of IgG 
glycopeptides. Specifically, acetonitrile was added to an aliquot (8 µl) of a tryptic digest 
of human plasma IgG (corresponding to ca. 2 µg intact IgG), and glycopeptides were 
adsorbed to the HILIC micro-SPE stationary phase. After three washes with 10 µl of 
83% acetonitrile containing 0.1% TFA, the retained glycopeptides were eluted directly 
onto a MALDI plate with 2 µl of water, followed by MALDI-TOF-MS profiling of 
IgG Fc N-glycopeptides. The obtained MALDI profiles represent the N-glycopeptide 
microheterogeneity of IgG1, 2 and 4 subclasses. Examples of the glycopeptide profiles 
registered by reflectron mode and linear mode MALDI-TOF-MS are shown in Figure 




1 cm 1 cm
Figure 1. Preparation of a cotton HILIC SPE microtip. From a cotton wool pad (A), approximately 
500 µg is taken (B) and pushed into a 10 µl pipette tip using a blunt metal needle (C). The cotton 
is pushed down into the end part of the tip (D).
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literature knowledge of IgG N-glycosylation.3,4,9,10,79,148 The most abundant signals were 
obtained for the glycopeptides of IgG2 followed by IgG1 and IgG4. While reflectron 
mode MALDI-TOF-MS analysis provided IgG glycopeptide spectra with isotopic 
resolution, only neutral glycoforms were observed. By contrast, linear mode MALDI-
TOF-MS allowed low resolution detection of both sialylated glycopeptides and species 
with neutral glycoforms.
In addition to cotton we evaluated 1 and 3 mm Whatman cellulose chromatography 
paper for IgG glycopeptide enrichment. Glycopeptide profiles were obtained which 
were similar to those observed with cotton (data not shown). However, due to 
complications with inserting small pieces of paper into microtips without blocking the 
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Figure 2. MALDI-TOF-mass spectrometric profiles of IgG glycopeptides prepared using 
cotton HILIC SPE microtips. Mass spectra were registered in reflectron positive mode using 
CHCA matrix (A) and in linear positive mode using DHB matrix (B). Continued arrows, IgG1 
glycopeptides; dashed arrows, IgG2 glycopeptides; glycan code as in Figure 1 of Chapter 1.
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Validation of cotton HILIC micro-SPE. One cotton HILIC microtip was used 8 times 
for glycopeptide purification from a tryptic IgG digest pool followed by reflectron mode 
MALDI-TOF-MS of the eluted glycopeptides (Figure S-1 A and B). This experiment was 
repeated on four different days using each time a new cotton HILIC SPE tip. In another 
set of experiments, 8 different tips were used for IgG Fc N-glycosylation profiling from 
the above-mentioned tryptic IgG digest pool (Figure S-1 C and D). This experiment 
was also repeated on four different days using new tips for each experiment. Highly 
reproducible IgG Fc N-glycosylation profiles were obtained after cotton HILIC micro-
SPE, independent of using the same tip repeatedly or using different tips for micro-
scale purification.
Validation of the complete method. IgG Fc N-glycosylation profiling was performed 
in parallel on eight plasma aliquots of a control individual. This involved Protein A 
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Figure 3. Repeatability of IgG1 glycopeptide profiling applying cotton HILIC SPE microtips. 
IgG1 glycopeptides were detected by MALDI-TOF-MS in reflectron positive mode using CHCA 
matrix (A, C) and in linear positive mode using DHB matrix (B, D). Samples were prepared 
after digestion using the neutralization method followed by desalting with cotton HILIC SPE 
microtips prepared from three different brands of cotton wool pads (A, B). The resulting profiles 
were compared with the pattern of glycoforms purified by Sepharose beads or cotton HILIC SPE 
microtips after drying by vacuum centrifugation, and digestion with sequencing grade trypsin 
(C, D). For each independent experiment, relative intensities and standard deviations (STD) 
were calculated from 8 replicates. Glycan code as in Figure 1 of Chapter 1.
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HILIC micro-SPE, and MALDI-TOF-MS analysis. This procedure was repeated 
on three different days. Mass spectrometric analyses were performed in reflectron 
mode and linear mode, demonstrating that both IgG1 (Figure 3A and B) and IgG2 
(Figure S-2A and B) Fc N-glycosylation profiles could be registered with low intraday 
and interday variability. Next to the hitherto used cotton material, two other brands 
of cotton wool pads were used for HILIC SPE microtip preparation and IgG Fc 
N-glycosylation profiling. All three brands of cotton wool pads provided very similar 
results for both IgG1 (Figure 3A and B) and IgG2 (Figure S-2A and B). Moreover, the 
method was compared to a previously described approach.148 The major differences 
compared to the previous method are that (1) drying of Protein A eluates by vacuum 
centrifugation was replaced for a neutralization step, (2) sequencing grade trypsin was 
replaced by TPCK-treated trypsin, and (3) cotton HILIC micro-SPE was performed 
instead of 96-well plate HILIC SPE using Sepharose beads. A third approach combined 
the previously described sample preparation148 (i.e. protein A capturing, drying by 
vacuum centrifugation, and cleavage of IgG with sequencing grade trypsin) with 
cotton HILIC micro-SPE purification and reflectron mode MALDI-TOF-MS analysis. 
With all different protocols, very similar IgG1 (Figure 3C and D) and IgG2 (Figure 
S-2C and D) Fc N-glycosylation profiles were obtained by reflectron mode (Figure 3A 
and C and Figure S-2A and C) and linear mode MALDI-TOF-MS (Figure 3B and D 
and Figure S-2B and D).
In order to evaluate the suitability of cotton microtips for the purification of 
glycoconjugates with a high level of sialylation, we evaluated the performance of 
cotton HILIC micro-SPE and 96-well plate Sepharose HILIC SPE for glycopeptide 
extraction from a tryptic digest of bovine fetuin (5 µg). Reverse phase nanoLC-MS 
analyses of the HILIC micro-SPE (Figure 4B) and Sepharose (Figure 4C) eluates were 
dominated by glycopeptide signals and showed a glycopeptide pattern very similar to 
the one observed for the total fetuin tryptic digest (Figure 4A). Glycopeptides were 
identified and assigned based on MS and MS/MS data (Figure 4D). Non-glycosylated 
fetuin peptides were efficiently removed by both HILIC procedures: for example, fetuin 
peptides E29PACDDPDTEQAALAAVDYINK50 (at m/z 802.7 and 1203.6 in triple and 
double charged form; Figure 4A) and Q121DGQFSVLFTK131 (native at m/z 1269.7 and 
with pyroglutamate formation at m/z 1252.6, [M+H]+; Figure 4A) were absent from 
the HILIC eluates (Figure 4B and C). Together with the results obtained for IgG, these 
data show that the two HILIC SPE methods employing Sepharose and cotton microtips 
are equally suitable for enriching sialylated as well as non-sialylated glycopeptides with 
both small and large peptide moieties.
Glycan purification using cotton HILIC SPE microtips. As another field of application 
we tested the use of cotton HILIC SPE microtips for sample preparation of PNGase-F 
released glycans for MALDI-TOF-MS. N-glycans were enzymatically released from 
human IgG and human transferrin samples containing detergents (SDS, NP-40) and salts 
(PBS). Both neutral and acidic (sialylated) N-glycans were detected by MALDI-TOF-MS 
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after cotton HILIC micro-SPE purification whilst direct MALDI-TOF-MS analysis of the 
glycan release samples without SPE purification did not allow registration of N-glycans 
but was dominated by detergent clusters (Figure S-3). Hence, these experiments 
demonstrated the successful clean-up of N-glycan release samples for MALDI-TOF-MS 
analysis by removing detergents and salts with cotton HILIC SPE microtips.
Cotton HILIC SPE microtip capacity and recovery. To evaluate the capacity and 
recovery of the developed cotton SPE microtips, a dilution series of 2-AA labeled 
maltoheptaose was prepared with and without cotton micro-SPE and analyzed by 
HPLC-Flu. Initially, the 2-AA labeled maltoheptaose dilution series was prepared 
with the original cotton micro-SPE conditions using 83% acetonitrile. While this 
revealed a linear relation over the entire dilution curve (data not shown) recoveries 
were low (average recovery ~ 40%). By increasing the acetonitrile concentration to 
90% the 2-AA labeled maltoheptaose recoveries could substantially be increased 
(average recovery 82% when employing 2-AA labeled maltoheptaose amounts of 
up to 2.5 µg (Figure S-4). When 10 µg of 2-AA labeled maltoheptaose were used, a 
recovery of approximately 50% was observed, indicating that the capacity is at least 
5 µg 2-AA labeled maltoheptaose per 500 µg cotton. In addition, graphitized carbon 
nanoLC-MS176 was employed to analyze the cotton HILIC micro-SPE efficacy of native 
(unlabeled) maltoheptaose resulting in an average recovery of 94% when applying up 


























































Figure 4. Reverse phase nanoLC-MS analysis of a tryptic fetuin digest without purification 
(A) and after additional HILIC purification by cotton micro-SPE (B) or Sepharose (C). Tryptic 
glycopeptides covering all three N-glycosylation sites of fetuin were observed (D).173,174 *, Fetuin 
SwissProt entry number; ¥, signals related from peptides; **, cleavage between H and V175; glycan 
code as in Figure 1 of Chapter 1.
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Discussion
We here established cotton wool HILIC microtips for the purification of glycopeptides 
with various degrees of sialylation and peptide moieties of different sizes. In addition, 
cotton HILIC micro-SPE was applied to purify neutral and sialylated N-glycans 
released by PNGase-F followed by mass spectrometric detection. Similar to Poly HEA 
and carbohydrate HILIC stationary phases such as Sepharose and microcrystalline 
cellulose, cotton wool is a non-ionic, neutral stationary phase, and HILIC retention is 
expected to be caused solely by hydrogen bonding.139 By contrast, ionic interactions may 
contribute to HILIC retention on ZIC-HILIC as well as amine-based stationary phases, 
which may be modulated by the addition of salt and/or ion-pairing reagents.138,139
Cotton wool microtips are cheap and can easily and quickly be prepared in every 
lab. Microtips have been introduced with various stationary phases,177,178 including 
ZIC-HILIC microtips.179 In contrast to some other microtips,178,179 the cotton stationary 
phase stays in position, both with liquid aspiration and dispension. Moreover, the 
stationary phase appeared to be compatible with acidic and high acetonitrile conditions.
Raw cotton is mainly composed of cellulose (over 90%).180 Cotton is used in a variety 
of commercial products such as clothing, cotton swabs (q-tips) and cotton wool pads. 
For the manufacturing of cotton wool for pads and q-tips, the raw cotton is subjected 
to extensive bleaching after which the fibers are carded, randomized and treated with 
water at high pressure to cross and tie the fibers. During the manufacturing process 
traces of wax and proteins are removed from cotton, and as a result cotton wool pads 
are composed of virtually pure cellulose.
The cotton wool HILIC micro-SPE procedure was used for the extraction of Fc 
N-glycopeptides from human tryptic plasma IgG digests followed by MALDI-TOF-
MS analysis. The method showed good repeatability and did not appear to depend on 
a specific brand or batch of cotton wool pads. The results were very similar to those 
obtained previously after 96-well plate sample preparation of IgG glycopeptides using 
either reverse phase-SPE desalting, or HILIC SPE purification with Sepharose and 
microcrystalline cellulose.148 When analyzed in reflectron mode MALDI-TOF-MS, 
no registration of sialylated glycopeptides was achieved due to loss of sialic acids by 
in-source and metastable decay. By contrast, in linear mode MALDI-TOF-MS the lack of 
an extraction delay strongly reduced in-source decay, and metastable decay products are 
not resolved from their precursor ions, allowing detection of sialylated glycopeptides.
Next to establishing the HILIC SPE microtips, we introduce two additional 
modifications to a previously described IgG Fc N-glycosylation profiling protocol.148 
First, tryptic cleavage was performed using TPCK-treated trypsin instead of the 
more expensive sequencing-grade trypsin. Second, the rather laborious vacuum 
centrifugation step, which was applied to remove formic acid from the Protein A 
eluates, has been substituted by a simple neutralization, making the protocol easier 
and more suitable for automation.
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The here described cotton wool microtips are convenient devices for simple and 
fast sample preparation of tryptic IgG digests, and allow the determination of IgG Fc 
N-glycosylation features such as galactosylation, sialylation, fucosylation, and incidence 
of bisecting N-acetylglucosamine by MALDI-MS analysis. IgG Fc N-glycosylation 
has an important biological role in modulating both antibody-dependent cellular 
cytotoxicity and complement-dependent cytotoxicity.181 Hence, IgG Fc N-glycosylation 
of biotechnologically produced IgGs is being designed in order to maximize the 
efficacy in e.g. anti-cancer therapy (next generation therapeutic antibodies). Cotton 
wool microtips are particularly convenient tools for the preparation of low amounts 
of samples for mass spectrometric analysis and may be applied in (1) IgG Fc 
N-glycosylation profiling of clinical samples which often show disease-associated IgG 
glycosylation changes,15,22,24,67,147 and (2) analysis of recombinantly expressed IgG. 
Carbohydrate-based stationary HILIC phases have previously been used for total 
plasma N-glycome analysis by mass spectrometry.85,94 2-AA labeled N-glycans are 
purified from the labeling mix which contains excess label, reducing agent, various 
salts, plasma lipids, and large amounts of detergents together with denatured proteins, 
followed by glycan detection using MS.85,94 Notably, cotton wool microtips are likewise 
suitable for removal of salts and detergents after enzymatic N-glycan release which, 
together with the high capacity and favorable SPE elution conditions, resulted in 
efficient mass spectrometric detection of N-glycans (Figure S-3). 
Cotton wool microtips may serve as sample clean-up devices in glycomics and 
proteomics applications in which denaturants and surfactants are often added to 
improve protein solubility and proteolytic cleavage.143,182-186 Moreover, we expect that 
the tips could provide a valuable tool for the enrichment of other hydrophilic molecules 
as well. Minor modifications of the here presented protocol may, however, be required. 
While cotton wool HILIC microtips appear to be a good choice for processing low 
numbers of samples, they may be applicable to larger numbers of samples by using 
multi-channel pipettes or by transferring the SPE method to a robotic platform.
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Figure S-1. Repeatability of cotton HILIC microtips for desalting and purification of IgG 
glycopeptides. Analysis was performed by reflectron mode MALDI-TOF-MS with CHCA 
matrix. A tryptic IgG digest pool was desalted 8 times either with one cotton HILIC microtip (A 
and B) or with eight different cotton HILIC microtips (C and D). The experiment was repeated 
on four different days. Glycan code as in Figure 1 of Chapter 1.
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Figure S-2. Repeatability of IgG2 glycopeptide profiling applying cotton HILIC SPE microtips. 
IgG2 glycopeptides were detected by MALDI-TOF-MS in reflectron mode using CHCA matrix 
(A, C) and in linear mode using DHB matrix (B, D). Samples were prepared after digestion using 
the neutralization method followed by desalting with cotton HILIC SPE microtips prepared 
from three different brands of cotton wool pads (A, B). The resulting profiles were compared 
with the pattern of glycoforms purified by Sepharose beads or cotton HILIC SPE microtips after 
drying by vacuum centrifugation, and digestion with sequencing grade trypsin (C, D). For each 
independent experiment relative intensities and STDs were calculated from 8 replicates. Glycan 






























































































































Figure S-3. MALDI-TOF-MS of N-glycans after cotton HILIC micro-SPE purification. N-glycans 
enzymatically released from IgG (A-F) and human transferrin (G, H) were analyzed by MALDI-TOF-MS 
in the reflectron positive mode (A, B), linear positive mode (C, D), and linear negative mode (E-H) without 
(left panels: A, C, E, G) and with (right panels: B, D, F, H) purification by cotton HILIC micro-SPE. Glycans 
were registered as sodium adducts in positive-ion mode and as deprotonated species in negative-ion mode. 
*, Potassium adducts; glycan code as in Figure 1 of Chapter 1.
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Figure S-4. Cotton HILIC microtip capacity and recovery. HILIC-Flu analysis of a 2-AA labeled 
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Abstract
Immunoglobulin G Fc glycosylation is essential for Fcγ-receptor mediated activities. 
Changes in IgG Fc glycosylation have been found to be associated with various diseases. 
Here we describe a high-throughput IgG glycosylation profiling method. Sample 
preparation is performed in the 96-well plate format: IgGs are purified from 2 ml of 
human plasma using immobilized Protein A. IgGs are cleaved with trypsin, and the 
resulting glycopeptides purified by reverse phase or hydrophilic interaction solid-phase 
extraction. Glycopeptides are analyzed by intermediate pressure MALDI-FTICR-MS. 
Notably, both DHB and CHCA matrices allowed the registration of sialylated as well 
as non-sialylated glycopeptides. Data were automatically processed, and IgG isotype-
specific Fc glycosylation profiles were obtained. The entire method showed an interday 
variation below 10% for the 6 major glycoforms of both IgG1 and IgG2. The method 
was found suitable for isotype-specific high-throughput IgG glycosylation profiling 
from human plasma. As an example we successfully applied the method to profile the 





In human polyclonal immunoglobulin Gs (IgG) are present in high abundances (total 
concentration ca. 10 mg/ml plasma). Each IgG molecule consists of 4 polypeptide 
chains, i.e., two heavy chains and two lights chains. IgGs occur in four subclasses 
(IgG1, IgG2, IgG3, and IgG4)4 which all carry N-glycans at asparagine 297 in the 
conserved CH2 region of the fragment crystallizable (Fc) part of their heavy chains. Fc 
N-glycans of human IgG are bi-antennary complex-type structures which often carry a 
core-fucose.147 The N-glycans vary in the number of galactose residues and are referred 
to as G0F (no galactoses), G1F (one galactose), and G2F (2 galactoses). A small portion 
of the N-glycans may contain a sialic acid residue on the antennae and/or a bisecting 
N-acetylglucosamine.147 
The biological activity of IgG is modulated by its Fc N-glycosylation. First, lack 
of core-fucoses on the Fc N-glycans of IgG1 may lead to a drastic enhancement of 
antibody-dependent cellular cytotoxicity (ADCC).43,44 Therefore, glycosylation of 
therapeutic antibodies is often engineered to achieve lower core-fucosylation and 
high ADCC activity.5,46 Second, as shown in a mouse arthritis model35,47,48 the anti-
inflammatory properties of intravenous immunoglobulin are dependent on sialylation 
of the Fc N-glycans. For a variety of diseases147 such as rheumatoid arthritis,3,14 Crohn’s 
disease,21,27 and HIV infection31 IgG galactosylation has been shown to be low. Moreover, 
in healthy individuals age, gender, and pregnancy are reflected by IgG glycosylation 
features.4,8-10,13,14
IgG glycosylation analysis is important for the characterization of monoclonal 
therapeutic antibodies as well as the determination of glycosylation changes of 
polyclonal IgGs as part of humoral immune responses. Two potential strategies 
to determine IgG Fc N-glycosylation are analysis of glycopeptides or released 
N-glycans by mass spectrometry (MS).77,147 Although both strategies provide valuable 
information regarding N-glycan heterogeneity, only IgG glycopeptide analysis allows 
discrimination between different IgG subclasses and provides N-glycan profiles that are 
Fc specific.4 Analysis of IgG glycopeptides is often performed by reverse phase liquid 
chromatography (RP-HPLC)4,50,79 or hydrophilic interaction liquid chromatography 
(HILIC)92 coupled to MS. LC-MS analyses provide very detailed IgG Fc glycosylation 
profiles, yet these methods suffer from relatively long analysis times and extensive 
data processing. Another strategy to determine IgG glycopeptide microheterogeneity 
involves analysis by matrix-assisted laser desorption (MALDI)-MS.77,102,119 While 
MALDI-MS is inherently suited for high-throughput analysis, complementation 
with high-throughput sample preparation and data processing techniques is required 
for high-throughput IgG glycosylation analysis. Other challenges in automated, 
high-throughput MALDI-MS analysis include controlled matrix crystallization and 
minimization of in-source and metastable decay in order to retain the labile sialic acid 
groups. 
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Here, we address these challenges and describe the development, validation, 
and application of a high-throughput IgG glycosylation profiling method by 
intermediate pressure MALDI Fourier transform ion cyclotron resonance (FTICR) 
MS of glycopeptides. The entire high-throughput sample preparation procedure (IgG 
capturing, cleavage, desalting and purification) is performed at the 96-well plate level. 
The developed method was applied to IgG Fc glycopeptide profiling of 62 human 
samples.
Experimental section
IgG purification. IgGs were affinity captured from total human serum or plasma 
according to Wuhrer et al. 2007, with minor modifications.4 Briefly, rProtein 
A-SepharoseTM Fast Flow beads (90 µm; GE Healthcare, Eindhoven, the Netherlands) 
were washed three times with 10 volumes of PBS. To each well of a 96-well filter plate 
(Multiscreen Solvinert, 0.45 µm pore-size low-binding hydrophilic PTFE; Millipore, 
Billerica, MA), 50 µl of slurry containing ca. 15 µl beads, 150 µl PBS and 2 µl serum 
were applied. The plate was sealed with adhesive tape and incubated on a shaker for 
1 hour at room temperature. After incubation, the beads were washed on a vacuum 
manifold with 3x 200 µl PBS and 3x 200 µl water. Captured IgGs (IgG1, IgG2, and 
IgG4) were eluted into a V-bottom microtitration plate with 100 µl of 100 mM formic 
acid (Fluka, Steinhem, Germany). Samples were dried by vacuum centrifugation before 
trypsin digestion.
Trypsin digestion. Captured IgGs were dissolved in 20 µl of 50 mM ammonium 
bicarbonate buffer (Fluka) containing 15% acetonitrile (ACN; Biosolve BV, 
Valkenswaard, the Netherlands), and shaken for 10 minutes. To minimize potential 
autolysis, lyophilized sequencing grade modified trypsin (Promega, Madison, WI) was 
first dissolved in ice-cold 20 mM acetic acid (Merck, Darmstadt, Germany) to a final 
concentration of 0.2 µg trypsin per µl. Trypsin was further diluted to 0.01 µg trypsin 
per µl with ice-cold 15% ACN, and immediately 20 µl was added to the IgG samples. 
Samples were shaken for 1 minute, checked for the correct pH (>6) and incubated 
overnight at 37ºC. Glycopeptides were desalted and purified by 96-well solid phase 
extraction (SPE) with RP or HILIC.
RP-SPE. For RP desalting and purification, 5 mg Chromabond C18end material (45 
µm; Macherey-Nagel, Düren, Germany) was applied to each well of an OF1100 96-well 
polypropylene filter plate with a 10 µm polyethylene frit (Orochem Technologies Inc., 
Lombard, IL). The RP stationary phase was activated and conditioned with 3x 200 µl 
80% ACN containing 0.1% trifluoroacetic acid (TFA; Fluka) and 3x 200 µl 0.1% TFA, 
respectively. Whole IgG digests (40 µl) were diluted 10x in 0.1% TFA, loaded onto the 
C-18 beads, and washed with 3x 200 µl 0.1% TFA. The entire procedure was performed 




peptides were eluted into a V-bottom microtiter plate by centrifugation at 500 rpm with 
60 µl of 18% ACN containing 0.1% TFA. Samples were dried by vacuum centrifugation, 
reconstituted in 60 µl water and stored at -20ºC until analysis by MALDI-MS. 
HILIC-SPE. For HILIC desalting and purification, 5 mg cellulose microcrystalline 
particles for column chromatography (Merck) or 5 µl Sepharose Cl-4B beads (45-165 
µm; GE Healthcare, Uppsala, Sweden) were applied to each well of a 96-well filter plate 
(Multiscreen Solvinert, 0.45 µm pore-size low-binding hydrophilic PTFE; Millipore, 
Billerica, MA). The HILIC stationary phases were activated and conditioned with 2x 
200 µl of water and 2x 200 µl 83% ACN, respectively. Whole IgG digests (40 µl) were 
diluted with ACN to a final concentration of 83% ACN, loaded to the HILIC stationary 
phases and shaken for 5 minutes. SPE activation, conditioning and sample loading 
were performed on a vacuum manifold under slight pressure reduction of ca. 3 mbar. 
The captured IgG glycopeptides were washed and eluted at 170 mbar vacuum with 3x 
200 µl 83% ACN with 0.1% TFA, 3x 200 µl 83% ACN and 3x 30 µl water, respectively. 
All samples were stored at -20ºC until MALDI-MS analysis.
Preparation of MALDI samples. For MALDI-MS analysis, purified and desalted 
tryptic (glyco)peptides (1 µl) were spotted onto polished stainless steel or AnchorChip 
600/384 MALDI plates (Bruker Daltonics, Bremen, Germany). Samples spotted onto 
AnchorChip MALDI plates were overlaid with 1 µl dihydroxybenzoic acid (DHB, 5 
mg/ml 50% ACN with 0.1% TFA), and samples spotted onto polished stainless steel 
MALDI plates were overlaid with 1 µl α-cyano-4-hydroxycinnamic acid (CHCA, 5 mg/
ml 50% ACN). The AnchorChip plates were covered with a pierced cap containing 
5 holes of ca. 5 mm (i.d) and both matrixes were allowed to dry in air at room 
temperature. Samples were analyzed on an Ultraflex II MALDI-TOF/TOF-MS and on 
an APEX-ultra 9.4 tesla FTICR-MS (Bruker Daltonics).
MALDI-TOF-MS. Analysis by MALDI-TOF-MS was performed in the reflectron 
positive and linear positive mode. The samples were irradiated by a smartbeam™ 200 
Hz solid-state laser. The acceleration voltage was 25 kV, and the ions between m/z 
1300-4600 were recorded. Each mass spectrum was generated by summing the ions of 
2000 laser shots. To allow homogeneous spot sampling a random walk laser movement 
with 50 laser shots per raster spot was applied. The laser intensity was optimized to 
give the best signal-to-noise ratio and resolution for each sample. During automatic 
MALDI-TOF-MS the masses between 2000-3500 Dalton (Da) were evaluated after 
every set of 100 laser shots. Evaluation in the reflectron mode was performed by a 
SNAP peak detection algorithm with a Signal to Noise Threshold of 6, Quality Factor 
Threshold of 50 and a TopHat baseline subtraction. During linear mode MALDI-TOF-
MS evaluation was performed by a centroid peak detection algorithm with a Signal to 
Noise Threshold of 3, a Peak Width of 1 m/z, a Height of 80%, and a TopHat baseline 
subtraction. All sets of 100 laser shots not fitting these criteria were not added to the 
sum spectrum. All data processing and evaluation were performed with flexAnalysis 
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Software (Bruker Daltonics) and Microsoft Excel, respectively. Typically, reflectron 
positive and linear positive spectra were calibrated internally followed by peak picking 
using the interactive SNAP and interactive centroid algorithm, respectively. 
MALDI-FTICR-MS. The 9.4 tesla FTICR APEX-ultra mass spectrometer was equipped 
with a dual ESI/MALDI ion source (Apollo II) incorporating a quadrupole mass filter 
and a smartbeam™ laser system. The MALDI source is at intermediate pressure enabling 
the detection of the labile glycosylated peptides.144 All experiments used a laser spot size 
of approximately 150 µm, laser fluence slightly above threshold and a laser repetition 
rate of 200 Hz. The quadrupole was operated in RF-only mode with the selection 
mass set to m/z 2500, thus ejecting all ions below m/z 1800. The MALDI-FTICR-MS 
experiments utilized a customized experiment sequence (the pulse program). Briefly, 
the ions produced from 50 laser shots were accumulated in a hexapole and then 
transferred through the RF-only quadrupole to the collision cell. The sample stage was 
then moved 200 µm and fresh sample interrogated with the next 50 laser shots. This 
cycle was performed 9 times, effectively accumulating ions from 450 laser shots in 
the collision cell. The accumulated ions were then transferred to the ICR cell for a 
mass analysis scan. Each spectrum is the sum of 8 such scans. All data were acquired 
using Bruker ApexControl 3.0.0 software in expert mode. Mass spectra were internally 
calibrated using a list of known glycopeptides and Bruker DataAnalysis 3.4 in batch 
mode. After calibration, the spectra were exported to an ASCII format consisting of 
pairs of m/z and intensity values in two columns. A list of pre-defined features were 
then extracted from each spectrum and merged to a complete data matrix using the 
in-house developed software “Xtractor”. As input, Xtractor takes a mass spectrum in 
the ASCII format and a list of pre-defined peaks or m/z windows. The program then 
integrates the peaks by summing all intensities in the defined windows. The software 
is freely available at www.ms-utils.org/Xtractor. The complete sample-data matrix was 
finally evaluated using Microsoft Excel.
MALDI-FTICR-MS glycopeptide profiling of a human sample cohort. Twenty 
human sera (12 male, 8 female) and 42 human citrate plasma samples (20 male, 22 
female) were obtained from volunteers ranging in age between 22 and 79 years. As no 
selection on the health status was performed, prevalence of diseases which are known 
to interfere with IgG glycosylation (autoimmune diseases, inflammatory diseases, 
and cancer)147 is assumed to be low within the cohort. Human polyclonal IgGs were 
purified by Protein A affinity chromatography and digested overnight with trypsin. 
The resulting glycopeptides were desalted by Sepharose SPE, spotted on a polished 
stainless steel MALDI target plate, overlaid with CHCA, and analyzed by MALDI-
FTICR-MS. Spectra were processed automatically and data evaluation was performed 





IgG glycopeptide profiling by MALDI-MS. To evaluate the potential of MALDI-MS 
for high-throughput profiling of IgG glycosylation at the glycopeptide level, human 
polyclonal IgGs were captured from the plasma of a volunteer using immobilized 
protein A. The captured IgGs were digested overnight with trypsin in the presence of 
ACN to ensure maximum trypsin activity. Desalting and purification of the tryptic 
glycopeptides was performed by C18 SPE, and the IgG glycopeptides were spotted, 
overlaid with matrix and analyzed by different MALDI-MS techniques. First, the 
N-glycopeptide profiles were determined by MALDI-TOF-MS in the linear positive 
mode. To this end, IgG glycopeptides were spotted onto an AnchorChip target plate 
and overlaid with DHB. The target plate was covered with a pierced cap to slow down 
and control the drying process. This resulted in a dense and rather homogeneous 
preparation of DHB crystals and improved the spot to spot reproducibility during 
automatic measurement. The profiles obtained represent the tryptic N-glycopeptide 
microheterogeneity of IgG1, 2 and 4 subclasses (Figure 1A). Structural assignment 
of the detected glycoforms was performed on the basis of literature knowledge of 
IgG N-glycosylation.3,4,9,10,79,148 The most abundant signals were obtained for the 
glycopeptides of IgG2 followed by IgG1 and IgG4. Sialylated glycopeptides were detected 
next to species with neutral glycoforms. Isotopic resolution could not be achieved with 
linear mode MALDI-TOF-MS. Second, the IgG glycopeptide profile was determined 
with reflectron positive MALDI-TOF-MS using DHB (data not shown) and CHCA 
matrix (Figure 1B). The two matrices resulted in similar IgG glycopeptide profiles with 
isotopic resolution. IgG glycopeptide profiles were similar to those obtained with linear 
positive MALDI-TOF-MS, except sialylated glycopeptides could not be detected in the 
reflectron mode. Third, high mass resolution detection glycopeptides was achieved by 
MALDI-FTICR-MS using DHB and CHCA as matrix (Figure 1C and D). The DHB 
overlaid samples provided signals for all glycopeptides including the sialylated species 
which were similar to those obtained during linear positive MALDI-TOF-MS. Notably, 
the samples prepared with CHCA also allowed the detection of sialylated glycopeptides 
(Figure 1D), albeit at a lower relative intensity than with the DHB matrix (Figure 1C). 
A wide range of Fc N-glycopeptides could unambiguously be assigned to IgG1, 2 and 
4 by high resolution MALDI-FTICR-MS (Table 1). Spectra were characterized by a 
particularly good signal-to-noise ratio.
In conclusion, the different MALDI-MS techniques provided similar IgG 
glycopeptide profiles. Major differences were only observed for sialylated glycopeptides, 
which were not observed by MALDI-TOF-MS in the reflectron positive mode. The 
high resolution, excellent signal-to-noise ratio, and the possibility to profile both 
sialylated and non-sialylated glycopeptides independent of the MALDI matrix used, 
made intermediate pressure MALDI-FTICR-MS extremely suited for IgG glycopeptide 
profiling.
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Table 1. Tryptic glycopeptides of human IgG subclasses 1, 2 and 4.
Glycan species IgG1 P01857c [M+H]+ IgG2 P01859c [M+H]+ IgG4 P01861c [M+H]+
no glycan 1189.5120 1157.5222 1173.5171
G0Fd 2634.0459b1 2602.0561 2618.0510a1
G1F 2796.0987b2 2764.1089 2780.1038a2
G2F 2958.1515 2926.1617 2942.1566
G0FN 2837.1253b3 2805.1355 2821.1304a3
G1FN 2999.1781b4 2967.1883 2983.1832a4
G2FN 3161.2309 3129.2411 3145.2360
G1FS 3087.1941b5 3055.2043 3071.1992a5
G2FS 3249.2469 3217.2571 3233.2520
G0 2487.9880 2455.9982 2471.9931
G1 2650.0408 2618.0510a1 2634.0459b1
G2 2812.0936 2780.1038a2 2796.0987b2
G0N 2691.0673 2659.0775 2675.0724
G1N 2853.1202 2821.1304a3 2837.1253b3
G2N 3015.1730 2983.1832a4 2999.1781b4
G1S 2941.1362 2909.1464 2925.1413
G2S 3103.1890 3071.1992a5 3087.1941b5
a1 – a5isomeric glycopeptide species of IgG4 and IgG2.
b1 – b5isomeric glycopeptide species of IgG1 and IgG4.
cSwissProt entry number
dglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
Repeatability MALDI mass analyzers. To determine the repeatability of the various 
MALDI mass analyzers, the IgG glycopeptide sample described above was spotted 
eight times onto an AnchorChip target plate and a polished stainless steel target 
plate, overlaid with matrix and analyzed by linear positive MALDI-TOF-MS (DHB), 
reflectron positive MALDI-TOF-MS (CHCA) and MALDI-FTICR-MS (DHB and 
CHCA). This experiment was performed three times each on different days. Mass 
spectra were processed automatically which involved internal calibration, baseline 
subtraction (MALDI-TOF only), and peak picking. The best interday repeatability 
was observed for the MALDI-TOF-MS techniques, providing less than 5% relative 
standard deviation (RSD) of the normalized peak heights for the 6 major glycoforms of 
both IgG1 and IgG2 independent of the matrix used (data not shown). For these major 
glycoforms, the interday repeatability test with MALDI-FTICR-MS, gave RSDs below 
10% with both matrices (data not shown). 
Sample preparation by RP-SPE. Desalting and purification of tryptic IgG glycopeptides 




Figure 1. Comparison of four MALDI-MS methods for profiling of purified tryptic IgG Fc 
glycopeptides. Profiling was performed after RP-SPE desalting by linear mode MALDI-TOF-MS 
with DHB (A), reflectron mode MALDI-TOF-MS using CHCA (B), and MALDI-FTICR-MS 
using DHB (C) and CHCA (D). Continued arrows, IgG1 glycopeptides; dashed arrows, IgG2 
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sample preparation. The IgG glycopeptides were eluted from the C-18 material 
with low concentrations of ACN in the presence of TFA, to minimize co-elution of 
interfering peptides. The robustness and repeatability of the entire analytical method 
including sample preparation (protein A affinity, digestion and C-18 SPE) and mass 
spectrometry was assessed by performing three independent experiments comprising 
eight replicates each. In all three experiments, the eight replicates were spotted both 
on an AnchorChip and on a polished stainless steel target plate, overlaid with matrix, 
and analyzed by the different MALDI-MS techniques. Within the three experiments, 
the intraday variability was determined for IgG1 (Figure 2) and IgG2 (Figure S-1). 
For both IgG1 and IgG2, the RSDs of the normalized peak heights for the 6 major 
glycoforms were below 5% with MALDI-TOF-MS and below 10% with MALDI-
FTICR-MS. Moreover, the interday repeatability was determined by comparing the 





































Figure 2. Repeatability of 96-well RP-SPE for desalting and purification of tryptic IgG1 Fc 
glycopeptides. Analysis was performed by linear mode MALDI-TOF-MS with DHB (A), reflectron 
mode MALDI-TOF-MS using CHCA (B), and MALDI-FTICR-MS using DHB (C) and CHCA 
(D). Relative intensities and standard deviations (STD) were determined from three independent 




5% with MALDI-TOF-MS and below 10% with MALDI-FTICR-MS for both IgG1 and 
IgG2. No difference was observed between the measurement variability and the intra- 
and interday variability of the sample preparation, independent of the MALDI-MS 
technique used. This indicated that the variability of the sample preparation was below 
the 5% measurement variability observed for MALDI-TOF-MS.
Sample preparation by HILIC-SPE. In an effort to simplify the sample preparation 
for high-throughput IgG glycopeptide profiling, we replaced the RP-SPE step by HILIC-
SPE. In the RP-SPE protocol, elution of IgG glycopeptides is achieved with ACN/water 
in the presence of TFA. To prevent acidic hydrolysis of sialylated glycopeptides and to 
simplify sample spotting, a 1 to 2 hours drying step by vacuum centrifugation is required 
to remove the acid. Samples are then dissolved in water. With HILIC-SPE, elution can 
be achieved with water, thus bypassing the long drying step. The potential of cellulose 
and Sepharose SPE at the 96-well filter plate level was evaluated for high-throughput 
IgG glycopeptide desalting and purification. The two HILIC stationary phases were pre-
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Figure 3. MALDI-FTICR-MS analysis of Sepharose-SPE purified and desalted tryptic IgG 
glycopeptides using DHB (A) and CHCA (B) as matrix substance. Continued arrows, IgG1 
glycopeptides; dashed arrows, IgG2 glycopeptides; glycan code as in Figure 1 of Chapter 1. 
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washed with water and conditioned with 80% ACN. Tryptic IgG digests were diluted 
with ACN to a final concentration of 80% ACN, loaded onto the two HILIC stationary 
phases, washed with 80% ACN and eluted with water. Compared to IgG glycopeptide 
profiles after RP-SPE, lower relative intensities were obtained for agalactosylated and 
sialylated glycopeptides (data not shown). To determine the reason for this signal 
reduction the samples were additionally purified by RP-SPE, after HILIC-SPE. This had 
no effect for the agalactosylated glycopeptides, but it completely restored the relative 
intensities for all sialylated glycopeptides (data not shown). This indicated that the 
lower relative intensities for sialylated glycopeptides after HILIC-SPE were caused by 
mass spectrometric signal suppression.187 We eliminated the suppression by including 
an extra washing step with ACN containing 0.1% TFA. Next, we tested different 
ACN concentrations in the washing steps to avoid potential losses of agalactosylated 
glycopeptides known to have the lowest retention on HILIC.140 We found that for both 





































Figure 4. Repeatability of 96-well Sepharose-SPE for desalting and purification of tryptic IgG Fc 
glycopeptides. Analysis of IgG1 (A and B) and IgG2 (C and D) glycopeptides was performed by 
MALDI-FTICR-MS using DHB (A and C) and CHCA (B and D). Relative intensities and STDs 
were determined from three independent experiments comprising eight replicates each. Glycan 




washing steps consistently resulted in N-glycopeptide profiles (Figure 3 and Figure 
S-2) similar to those obtained after RP-SPE (Figure 1D). 
Robustness and repeatability were similar for HILIC-SPE (Figure 4 and Figure 
S-3) and RP-SPE (Figure S-1D). Hence, we concluded that RP-SPE followed by the 
time-consuming vacuum centrifugation and dissolving of the samples in water could 
be replaced by HILIC-SPE, resulting in a considerable simplification of the protocol. 
While similar N-glycopeptide profiles were obtained with cellulose and Sepharose SPE, 
the latter was chosen for further application due to more homogeneous particle sizes 
which allowed a faster and more constant flow.
IgG glycopeptide profiling of a human sample cohort. The developed technique 
was used to analyze IgG glycosylation from samples of 62 individuals (32 male and 30 
female) in an age range between 22 and 79 years. We chose for 96-well plate HILIC-SPE 
with Sepharose beads and spotted the samples on a polished stainless steel MALDI 
target plate. Samples were overlaid with CHCA matrix and analyzed by MALDI-
FTICR-MS, and the resulting spectra were processed automatically. The obtained data 
showed an increase of the relative abundances of IgG1 G0F and IgG2 G0F glycoforms 
with age (Figure 5A and E) which was in accordance with literature.8-10 Glycoforms 
exhibiting two galactoses, in contrast, were lower at higher age, which was true for G2F 
species (Figure 5B and F) as well as for their sialylated counterparts, G2FS (Figure 5C 
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Figure 5. Changes in IgG glycosylation with age. IgG Fc N-glycan microheterogeneity was 
determined for a cohort of 62 individuals. The tryptic IgG glycopeptides were desalted and 
purified by Sepharose, spotted on a MALDI target plate, overlaid with CHCA, and analyzed 
by high resolution MALDI-FTICR-MS. Next to the age dependencies of G0F, G2F, and G2FS 
glycoforms of IgG1 and IgG2 (A-C and E-G), a correlation between G2F and G2FS was 
demonstrated (D and H).
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and G). Moreover, two tailed Pearson correlation analysis revealed a strong correlation 
(p-values < 0.001) between galactosylation of the IgG1 and IgG2 Fc N-glycans and the 
level of sialylation, as exemplified for the glycoforms G2F and G2FS (Figure 5D and H). 
We additionally observed a significant correlation between the incidence of bisecting 
N-acetylglucosamine and age (p-values < 0.001) with increasing levels of bisecting 
N-acetylglucosamine at higher age (Figure S-4).
Discussion
We developed and applied a high-throughput method for IgG glycosylation profiling 
comprising sample preparation, mass spectrometric analysis, and data processing. 
The entire sample preparation was performed using the 96-well plate format. Human 
polyclonal IgGs were captured and purified from total plasma or serum using 
immobilized protein A, and cleaved with trypsin. The obtained glycopeptides were 
desalted by SPE and analyzed with MALDI-MS. In a first version of the protocol 
desalting and purification of the obtained glycopeptides was achieved with RP-SPE. 
Elution was performed with 18% ACN containing 0.1% TFA. Because such acidic 
conditions quickly lead to partial desialylation of glycopeptides, samples were dried 
after RP-SPE by vacuum centrifugation and dissolved in water, before they were used 
for sample spotting and MALDI-MS analysis. In order to shorten and simplify the 
sample preparation method, and to avoid possible sources of sample contamination, 
we replaced the RP-SPE by HILIC-SPE. Both HILIC materials tested (cellulose and 
Sepharose) provided very selective glycopeptide enrichment, which was in accordance 
to literature.102,188 Compared to the RP-SPE, the HILIC-SPE method was easier and 
faster, as eluates did not have to be dried by vacuum centrifugation and dissolved in 
water prior to mass spectrometric analysis. Elution from HILIC was performed with 
water making the samples directly available for analysis and long term storage. For 
both RP-SPE and HILIC-SPE some non-glycopeptide signals were observed which did 
not interfere with glycopeptide signals (Table S-1).
To our knowledge, the Fc N-glycosylation sites of human plasma IgG are fully 
occupied. Recombinant expression of antibodies, however, may result in only partial 
occupation of Fc N-glycosylation sites, as has been shown for single-chain Fv-Fc 
antibodies expressed in Arabidopsis thaliana seeds.189 Therefore, monitoring of non-
glycosylated variants of the tryptic Fc peptides carrying the N-glycosylation consensus 
sequence may be desirable in some cases. Notably, implementation of this analysis 
into the presented workflow is not compatible with HILIC-SPE, as non-glycosylated 
peptides will be lost during this purification step. RP-SPE, however, should be suitable 
for this purpose, as glycosylated as well as non-glycosylated versions of the tryptic Fc 
peptides will elute together.
For high-throughput IgG glycopeptide analysis we compared MALDI-TOF-MS with 




using delayed extraction, sialylated glycopeptides showed massive desialylation due to 
in-source and metastable decay. By contrast, detection of sialylated glycopeptides was 
allowed by linear mode MALDI-TOF-MS, since the lack of an extraction delay strongly 
reduced in-source decay, and metastable decay products formed after ion acceleration 
were not separated from their precursor ions. However, in this configuration the 
glycopeptides from polyclonal human IgG were poorly resolved, undermining the 
relative quantification of the different glycoforms. By using a 9.4 tesla FTICR-MS 
equipped with an intermediate pressure MALDI source, IgG Fc glycopeptides could 
be ionized without in-source decay of sialic acids allowing high mass resolution 
profiling of all IgG Fc N-glycopeptides. Notably, also other MALDI-MS systems with 
intermediate pressure sources such as MALDI-quadrupole-TOF instruments are 
suitable for profiling of IgG Fc glycopeptides including sialylated IgG glycopeptides. 
Analysis of the IgG glycopeptide samples by MALDI ionization on a SYNAPT™ High 
Definition Mass Spectrometry™ system (Waters) gave glycopeptide profiles which were 
comparable to those obtained by MALDI-FTICR-MS (data not shown).
With MALDI-FTICR-MS DHB and CHCA matrix both provided very robust 
and reproducible IgG glycopeptide profiles of similar intensities, which were stable 
over a wide laser power range. Notably, sialylated glycopeptides were registered with 
both matrices. The DHB preparations provided higher relative intensities of sialylated 
glycopeptides than observed with CHCA, possibly as a result of the “colder” character 
of DHB190,191 or by differences in ionization efficiencies. This indicated that in-source 
and metastable fragmentation were effectively reduced due to a combination of 
collisional cooling and low acceleration voltages applied in the intermediate pressure 
MALDI source. To our knowledge this is the first time that IgG glycopeptide analysis 
with detection of sialylated species is reported with CHCA. This mass spectrometric 
method offers the possibility to use stainless steel MALDI target plates, which are 
cheaper, more robust and less prone to contamination. Furthermore, the big spots with 
homogeneous, microcrystalline sample preparation allow multiple repeated analyses 
of the same sample.
The entire method comprising IgG capturing, tryptic cleavage, desalting by 
HILIC-SPE with Sepharose, MALDI-FTICR-MS using a polished stainless steel plate 
and sample overlay with CHCA, and automatic spectra processing was validated. 
This showed an interday variability below 10%, which was mainly due to the mass 
spectrometric measurement and was similar to the results obtained with LC-MS.4 
Compared to LC-MS, however, MALDI-FTICR-MS analysis times are much shorter, 
and our method allows high-resolution IgG Fc glycosylation profiling of 384 samples 
in less than 36 hours, of which only roughly 18% account for the MALDI-FTICR-MS 
measuring time. 
Here, we applied the method for analyzing polyclonal human IgGs, which results in 
some ambiguities in peak assignment due to structural isomers, i.e., non-fucosylated 
glycopeptides of one IgG subclass showing exactly the same molecular composition as 
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fucosylated glycopeptides of another IgG subclass (Table 1). This effect will not occur 
when the method is applied for the analysis of bioengineered monoclonal therapeutic 
antibodies, for which unambiguous assignment of molecular compositions of Fc 
N-glycopeptides will be possible. 
IgG Fc N-glycans are known to show a low galactosylation in many diseases.147 
Moreover, IgG glycosylation features in healthy individuals reflect age, gender, and 
pregnancy.4,8-10,13,14 It was found that the percentage of agalactosylated IgG decreased 
during pregnancy and increased after delivery to values similar to those prior to 
conception.14 Moreover, IgG galactosylation has been found to be high at age 25 and 
is decreasing at higher age.8 Here, the developed high-throughput MALDI-FTICR-
MS method was successfully applied to profile IgG Fc glycosylation of a group of 62 
individuals. From these data, we were able to confirm the previous described age 
dependency of IgG galactosylation.8-10 We additionally observed an increased level for 
the incidence of bisecting N-acetylglucosamine with aging (Figure S-4), as described by 
Yamada et al..9 We did, however, not observe the described plateau reached at an age of 
50 years. Notably, next to the age dependency of galactosylation, we found a pronounced 
age-dependency of sialylation, with IgG Fc sialylation being lower in old individuals 
than in young individuals (Figure 5C and G). The G2F glycan structure represents the 
substrate of the sialyltransferase reaction which results in G2FS. Not surprisingly, our 
data revealed a strong and significant correlation between Fc N-glycan galactosylation 
(G2F) and sialylation (G2FS) for both IgG1 and IgG2 (Figure 5D and H). 
The IgG glycosylation analysis method described in this paper can handle large 
sample collections and reveals glycosylation features such as galactosylation, sialylation, 
fucosylation, and the incidence of bisecting N-acetylglucosamine in an IgG subclass-
specific manner. The method is suitable for revealing IgG glycosylation features in large 
clinical cohorts and population studies. Moreover, it can be applied to analyze the Fc 
glycosylation of recombinantly produced IgG. 
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Figure S-1. Repeatability of 96-well RP-SPE for desalting and purification of tryptic IgG2 Fc 
glycopeptides. Analysis was performed by linear mode MALDI-TOF-MS with DHB (A), 
reflectron mode MALDI-TOF-MS using CHCA (B), and MALDI-FTICR-MS using DHB (C) and 
CHCA (D). Relative intensities and STDs were determined from three independent experiments 
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Figure S-2. MALDI-FTICR-MS analysis of cellulose-SPE purified and desalted tryptic IgG 
glycopeptides using DHB (A) and CHCA (B) as matrix substance. Continued arrows, IgG1 








































Figure S-3. Repeatability of 96-well cellulose-SPE for desalting and purification of tryptic IgG 
Fc glycopeptides. Analysis of IgG1 (A and B) and IgG2 (C and D) glycopeptides was performed 
by MALDI-FTICR-MS using DHB (A and C) and CHCA (B and D). Relative intensities and 
STDs were determined from three independent experiments comprising eight replicates each. 









































































Figure S-4. Age related changes in the level of bisecting N-acetylglucosamine for IgG1 (A and B) and IgG2 (C and D). IgG Fc Nglycan
microheterogeneity was determined for a cohort of 62 individuals. The tryptic IgG glycopeptides were desalted and puried by
Sepharose, spotted on a MALDI target plate, overlaid with CHCA, and analyzed by high resolution MALDI-FTICR-MS. The
incidence of N-acetylglucosamine was determined (G0FN+G1FN+G2FN)/(G0F+G1F+G2F+G0FN+G1FN+G2FN) and showed
signicant correlation with age for both IgG1 (B) and IgG2 (D).
Figure S-4. Age-related changes in the level of bisecting N-acetylglucosamine for IgG1 (A and 
B) and IgG2 (C and D). IgG Fc N-glycan microheterogeneity was determined for a cohort of 62 
individuals. The tryp ic IgG glycop ptides were desalted and pu ified by Sepharose, spotted on a 
MALDI t rget plate, overlaid with CHCA, an  analyzed by high resolution MALDI-FTICR-MS. 
The incidence of N-acetylglucosamine as determi ed with the formula (G0FN+G1FN+G2FN)/
(G0F+G1F+G2F+G0FN+G1FN+G2FN) and showed significant correlation with age for both 




Table S-1. Most frequently observed contamination peaks in MALDI-FTICR-MS IgG 
glycopeptide profiling of RP and HILIC-SPE preparations.
C18end SPE [M+H]
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Abstract
For MALDI analysis of glycans and glycopeptides the choice of matrix is crucial in 
minimizing desialylation by mass spectrometric in-source and metastable decay. 
Here we evaluated the potential of 4-chloro-α-cyanocinnamic acid (Cl-CCA) for 
MALDI-TOF-MS analysis of labile sialylated tryptic N-glycopeptides and released 
N- and O-glycans. Similar to 2,5-dihydroxybenzoic acid (DHB), but in contrast to 
α-cyano-4-hydroxycinnamic acid (CHCA), the Cl-CCA matrix allowed the analysis of 
sialylated N-glycans and glycopeptides in negative ion mode MALDI-TOF-MS. Dried 
droplet preparations of Cl-CCA provided microcrystals with a homogeneous spatial 
distribution and high shot-to-shot repeatability similar to CHCA, which simplified the 
automatic measurement and improved the resolution and mass accuracy. Interestingly, 
reflectron-positive ion mode analysis of 1-phenyl-3-methyl-5-pyrazolone (PMP) 
labeled O-glycans with Cl-CCA revealed more complete profiles than with DHB and 
CHCA. In conclusion, we clearly demonstrate the high potential of this rationally 





During the last two decades MALDI-MS and ESI-MS have become the major soft 
ionization techniques widely applied for the analysis of a broad range of biomolecules. 
MALDI is most often combined with time-of-flight (TOF) mass analyzers and 
is particularly fast and easy to use. The development of faster instruments with 
higher mass accuracy and sensitivity, the implementation of new lasers, the advent 
of advanced TOF/TOF instruments as well as the introduction of new MALDI 
matrices have improved the technique and widened its application range. Since over 
two decades, 2,5-dihydroxybenzoic acid (DHB) and α-cyano-4-hydroxycinnamic 
acid (CHCA) are the ‘gold standard’ matrices for the MALDI-TOF-MS analysis 
of peptides, glycopeptides and glycans.191,192 Other matrices frequently applied 
include sinapinic acid, 3-hydroxypicolinic acid, 2,6-dihydroxyacetophenone and 
2,4,6-trihydroxyacetophenone (THAP).191,192
MALDI-TOF-MS is a very broadly applied method for the analysis of glycans and 
glycopeptides.148,191,192 However, when labile substituents such as sialic acids are present, 
the analysis can be complicated as these substituents may be lost by in-source and/or 
metastable decay. When analyzing glycans, sialic acids can be stabilized by methylation 
of carboxylic acid residues, or by permethylation.193-195 In case no such stabilization 
measures are undertaken, the degree of desialylation is strongly influenced by the 
chosen MALDI matrix. For example, CHCA as a hot matrix tends to lead to an almost 
complete loss of sialic acids, while DHB which is a colder matrix is less prone to sialic 
acids loss and, particularly in combination with negative ion mode and/or linear mode 
MALDI-TOF-MS, allows the analysis of sialylated glycans and glycopeptides without 
derivatization of the carboxylic acid groups.94,148,192
In MALDI sample preparation, DHB tends to form large needle-shaped crystals 
that originate at the periphery of the target spot and project towards the center.191 
Crystallization of released N-glycans with DHB (with or without sodium) generally 
results in more homogeneous microcrystals in the center of the spot whereas 
glycopeptides when subjected to identical crystallization conditions are found in the 
large crystals in the periphery191 and are detected preferably in protonated (positive 
ion mode) or deprotonated form (negative ion mode). The macrocrystalline nature of 
DHB often results in sample spot areas where certain analytes are highly concentrated 
(sweet spots), and in a very large spatial heterogeneity of mass spectra obtained 
from one sample spot.196-198 Moreover, MALDI-TOF-MS of macrocrystalline sample 
preparations on linear MALDI-TOF instruments (not on orthogonal MALDI-TOF 
instruments) is known to result in mass spectra of rather low resolution and mass 
accuracy. Recrystallization of sample spots using ethanol has been reported as a suitable 
mean to obtain a microcrystalline, more homogeneous glycan sample preparation with 
DHB,85 but this may lead to signal suppression. No similar procedure, however, has 
been established for glycopeptides.
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The large crystals obtained in sample preparations with DHB and the resulting 
large shot-to-shot variation, low mass accuracy and resolution made us search for an 
alternative, microcrystalline matrix that is compatible with the analysis of glycans and 
glycopeptides bearing labile substituents such as sialic acids. Here, we describe the use 
of 4-chloro-α-cyanocinnamic acid (Cl-CCA, systematic name 3-(4-chloro-phenyl)-2-
cyano-acrylic acid) for the analysis of glycans and glycopeptides in linear- and reflectron-
negative ion mode MALDI-TOF-MS. Cl-CCA has recently been introduced as a 
rationally designed MALDI matrix for proteomics199 and has been found to be suitable 
for the analysis of labile molecules.200 We compared Cl-CCA with conventionally used 
matrices, i.e. DHB, THAP and CHCA (see Scheme 1 in supporting information for the 
chemical structures) for the analysis of sialylated tryptic glycopeptides and released 
N- and O-glycans. We found Cl-CCA to be a colder matrix than CHCA, more similar 
to DHB,200 allowing the detection of sialylated species. Moreover, Cl-CCA preparations 
resulted in microcrystalline sample spots for glycans and glycopeptides, making this 
matrix highly suitable for automated measurement without compromising resolution 
and mass accuracy.
Experimental section
IgG purification. IgGs (ca. 20 µg) were affinity captured from total human plasma (2 
µl) as described previously.148
Reduction and alkylation. Bovine fetuin or human apo-transferrin (1 mg; Sigma-
Aldrich, Steinheim, Germany) was dissolved in 200 µl 50 mM ammonium bicarbonate 
buffer(aq) (Fluka) containing 10 mM dithiothreitol(aq) (Sigma-Aldrich) and reduced 
at 60°C for 40 min. Cysteine alkylation was achieved by addition of 30 µl 100 mM 
iodoacetamide(aq) (Sigma-Aldrich) dissolved in 50 mM ammonium bicarbonate buffer 
followed by 30 min incubation at RT in the dark. The alkylation reaction was stopped 
by putting the sample under a fluorescent lamp (gas discharge lamp) for 30 min.
Trypsin digestion. Purified plasma IgGs (ca. 20 µg) were digested with trypsin as 





























92 µl (0.4 mg) of the reduced and alkylated glycoprotein sample was digested overnight 
at 37°C with lyophilized sequencing grade modified trypsin (Promega, Madison, WI) 
in a 1:20 (w/w) enzyme to substrate ratio.
In solution N-Glycosidase F release. N-glycans were released from 60 µl (0.3 mg) of 
the reduced and alkylated tryptic digests of bovine fetuin or human apo-transferrin 
by an overnight incubation at 37°C with 10 mU PNGase F (Roche Applied Science, 
Mannheim, Germany).
HILIC SPE purification. 96-Well plate format cellulose hydrophilic interaction liquid 
chromatography solid phase extraction (HILIC SPE) of tryptic IgG glycopeptides 
(ca. 20 µg IgG) was performed as described previously.148 Cotton HILIC micro-SPE 
was performed as described previously201 with minor modifications. Briefly, 1 µl of 
tryptic glycopeptides (corresponding to ca. 4.3 µg protein) or 2 µl of PNGase F released 
N-glycans (corresponding to ca. 8.6 µg protein) from bovine fetuin and human apo-
transferrin  were brought to 83% acetonitrile (ACN) and adsorbed on a cotton HILIC 
microSPE conditioned with 83% ACN by aspirating and dispensing the sample twenty 
times. The retained analytes were washed 3 times with 10 µl of 83% ACN containing 
0.1% trifluoroacetic acid and eluted with 10 µl of water.
Glycopeptide and glycan spotting. Glycopeptides (1 µl) derived from 220 ng IgG, 
430 ng fetuin or transferrin, or released glycans (1 µl) derived from 860 ng fetuin or 
transferrin were spotted either onto an MTP AnchorChip 600/384 or polished stainless 
steel MALDI target plate (Daltonics, Bremen, Germany) and allowed to dry by air at RT. 
To the dry sample spots on the AnchorChip 1 μl of DHB (5 mg/ml 50% ACN(aq); purity 
not defined; Bruker Daltonics, Bremen, Germany),148 THAP (1 mg/ml 50% ACN(aq); 
purity not defined; Bruker Daltonics) or THAP/diammonium citrate (1 mg THAP and 
1mM diammonium citrate in 1 ml 50% ACN(aq))
202 was added. To the dry sample spots on 
the polished steel MALDI plate 1 μl of CHCA (5 mg/ml 50% ACN(aq); purity not defined; 
Bruker Daltonics),148 or Cl-CCA (5 mg/ml 70% ACN(aq); 95% purity; Bionet Research, 
Camelford, Cornwall, UK) was applied. Matrix specific spotting and drying conditions 
were chosen close or identical to previously described effective procedures.148,199,202 
N-glycan permethylation. Released N-glycans (derived from 1 mg fetuin or 
transferrin) were applied to a reversed-phase solid phase extraction (SPE) cartridge 
(500 mg Bakerbond end capped C18; Mallinckrodt Baker, Deventer, NL). The flow-
through and wash (5 ml water) were applied to a carbon cartridge (150 mg Carbograph; 
Grace, Lokeren, BE). The retained glycans were washed with water (5 ml), eluted 
with 25% aqueous ACN (5 ml) and dried by freeze-drying. The purified and desalted 
glycans were permethylated as described previously203 and reconstituted in 20 µl ACN. 
Aliquots (1 µl) were spotted onto a polished steel MALDI plate, dried by air at RT, 
overlaid with DHB (1 µl; 10 mg/ml 50% ACN(aq)) and analyzed by reflectron-positive 
ion mode MALDI-TOF-MS as described below.
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Preparation of PMP-labeled Mucin O-glycans. O-glycans were released from mucin 
of bovine submaxillary glands (Sigma-Aldrich) and labeled with 1-phenyl-3-methyl-5-
pyrazolone (PMP) as described previously.204 The yields of the reactions were checked 
by nanoRP-LC-MS204 to ensure sample suitability for O-glycan profiling. From the 
aqueous PMP-labeled O-glycan sample 10 μl aliquots (corresponding to approximately 
500 ng of mucin starting material) were purified with a RP C18 ziptip according to 
the manufacturers protocol (Millipore), directly eluted with 2 μl DHB (5 mg/ml 50% 
ACN(aq)) or 3 μl Cl-CCA (5 mg/ml 50% ACN(aq); Bionet Research) onto a MALDI target 
plate and analyzed by reflectron-positive ion mode MALDI-TOF-MS as described below. 
MALDI-TOF-MS analysis. Samples were analyzed on an Ultraflex II MALDI-TOF/
TOF-MS (Bruker Daltonics) in reflectron-positive, reflectron-negative, and linear-
negative ion mode. Calibration of the MALDI-TOF-MS spectra was performed with 
standard peptide mixtures from Bruker Daltonics. The samples were irradiated by a 
smartbeam™ 200 Hz solid-state laser. For reflectron mode analysis a 160 ns delayed 
extraction was applied after which the ions were accelerated with 25 kV, while the ions 
were accelerated immediately without delayed extraction in the linear mode. The ions 
were recorded between m/z 1300 and 4600 (N-glycans and IgG glycopeptides), m/z 
1300 and 8000 (fetuin and transferrin glycopeptides), m/z 960 and 4500 (permethylated 
fetuin and transferrin glycans) or m/z 440 and 3700 (O-glycans). The ions below m/z 300 
(O-glycans), 500 (N-glycans and N-glycopeptides) or 800 (permethylated N-glycans) 
were suppressed. Each mass spectrum was generated by summing the ions of 1000 (O-
glycans), 2000 (N-glycans and N-glycopeptides) or 4000 (permethylated N-glycans) 
laser shots. The laser intensity was optimized to give the best signal-to-noise (S/N) 
ratio for each sample. Automatic MALDI-TOF-MS analysis, was performed as describe 
previously.148 All data processing and evaluation were performed with FlexAnalysis 
Software (Bruker Daltonics) and Microsoft Excel, respectively. Relative intensities of 
the Fc N-glycopeptide species derived from IgG1 and IgG2 (8 glycoforms each) were 
obtained by normalization to the total IgG subclass specific glycopeptide intensities.
Limit of detection. To evaluate the limit of detection (LOD) of MALDI-TOF-MS with 
DHB and Cl-CCA we prepared a dilution series ranging from 0.001 to 50 ng/µl of a 
tryptic digest of a monoclonal antibody. In addition, a maltoheptaose dilution series 
was prepared ranging in concentration from 0.05 to 50 ng/µl. From each dilution 1 µl 
was spotted onto an AnchorChip target plate and dried by air. To the dried sample spots 
1 μl of DHB (5 mg/ml 50% ACN(aq)),
148 or 1 μl of Cl-CCA (1 mg/ml 70% ACN(aq)) was 
applied. Matrix specific spotting and drying conditions were chosen identical or close 
to previously described effective procedures.148,199 Spots were analyzed in reflectron-
positive and reflectron-negative ion mode. 
In the Fc portion of each antibody two N-glycans are located, which may vary in 
glycan composition. Calculation of the LOD for the Fc-derived tryptic glycopeptides 







MALDI-TOF-MS of IgG glycopeptides. Human polyclonal IgGs purified by protein A 
affinity chromatography from plasma of a healthy volunteer were digested by trypsin 
and subsequently desalted and purified using cellulose HILIC SPE. Purified IgG 
glycopeptides were spotted onto a MALDI target plate and co-crystallized with matrix 
(DHB, CHCA, THAP, or Cl-CCA). Initial Cl-CCA pilot experiments were performed 
with commercially obtained matrix and matrix kindly provided by the group of Prof. 
Dr. M. Karas. The matrix solution of the commercially obtained Cl-CCA was prepared 
in 50, 60 and 70% ACN at 5 mg/ml, while the matrix solution of the provided Cl-CCA 
was prepared as described previously.199 Matrices obtained from the two different 
sources gave very similar results, with the best S/N ratio being obtained for the 70% 
ACN preparation (data not shown).
DHB preparations showed very dense, thick crystals covering the AnchorChip 
spot (Figure 1A). For THAP matrix dried by vacuum fairly homogeneous crystals 
were observed. When dried at atmospheric pressure, however, THAP preparations 
were heterogeneous with long crystals more similar to DHB. By contrast, CHCA and 
Cl-CCA preparations showed small crystals with a homogeneous spatial distribution. 
The Cl-CCA preparations occasionally showed a white crust ring of matrix crystals 




Lowest measurable antibody amount on spot (g) * 2 (Number of Fc N-glycans)
150 000 (g/mol; molecular mass antibody) * Number of observed glycoforms
Figure 1. Magnified image of tryptic IgG glycopeptides co-crystallized with DHB onto 
an AnchorChip MALDI plate (A) or Cl-CCA onto a polished steel MALDI plate (B). The 
spot formation shows a heterogeneous macrocrystalline DHB spot and a homogeneous 
microcrystalline Cl-CCA matrix spot. Notably, Cl-CCA matrix is producing a thin white crust 
ring around the matrix spot.
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Analysis of the ring of such spots revealed similar glycopeptide profiles with a 
slightly lower S/N ratio and resolution compared to profiles obtained in the center. This, 
however, did not affect the automatic MALDI-TOF-MS measurements as the ring was 
not sampled with the used random walk laser movement. For Cl-CCA preparations, 
intense IgG glycopeptide signals were obtained over the entire sample spot. Spots older 
than 2 weeks and stored on the bench still provided intense glycopeptide signals. When 
stored under vacuum in the MALDI source during 8 h no decrease in IgG glycopeptide 
intensity was observed (data not shown). Sample spots stored for over 24 h in the 
MALDI source, however, allowed registration of IgG glycopeptides only in the larger 
not yet fully sublimated crystals of ring. The Cl-CCA and DHB preparations required 
a similar laser power for threshold signals, which were ca. 2-3% higher than for CHCA 
or 5-6% lower than for THAP (with or without diammonium citrate) preparations.
Independent of the measurement mode and MALDI matrix the most abundant 
signals were obtained for the glycopeptides of IgG2 followed by IgG1 and IgG4 (Figure 
2 and Figure S-1). The observed profiles closely resembled the reversed phase nanoLC-
ESI-MS IgG glycopeptide profiles obtained for the same sample. The assignments of 
the IgG glycopeptides were confirmed by MALDI-TOF/TOF-MS/MS and nanoLC-
ESI-ion trap-MS/MS analysis of the IgG1 and IgG2 G0F species providing IgG subclass 
specific peptide sequence information (data not shown). In reflectron-positive ion 
mode MALDI-TOF-MS using CHCA (Figure  S-1A) and Cl-CCA (Figure  S-1B) 
matrix, IgG glycopeptide spectra with a good S/N ratio were obtained showing almost 
exclusively neutral glycoforms with only very minor signals for the sialylated species. 
Similarly, sialylated glycoforms were of very low relative abundance when using CHCA 
matrix in reflectron-negative ion mode (Figure S-1C). By contrast, DHB (Figure 2A 
and C) and Cl-CCA (Figure 2B and D) allowed detection of sialylated glycopeptides 
next to the neutral glycoforms in the linear-negative (Figure 2A and B) and reflectron-
negative ion mode (Figure 2C and D). Interestingly, an in-source decay product at m/z 
2396.96 ([M-H]-) was observed at lower relative intensity with Cl-CCA as compared 
to DHB. This glycopeptides species is formed when the linkage breaks between an 
antenna GlcNAc and a core mannose of the IgG2 G0F or G1F species. The absence of 
this glycan species from the original IgG glycopeptide sample was confirmed by nano-
reversed phase liquid chromatography electrospray ionization MS, indicating that the 
observation of this glycopeptide ion in MALDI-TOF-MS is related to in-source decay 
(data not shown). With the THAP matrix only low quality IgG glycopeptide profile 
Figure 2. MALDI-TOF-MS spectra of tryptic IgG Fc N-glycopeptides co-crystallized with DHB 
(A, C) or Cl-CCA (B, D) and measured in linear-negative (A, B) and reflectron-negative ion 
mode (C, D). Profiling of IgG Fc N-glycopeptides was performed after 96-well format cellulose-
HILIC purification. Dashed arrows, IgG2 glycopeptides; solid arrows, IgG1 glycopeptides; *, 




































































































































































spectra with high levels of alkali salt adducts were obtained in reflectron-positive 
(Figure S-2A) and reflectron-negative (Figure S-2B) ion mode. While the presence of 
diammonium citrate in the THAP matrix significantly reduced the observed alkali salt 
adduct levels and improved the spectra quality (Figure S-2C and D), the observed S/N 
ratio and resolution were consistently lower compared to the other matrices. In an 
effort to improve the IgG glycopeptide spectra with THAP/diammonium citrate the 
matrix was dried underneath the pierced cap similar to the procedure applied with 
DHB. While this improved the observed IgG glycopeptide signals, the S/N ratio of ca. 
45 remained much lower than for DHB and Cl-CCA (Figure 3).
To evaluate the performance of DHB and Cl-CCA for glycopeptide profiling by 
negative ion mode MALDI-TOF-MS, the purified IgG Fc N-glycopeptide sample was 
spotted eight times on an AnchorChip and polished steel target plate and overlaid with 
DHB or Cl-CCA, respectively. For both matrices a single spot was measured eight times 
in linear- and reflectron-negative ion mode after which one spectrum was acquired 
2761 2762 2763 2764 2765 2766 2767 2768 2769
m/z
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Figure 3. Overlay of the IgG2 G1F species from 10 reflectron-negative ion mode MALDI-TOF-
MS spectra. Tryptic IgG Fc N-glycopeptide preparations were measured automatically on a 





for each of the remaining replicate spots. Mass spectra were processed automatically 
which involved internal calibration, baseline subtraction, and peak picking. Within 
the spot and between the spots the relative standard deviations of the normalized peak 
heights for the six major glycoforms of IgG1 and IgG2 remained below 6 and 8% for the 
reflectron- and linear-negative ion mode measurements, respectively.
Next, eight replicates of the above described IgG Fc N-glycopeptide sample were 
prepared, spotted onto an AnchorChip (DHB) or polished steel target plate (Cl-CCA), and 
analyzed by reflectron- and linear-negative ion mode MALDI-TOF-MS. This experiment 
was performed three times each on different days. Within the three experiments, the 
intraday and interday variability was determined for IgG1 (Figure S-3) and IgG2 (Figure 
S-4). Again the relative standard deviations for the six major glycoforms of IgG1 and 
IgG2 in the reflectron- and linear-negative ion mode measurements remained below 6 
and 8%, respectively. The homogeneous spatial distribution of the Cl-CCA microcrystals 
provided a high shot-to-shot repeatability, which simplified the automatic measurement 
and improved the resolution and mass accuracy of the MALDI-TOF-MS measurements 
as demonstrated by comparing replicate spectra (Figure 3).
To evaluate the LOD of MALDI-TOF-MS with DHB and Cl-CCA a dilution series 
of a tryptic digest of a monoclonal antibody was prepared. For both matrices, the 
dilutions were spotted onto an AnchorChip MALDI target plate, cocrystallized with 
DHB or Cl-CCA, and analyzed in the reflectron-positive and reflectron-negative ion 
mode. The lowest measurable monoclonal antibody amount in the reflectron-negative 
ion mode with DHB or Cl-CCA was 0.1 and 0.05 ng on spot, respectively. In the 
reflectron-positive ion mode with DHB or Cl-CCA the lowest measurable monoclonal 
antibody amount was 0.05 and 0.01 ng on spot, respectively. Upon reflectron mode 
(negative and positive) analysis with DHB or Cl-CCA of the lowest measurable 
monoclonal antibody amount three different glycoforms (S/N ratio ≥ 3) were observed. 
The LOD of the reflectron-negative ion mode measurements with DHB and Cl-CCA 
was, thereof, determined to be approximately 444 and 222 amol of glycopeptides on 
spot, respectively. In reflectron-positive ion mode the LOD was found to be 222 and 
44 amol glycopeptides on spot for DHB and Cl-CCA, respectively. In addition, we 
analyzed a maltoheptaose dilution series in reflectron-positive and reflectron-negative 
ion mode with DHB and Cl-CCA. In the positive ion mode both matrices provided 
a similar LOD of approximately 10 fmol on spot, while in the negative ion mode no 
maltoheptaose signals could be obtained.
MALDI-TOF-MS of highly sialylated glycopeptides. In order to evaluate 
the suitability of the Cl-CCA matrix for negative ion mode MALDI-TOF-MS of 
glycopeptides with a high level of sialylation, we additionally prepared tryptic digests 
of bovine fetuin and human apo-transferrin, selectively purified the glycopeptides 
by cotton HILIC micro-SPE,201 and spotted the sample directly onto an AnchorChip 
(DHB) and polished steel (Cl-CCA) MALDI target plate. MALDI-TOF-MS analysis 
was performed in the reflectron- and linear-negative ion mode. Fetuin glycopeptides 
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fetuin (Figure S-5) and transferrin (Figure S-6C and D) glycopeptides revealed large 
analysis with both matrices. In linear-negative ion mode with DHB good signals 
were obtained for the di- and tri-antennary sialylated fetuin N-glycopeptides with 
the most abundant signals for the Leu145-Arg159 glycopeptide cluster (small peptide 
moiety), followed by the Arg72-Arg103 and Val160-Arg187 glycopeptide clusters (big and 
intermediate-size peptide moieties, respectively; Figure 4A). Linear-negative ion 
mode MALDI-TOF-MS of Cl-CCA overlaid fetuin glycopeptides revealed similar but 
m/z 5000, while above m/z 5000 
glycopeptide intensities were rather low (Figure 4B). Spectra of comparable quality 
were observed for human apo-transferrin overlaid with DHB (Figure S-6A) and 
Figure 4






























































































Figure 4.  
glycopeptides  (SwissProt entry number: P12763). Tryptic glycopeptides   were   puried 
polished  steel  target plate  with Cl-CCA (B). Solid arrows, small molecular mass
(L    CPDCPLLAPLNDSR    );  dashed  arrows,  intermediate   molecular  mass145 159
(V   VHAVEVALATFNAESNGSYLQLVEISR    );   dotted  arrows,    large  molecular160 187
glycopeptide  (R   PTGEVYDIEIDTLETTCHVLDPTPLANCSVR    ); *,   post   source72 103
products; glycan code as in Figure 1 of Chapter 1. 
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were  in  addition  analyzed  in  the  reectron-positive  ion  mode.  As  expected,
unfocussed  metastable  peaks  for  highly  sialylated  structures  in  the  reectron
slightly more intense  proles  compared to DHB up to
tryptic
mode
 Linear-negative   ion    mode   MALDI-TOF-MS    spectra   of    tryptic   bovine









Cl-CCA (Figure S-6B), revealing similar relative intensities for the large (Gln622-Arg642) 
and small (Cys421-Lys433) N-glycopeptides.
MALDI-TOF-MS of released N-glycans. The performance of the Cl-CCA matrix 
was also evaluated for MALDI-TOF-MS analysis of released N-glycans. To this end, 
N-glycans were released from bovine fetuin and human apo-transferrin with PNGase 
F, purified by cotton HILIC micro-SPE,201 co-crystallized with DHB (AnchorChip), 
Cl-CCA (polished steel), THAP or THAP/diammonium citrate (AnchorChip) and 
analyzed by linear-negative ion mode MALDI-TOF-MS. 
With DHB, highly sialylated fetuin N-glycans were detected with a good S/N ratio, 
showing predominantly singly charged deprotonated, sodiated and potassiated species 
(Figure 5A). In addition, low amounts of adducts with two sodium, two potassium or a 
sodium and potassium were observed for the tri- and tetra-sialylated N-glycans. Spectra 
of Cl-CCA overlaid fetuin N-glycans revealed lower relative intensities for the mono-
sialylated fetuin glycopeptides compared to DHB, while similar relative intensities were 
observed for the multiple sialylated glycans with similar levels of alkali salt adducts 
(Figure 5B). Moreover, the relative abundance of partially sialylated species measured 
with Cl-CCA was lower compared to DHB. With Cl-CCA preparations very intense non-
glycan related signals were observed at m/z 1991.1 ([M-H]-, His313-Lys333) and 2119.3 
([M-H]-, His313-Gly332) which were present only at low intensity with DHB preparations 
and were identified by MALDI-TOF/TOF-MS as fetuin peptides. THAP (Figure S-7A) 
and THAP/diammonium citrate (Figure S-7B) co-crystallized fetuin glycans revealed 
linear negative ion mode spectra of low quality for the released fetuin glycans which 
were dominated by alkali salt adducts. To improve the glycan spectra, the fetuin samples 
were recrystallized with 60% ethanol or 60% ethanol containing 1 mM sodium acetate, 
revealing similar spectra as obtained prior to the recrystallization (data not shown). 
Analysis of Cl-CCA co-crystallized transferrin N-glycans (Figure S-8B) revealed 
spectra with N-glycan profiles and alkali salt adduct levels comparable to those 
observed with DHB (Figure S-8A) but with a lower S/N ratio. When analyzed in the 
linear- and reflectron-positive ion mode the Cl-CCA spots with released transferrin 
N-glycans revealed spectra with low intensity signals which predominantly originated 
from sodium adducts (data not shown). Transferrin glycans co-crystallized with 
THAP (Figure S-8C) or THAP/diammonium citrate (Figure S-8D) revealed similar 
linear-negative ion mode glycan profiles as obtained with DHB and Cl-CCA. While 
the spectra for transferrin N-glycans with DHB and Cl-CCA were dominated by 
deprotonated glycan species, spectra of transferrin N-glycans with THAP (with and 
without diammonium citrate) showed for a big part an exchange of acidic protons for 
sodium. As with the fetuin N-glycans, recrystallization of the transferrin N-glycans 
with 60% ethanol or 60% ethanol containing 1 mM sodium acetate resulted in similar 
spectra as observed prior to the recrystallization (data not shown).
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MALDI-TOF-MS of permethylated N-glycans. To evaluate the suitability of Cl-CCA 
for quantitative MALDI-TOF-MS analysis, the released fetuin and transferrin 
N-glycans were permethylated, co-crystallized with DHB and analyzed by reflectron-
positive ion mode MALDI-TOF-MS. The most abundant fetuin N-glycan intensities 
(Figure S-9A) originated from the fully sialylated bi- and triantennary glycans, 
while only low signals were observed for the partially sialylated bi- and triantennary 
glycans. For transferrin (Figure S-9B) the most abundant signals originated from the 
fully sialylated biantennary glycans, while low signals were observed for the partially 
sialylated biantennary glycans and fully and partially sialylated triantennary glycans. 
Interestingly, the observed N-glycan profiles after permethylation were more similar to 
the negative ion mode MALDI-TOF-MS N-glycan profiles observed with Cl-CCA than 
to those observed with DHB.
Comparison of PMP-labeled O-glycan profiles using DHB and Cl-CCA. To evaluate 
the applicability of Cl-CCA for profiling small glycans, PMP-labeled mucin O-glycans 
Figure 5. Linear-negative ion mode MALDI-TOF-MS spectra of PNGase F released bovine fetuin 
N-glycans. Released N-glycans were purified by cotton HILIC micro-SPE and co-crystallized 
with DHB on an AnchorChip (A) or Cl-CCA on a polished steel target plate (B) for analysis. 
~, Fetuin peptide H313TFSGVASVESSSGEAFHVG K333; *, sodium adduct; ¥, potassium adduct; 
glycan code as in Figure 1 of Chapter 1.

















































































were co-crystallized with DHB (AnchorChip), CHCA, or Cl-CCA (polished steel) and 
analyzed by reflectron-negative and positive ion mode MALDI-TOF-MS. While in 
reflectron-negative ion mode we were unable to generate spectra of good quality for 
PMP-labeled O-glycans, reflectron-positive analysis with Cl-CCA provided spectra 
with a higher S/N ratio as compared to DHB (Figure S-10). No PMP-labeled O-glycans 
were observed with CHCA (data not shown). However, we were unable to detect the 
entire PMP-labeled mucin O-glycan set that has been described previously.204,205 As an 
alternative attempt to improve the mucin O-glycan coverage we co-crystallized the PMP-
labeled O-glycans with Cl-CCA on an AnchorChip plate and repeated the analysis. More 
intense PMP-labeled O-glycan signals were obtained revealing two additional mucin 
O-glycans (m/z [1046.5+H]+ and [1062.6+H]+) corresponding to HexNAc2NeuAc1(PMP)2 
and HexNAc2NeuGc1(PMP)2, respectively (HexNAc, N-acetylhexosamine; NeuAc, 
N-acetylneuraminic acid; NeuGc, N-glycolylneuraminic acid; Figure S-11).
Discussion
MALDI-TOF-MS analysis of sialylated glycoconjugates often suffers from massive 
desialylation due to in-source and metastable decay. Recently, the group of Prof. Dr. 
M. Karas introduced the rationally designed MALDI matrix Cl-CCA for proteomics,199 
which showed a high potential for the analysis of labile molecules.200 Compared to 
CHCA, Cl-CCA was found to be a colder matrix that allowed more efficient analyte 
protonation due to the lower proton affinity. Moreover, improved peptide sequence 
coverage, sensitivity, and detection of labile peptides has been reported.206 Here, we 
have evaluated the potential of Cl-CCA for the detection of labile sialylated glycans and 
glycopeptides. To this end tryptic glycopeptides (IgG, fetuin and transferrin), released 
N-glycans (fetuin and transferrin), and released O-glycans (bovine submaxillary gland 
mucin) were prepared and analyzed by MALDI-TOF-MS.
In a first attempt we compared tryptic IgG Fc N-glycopeptide MALDI-TOF-MS 
profiles obtained with different matrices (i.e. DHB, THAP, CHCA and Cl-CCA) and 
detection modes (i.e. reflectron-positive, reflectron-negative and linear-negative). 
The observed profiles closely resembled the reversed phase nanoLC-ESI-MS IgG 
glycopeptide profiles obtained for the same sample. Subclass specific peptide sequence 
information could be obtained by fragmentation of the G0F species of IgG1 and IgG2, 
which combined with literature knowledge of IgG N-glycosylation3,4,9-11,79,148 allowed 
structural assignment of the detected glycoforms with good confidence. While IgG1 is 
present at a higher concentration in the blood circulation than IgG2, the latter showed 
higher MS intensities possibly due to a more efficient ionization of the phenylalanine 
containing IgG2 glycopeptide compared to the tyrosine containing IgG1 glycopeptide. 
The slightly higher hydrophobicity of the peptide portion of the IgG2 glycopeptide may 
also promote the efficient co-crystallization with the matrix substances. In reflectron 
mode MALDI-TOF-MS sialylated glycopeptides are prone to in-source and metastable 
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decay.192,207 Moreover, poor ionization of sialylated glycopeptides in the positive ion 
mode further hampers their detection. Interestingly, with DHB and Cl-CCA we 
observed intense signals for intact sialylated IgG Fc N-glycopeptides in reflectron- and 
linear-negative ion mode MALDI-TOF-MS. This might be explained by a similarly 
efficient ionization of neutral and acidic tryptic glycopeptides in the negative ion mode 
due to acidic groups of the peptide backbones.208 Moreover, the cold nature of the DHB 
and Cl-CCA matrices200 minimizes analyte fragmentation which is supported by the 
low intensity of the IgG2 G0F or G1F fragment ion observed at m/z 2396.96 ([M-H]-)
or 2398.98 ([M+H]+) (Figure 2 and Figure S-1). Interestingly, the relative abundances 
of these in-source decay products were even lower with Cl-CCA than with DHB. 
Human polyclonal IgG predominantly contains Fc N-glycans with one sialic acid which 
tends to be more stable during MALDI ionization than multiply sialylated structures. 
Analysis of intact monosialylated IgG glycopeptides was therefore accomplished by 
reflectron-negative ion mode MALDI-TOF-MS. In line with literature,94,148,192 accurate 
detection of intact highly sialylated glycopeptides with good intensity was only achieved 
with linear-negative ion mode MALDI-TOF-MS. The most intense glycopeptide signals 
for DHB and Cl-CCA were recorded below m/z 5000. Above m/z 5000 the signal strength 
decreases which is in line with literature data for DHB and CHCA.191
The Cl-CCA preparations showed a good stability when stored at atmospheric 
pressure but when stored at high vacuum matrix sublimation resulted in relatively 
fast spot disappearance which is in accordance with the previously reported high 
vacuum volatility of this matrix.206 While this could be considered a disadvantage, the 
duration of most automated MALDI-TOF-MS measurements remains far below one 
minute per sample spot, and thus results will be obtained before any effect of the matrix 
sublimation is perceived. Furthermore, matrix contamination in the MALDI source is 
significantly decreased as the sublimation process provides self cleaning of the system 
by the vacuum pumps.
Macrocrystalline dried droplet preparations of DHB show a distinct distribution of 
peptides and carbohydrates in large crystals offering the possibility to generate relative 
clean carbohydrate spectra in presence of contaminating peptides.197 By contrast, the 
more homogeneous distribution of compounds in microcrystalline preparations such 
as obtained with Cl-CCA increase the sensitivity to contaminations. Thus resulting 
spectra reveal carbohydrate information with additional peptide contamination such as 
observed by us for the N-glycans released from tryptic fetuin glycopeptides (Figure 5). 
Interestingly, when compared to DHB, Cl-CCA resulted in the registration of 
highly sialylated glycopeptides at relatively high abundance while partially sialylated 
species showed low signal intensities. The relative intensities of the glycan species 
observed with Cl-CCA more closely resembled the profiles observed for permethylated 
N-glycans (Figure S-9) and were more in-line with their previously reported abundance 
on bovine fetuin 174 than those observed with DHB. This might be explained by less 




reported to be a colder matrix than Cl-CCA.200 Alternatively, the differences in profiles 
obtained with DHB and Cl-CCA may be caused by different ionization efficiencies of 
fully sialylated versus partially sialylated and unsialylated structures.
For Cl-CCA high matrix background levels in negative ion mode MALDI-TOF-MS 
have already been described.200 For positive ion mode measurements, this background 
has been attributed to high levels of alkali salt contamination in the sample or 
matrix.209,210 The Cl-CCA matrix commercially obtained as a white powder with 95% 
purity revealed similar levels of alkali salt adducts as the highly purified DHB matrix. 
Additional purification of the Cl-CCA matrix by recrystallization might further 
reduce the level of observed sodium and potassium adducts.206 The high level of matrix 
cluster background with relatively low S/N ratio of released (hydrophilic) N-glycans in 
negative ion mode MALDI-TOF-MS is probably caused by the low tendency of these 
analytes to co-crystallize with the relative hydrophobic matrix and this matrix may, 
therefore, be better suited for labeled glycans. Indeed, Cl-CCA co-crystallized PMP-
labeled O-glycans analyzed in positive ion mode revealed superior signals as compared 
to DHB (see Figure S-10 and S-11). Structural assignment of the detected glycoforms 
was performed on the basis of literature knowledge.204,205 While LC–MS analyses of the 
PMP-labeled mucin O-glycan samples gave no indications of peeling (data not shown), 
the unassigned peaks present in the MALDI-TOF-MS spectra indicate that there are 
still some contaminants or side reaction products present in our purified sample. 
Nevertheless, we here clearly demonstrated that the use of Cl-CCA has a high potential 
for the positive ion mode MALDI-TOF-MS analysis of PMP-labeled O-glycans.
In conclusion, we showed that the rationally designed MALDI matrix Cl-CCA 
allows the sensitive analysis of intact labile sialylated glycopeptides by negative ion 
mode MALDI-TOF-MS with a low interday variability. The microcrystalline nature of 
Cl-CCA provided a high shot-to-shot repeatability, resolution and mass accuracy, and 
offered the possibility to use stainless steel MALDI target plates which are relatively 
cheap and very robust. This makes Cl-CCA a matrix with high potential in high-
throughput MALDI-TOF-MS profiling of glycopeptides. Moreover, we demonstrated 
the usefulness of Cl-CCA as a matrix for glycan analysis.
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Supporting information
Figure S-1. MALDI-TOF-MS spectra of 
tryptic IgG Fc N-glycopeptides measured 
in reflectron positive-ion mode with CHCA 
(A) and Cl-CCA (B) matrix and reflectron 
negative-ion mode with CHCA matrix 
(C). Profiling of IgG Fc glycopeptides was 
performed after 96-well format cellulose-
HILIC purification. Continued arrows, 
IgG1 glycopeptides; dashed arrows, IgG2 
glycopeptides; *, in-source fragment; glycan 
code as in Figure 1 of Chapter 1.
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Figure S-2. MALDI-TOF-MS spectra of tryptic IgG Fc N-glycopeptides measured in reflectron-
positive ion mode (A, C) and reflectron-negative ion mode (B, D) with THAP (A, B) and THAP/
diammonium citrate (C, D) matrix. Profiling of IgG Fc glycopeptides was performed after 
96-well format cellulose-HILIC purification. Dashed arrows, IgG2 glycopeptides; solid arrows, 





























































Figure S-3. Repeatability of 96-well cellulose HILIC purification and negative ion mode MALDI-
TOF-MS analysis for tryptic IgG1 Fc N-glycopeptides. Analysis of IgG1 glycopeptides with DHB 
(A, C) or Cl-CCA (B, D) was performed by linear- (A, B) and reflectron- (C, D) negative ion 
mode MALDI-TOF-MS. Relative intensities and standard deviations were determined from 
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Figure S-4. Repeatability of 96-well cellulose HILIC purification and negative ion mode MALDI-
TOF-MS analysis for tryptic IgG2 Fc N-glycopeptides. Analysis of IgG2 glycopeptides with DHB 
(A, C) or Cl-CCA (B, D) was performed by linear- (A, B) and reflectron- (C, D) negative ion 
mode MALDI-TOF-MS. Relative intensities and standard deviations were determined from 
































































































































































































































Figure S-5. Reflectron-negative (A, B) and reflectron-positive (C, D) ion mode MALDI-TOF-
MS spectra of tryptic bovine fetuin glycopeptides (SwissProt entry number: P12763). Tryptic 
glycopeptides were purified by cotton HILIC micro-SPE and measured on an AnchorChip 
target plate with DHB (A, C) and a polished steel target plate with Cl-CCA (B, D). Solid arrows, 
small molecular mass glycopeptide (L145CPDCPLLAPLNDSR159); dashed arrows, intermediate 
molecular mass glycopeptide (V160VHAVEVALATFNAESNGSYLQLVEISR187); dotted arrows, 
large molecular mass glycopeptide (R72PTGEVYDIEIDTLETTCHVLDPTPL ANCSVR103); *, 
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Figure S-6. Linear-negative (A, B) and reflectron-negative (C, D) ion mode MALDI-TOF-MS 
spectra of tryptic human apo-transferrin glycopeptides (SwissProt entry number: P02787). 
Tryptic glycopeptides were purified by cotton HILIC micro-SPE and measured on an AnchorChip 
target plate with DHB (A, C) and a polished steel target plate with Cl-CCA (B, D). Solid arrows, 
small molecular mass glycopeptide (C421GLVPVLAENYNK433); dashed arrows, large molecular 
mass glycopeptide (Q622QQHLFGSNVTDCSGNFCLFR642); ¥, post source decay products; 









































































Figure S-7. Linear-negative ion mode MALDI-TOF-MS spectra of PNGase F released bovine 
fetuin N-glycans. Released N-glycans were purified by cotton HILIC micro-SPE and prepared 
with THAP (A) and THAP/diammonium citrate (B) on an AnchorChip target plate for analysis. 
*, Sodium adduct; ~, fetuin peptide H313TFSGVASVESSSGEAFHVG K333; glycan code as in 






























































































Figure S-8. Linear-negative ion mode MALDI-TOF-MS spectra of PNGase F released human 
apo-transferrin N-glycans. Released N-glycans were purified by cotton HILIC micro-SPE and 
prepared on an AnchorChip with DHB (A), THAP (C) or THAP/diammonium citrate (D) or on 
a polished steel target plate with Cl-CCA (B) for analysis. *, Sodium adduct; ¥, potassium adduct; 
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Figure S-9. Reflectron-positive ion mode MALDI-TOF-MS spectra of released and permethylated 
fetuin (A) and transferrin (B) N-glycans prepared on an AnchorChip with DHB. Glycan code as 
in Figure 1 of Chapter 1.
Figure S-10. Reflectron-positive ion mode MALDI-TOF-MS spectra of released mucin 
O-glycans. Released and PMP-labeled O-glycans were purified with a reversed phase ziptip and 
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Figure S-11. Reflectron-positive ion mode MALDI-TOF-MS spectra of released mucin 
O-glycans prepared on a AnchorChip plate with Cl-CCA. Released and PMP-labeled O-glycans 
were purified with a reversed phase ziptip and spotted directly for analysis. A. high abundant 
O-glycans, B. zoom-in of low abundant O-glycans. Glycan code as in Figure S-10.
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Abstract
Antibody effector functions have been shown to be influenced by the structure of the 
Fc N-glycans. Here we studied the changes in plasma or serum IgG Fc N-glycosylation 
upon vaccination of 10 Caucasian adults and 10 African children. Serum/plasma 
IgG was purified by affinity chromatography prior to and at two time points after 
vaccination. Fc N-glycosylation profiles of individual IgG subclasses were determined 
for both total IgG and affinity-purified anti-vaccine IgG using a recently developed fast 
nanoLC-ESI-MS method. While vaccination had no effect on the glycosylation of total 
IgG, anti-vaccine IgG showed increased levels of galactosylation and sialylation upon 
active immunization. Interestingly, the number of sialic acids per galactose moiety (SA/
Gal) increased during the vaccination time course, suggesting a distinct regulation of 
galactosylation and sialylation. In addition we observed a decrease in the level of IgG1 
bisecting N-acetylglucosamine while no significant changes were observed for the level 
of fucosylation. Our data indicate that depending on the vaccination time point the 
infectious agent will encounter IgGs with different glycosylation profiles which are 
expected to influence the antibody effector functions relevant in immunity.
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Introduction
Millions of individuals are vaccinated worldwide each year to stimulate the adaptive 
immune system to produce protective antibodies as well as T-cell responses against 
a variety of pathogens. Vaccination with attenuated microbe strains and purified 
proteins results in lymphocyte sensitization, cytokine release, and the production of 
immunoglobulins (Igs) which may provide long-term immunity.
The most abundant Ig class in the humoral immune response is IgG being present 
at concentrations of approximately 10 mg/ml in plasma and serum.1,2 IgGs are 
glycoproteins, and their glycosylation is known to modulate antibody activity and 
effector mechanisms.19,35,43,44,146 Four different IgG subclasses are present in humans 
(IgG1-4). IgGs consist of two heavy and two light chains. The two light chains together 
with the N-terminal domains (VH and CH1) of the two heavy chains form the fragment 
antigen binding (Fab) moiety, whilst the fragment crystallisable (Fc) moiety is formed 
by the C-terminal domains (CH2 and CH3) of the two heavy chains. A single biantennary, 
often core fucosylated N-glycan is attached to the asparagine residue at position 297 in 
the CH2 domain of the heavy chains. These N-glycans vary in the number of antenna 
galactoses and may carry a sialic acid on one of the antennae. Part of the N-glycans 
contain a bisecting N-acetylglucosamine (bisecting GlcNAc).147
Recently, some B-cell stimuli have been identified which resulted in changes in 
antibody glycosylation and indicated a pronounced short-term regulation of IgG 
glycosylation in humans.57 In-vitro stimulation of B-cells with the environmental factor 
all-trans retinoic acid resulted in the expression of IgG1 with decreased galactosylation 
within a time-range of several days, while increased galactosylation and reduced 
bisecting GlcNAc have been observed after stimulation with CpG oligodeoxynucleotide 
(stimulates the innate immune system) or interleukin 21 (stimulates the adaptive 
immune system).57
Hitherto, induction of specific glycosylation patterns of IgGs upon immunization 
has only been shown in animal experiments.34,35,211 Specific pathogen free CBA/Ca mice 
immunized with bovine serum albumin (BSA) in incomplete Freund’s adjuvant showed 
an initial decrease in galactose content on anti-BSA IgG with increasing antibody titer 
which returned to original levels when titers fell.34 In a murine nephrotoxic serum 
nephritis model, total IgG sialylation has been shown to reduce drastically in mice pre-
sensitized with sheep IgG and challenged with sheep anti-mouse glomerular basement 
membrane preparation compared to unimmunized controls.35 This suggests that the 
sialylation change may provide a switch from innate anti-inflammatory activity in the 
steady state to an adaptive pro-inflammatory response. Repeated immunization of male 
ICR mice with ovalbumin (OVA) in physiological saline resulted in an increase of the 
fucose content on anti-OVA IgG, while mannosylation, galactosylation and sialylation 
were unaffected.211 These animal studies demonstrate that upon immunological 
challenge glycosylation of the produced antibodies differ.
IgG glycosylation with vaccination
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Measurement of IgG glycosylation at the glycopeptide level ensures specificity 
as it allows the assignment of glycan structures to the Fc portions of individual IgG 
subclasses, which is important since Fc glycosylation and Fab glycosylation appear to 
have very distinct functions.212 Due to the high sensitivity of the mass spectrometric 
detection it is possible to set up affinity-based microtitration well plate IgG capturing 
and purification assays as modifications of (commercially available) enzyme-linked 
immunosorbent assays and combine them successfully with IgG glycosylation profiling 
of glycopeptides.56 This allows glycan profiling at the level of antigen-specific IgG. 
Interestingly, antigen-specific IgGs have repeatedly been shown to be glycosylated in a 
very distinct manner that differs considerably from the pool of total IgG.22,24,45,56
Here, we describe IgG glycosylation changes induced by vaccination in humans. 
We analyzed the Fc glycosylation of IgG1 induced by vaccination against Mexican flu 
(Caucasian adults), seasonal flu (African children) and tetanus (African children). 
Consistently we observe a transient increase of both galactosylation and sialylation, 
together with a decrease of the incidence of bisecting GlcNAc. This glycosylation time 
course is specifically observed for the vaccine-induced IgG1 whilst the glycosylation 
of total IgG1 is unaffected. On the basis of the known association of IgG glycosylation 
features with antibody efficacy in in-vitro assays and animal models,35,43,44,47,48,213,214 we 
expect that the specific IgG1 glycosylation features observed upon vaccination will 
influence antibody effector functions.
Experimental section
Study cohort. The study cohort is described in Table 1. From 10 healthy Caucasians 
who were vaccinated twice (at day 0 and at day 21) with MF59-adjuvanted 2009 
pandemic influenza A(H1N1) (Focetria 2009, Novartis Vaccines and Diagnostics, 
Rosia, Italy), serum was obtained at day 0 (just before vaccination), day 21 (just before 
the second dose) and day 56.215 This study was approved by the ethics committee of 
Leiden University Medical Center (protocol number 09.187). Subjects provided written 
informed consent for participation in the study and for the use of stored serum samples 
for the purpose of this study.215
From 10 Gabonese children heparin plasma was obtained prior to vaccination (day 
0) and at day 14 and 28 after vaccination with Begrivac 2004/2005 (Chiron Behring 
GmbH, Marburg, Germany).216 Simultaneously with the influenza vaccination, the 
African children were vaccinated with a tetanus toxoid booster (NIPHE, Bilthoven, The 
Netherlands). For six of the ten children enough material was available to additionally 
evaluate tetanus specific IgG Fc N-glycosylation changes. Three girls and all boys were 
tested positive for helminth infection and one girl was tested positive for malaria. The 
study was approved by the ethics committee of the International Foundation of the 
Albert Schweitzer Hospital in Lambaréné. Written informed consent was obtained from 
the parents or legal guardians of each child prior to participation in the study.216
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Preparation of antigen-specific affinity beads. For the preparation of antigen-specific 
beads pooled vaccine doses of Focetria (20 doses), Begrivac 2004/2005 (4 doses) and 
tetanus toxoid (10 doses) were buffered 4:1 (v:v) with 0.2 M sodium bicarbonate (Fluka, 
Steinheim, Germany) containing 0.5 M sodium chloride (Merck, Darmstadt, Germany). 
NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare, Uppsala, Sweden) were 
washed 3 times with 10 volumes of ice-cold 1 mM hydrochloric acid (HCl; Merck), and 
to 200-400 µl of the beads buffered Focetria, Begrivac or tetanus toxoid was applied. 
The antigens were immobilized overnight at 4ºC under continuous shaking followed 
by a 4 h blocking of residual NHS groups at RT with 0.1 M tris(hydroxymethyl)
aminomethane (Tris; Roche Diagnostics, Manheim, Germany) brought to pH 8.5 with 
HCl (Merck). Beads were washed 3 times with alternating pH using 0.1 M glacial acetic 
acid (Merck) with 0.5 M sodium chloride (pH 4-5) and Tris-HCl (pH 8.5) and stored 
in 0.1 M Tris-HCl (pH 8.5) with 20% ethanol at 4ºC until usage.
IgG glycosylation analysis. Human polyclonal IgGs (IgG1, 2 and 4) were captured from 
2 µl plasma or serum by affinity chromatography with Protein A-SepharoseTM Fast Flow 
beads (GE Healthcare) in 96-well plates as described previously.148 Vaccine-specific 
IgGs were purified from 20 µl human plasma or serum by incubation with 3-5 µl of the 
immobilized tetanus toxoid or influenza antigen beads in 96-well filter plates for one hour. 
Captured antibodies were washed with 3 x 200 µl PBS, 3 x 200 µl water, eluted with 100 µl 
of 100 mM formic acid (Fluka) and dried by vacuum centrifugation. Purified IgGs (total 
and vaccine-directed) were dissolved in 20 µL of 50 mM ammonium hydrogencarbonate 
buffer (Fluka), and shaken for 10 minutes. To minimize potential autolysis and missed 
cleavages, lyophilized sequencing grade modified trypsin (Promega, Madison, WI) was 
dissolved in ice-cold 1 mM acetic acid (Merck, Darmstadt, Germany), and immediately 
20 µL was added to the IgG samples. Samples were shaken for 1 minute, checked for 
the correct pH (>6) and incubated overnight at 37ºC. The digests were centrifuged at 
4000 rpm for 5 min and aliquots (250 nl for total IgG, 5000 nl for vaccine specific IgG) 
were analyzed by fast nanoLC-ESI-MS217 on a Ultimate 3000 HPLC system (Dionex 
Corporation, Sunnyvale, CA) equipped with a Dionex Acclaim PepMap100 C18 (5 μm 
Table 1. Human sample cohort.
Group Sex Counts Vaccination
Age (years)
Youngest Oldest Mean STD
Caucasian Female 7 Influenza (Focetria) 33 58 45.7 9.9
Male 3 Influenza (Focetria) 26 59 40.7 16.8
African Female 6 Influenza (Begrivac) 7 11 8.8 1.6
Male 4 Influenza (Begrivac) 8 10 9.0 0.8
African Female 4 Tetanus 7 11 9.3 1.71
Male 2 Tetanus 9 10 9.5 0.71
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particle size, 5 mm x 300 μm i.d.) trap column and an Ascentis Express C18 nano column 
(2.7 μm HALO fused core particles, 50 mm x 75 μm i.d.; Supelco, Bellefonte, USA), 
which were coupled to a micrOTOF-Q mass spectrometer (Bruker Daltonics, Bremen, 
Germany) by a sheath-flow-ESI sprayer (capillary electrophoresis ESI-MS sprayer; 
Agilent Technologies, Santa Clara, USA).217 Scan spectra were recorded from 300 to 2000 
dalton with 2 average scans at a frequency of 1 Hz. The Ultimate 3000 HPLC system and 
the Bruker micrOTOF-Q were respectively operated by Chromeleon Client version 6.8 
and micrOTOF control version 2.3 software. Liquid chromatography-mass spectrometry 
datasets were internally calibrated using a list of known glycopeptides and exported to 
the open mzXML using Bruker DataAnalysis 4.0 in batch mode. Data processing was 
performed with the in-house developed software msalign2,153 a simple warping script 
in AWK,154 “Xtractor2D” and Microsoft Excel. The software and ancillary scripts are 
freely available at www.ms-utils.org/Xtractor2D. Relative intensities of 46 glycopeptide 
species (Table 2) derived from IgG1 (18 glycoforms), IgG4 (10 glycoforms), and IgG2 (18 
glycoforms) were obtained by integrating and summing three isotopic peaks followed by 
normalization to the total subclass-specific glycopeptide intensities. 
On the basis of the normalized intensities for the various IgG Fc N-glycoforms the 
level of galactosylation, sialylation, bisecting N-acetylglucosamine and fucosylation 
was calculated. The level of galactosylation was calculated according to the formula 
(G1F + G1FN + G1FS + G1FNS + G1 + G1N + G1S) * 0.5 + G2F + G2FN + G2FS + 
G2FNS + G2 + G2N + G2S for the IgG1 and IgG2 subclasses and (G1F + G1FN + G1FS 
+ G1FNS) * 0.5 + G2F + G2FN + G2FS + G2FNS for the IgG4 subclass. The prevalence 
of IgG sialylation was determined by summation of all sialylated Fc N-glycopeptide 
species (G1FS, G2FS, G1FNS, G2FNS, G1S and G2S for IgG1 and IgG2, and G1FS, 
G2FS, G1FNS and G2FNS for IgG4). The number of sialic acid moieties present on the 
galactose moieties (SA/Gal) is calculated by dividing the prevalence of IgG sialylation 
by 2 * the level of galactosylation. The incidence of bisecting N-acetylglucosamine is 
obtained by summing all bisected Fc N-glycopeptide species (G0FN, G1FN, G2FN, 
G1FNS, G2FNS, G0N, G1N and G2N for the IgG1 and IgG2 subclass or G0FN, G1FN, 
G2FN, G1FNS and G2FNS for the IgG4 subclass). The percentage of IgG1 and IgG2 
fucosylation was determined by summing the relative intensities of all fucosylated Fc 
N-glycopeptide species (G0F, G1F, G2F, G0FN, G1FN, G2FN, G1FS and G2FS). For 
the IgG4 subclass no fucosylation level was determined as the afucosylated species 
remained below the limit of detection.
Statistical analysis. Differences between the 3 vaccination time points were evaluated 
using the Friedman test. Uncorrected p-values < 0.05 were considered statistically 
significant. In depth analyses of the differences between protein A (total IgG1) and 
vaccine-specific purified IgG1 were performed with the Wilcoxon Signed Rank test. 
p-Values were adjusted for multiple comparisons by Bonferroni correction, and 
p-values < 0.013 were considered statistically significant. Data evaluation and statistical 
analyses were performed with Microsoft Excel and SPSS 16.0, respectively.
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[M+2H]2+  [M+3H]3+ [M+2H]2+  [M+3H]3+ [M+2H]2+  [M+3H]3+
No glycan 595.260 397.176 579.265 386.513 587.262 391.844
G0Fc 1317.527 878.687 1301.532 868.024 1309.529 873.356a1
G1F 1398.553 932.705 1382.558 922.042 1390.556 927.373a2
G2F 1479.580 986.722 1463.585 976.059 1471.582 981.391
G0FN 1419.067 946.380 1403.072 935.717 1411.069 941.049a3
G1FN 1500.093 1000.398 1484.098 989.735 1492.096 995.066a4
G2FN 1581.119 1054.416 1565.124 1043.752 1573.122 1049.084
G1FS 1544.101 1029.737 1528.106 1019.073 1536.104 1024.405a5
G2FS 1625.127 1083.754 1609.132 1073.091 1617.130 1078.423
G1FNS 1645.641 1097.430 1629.646 1086.766 1637.643 1092.098
G2FNS 1726.667 1151.447 1710.672 1140.784 1718.670 1146.116
G0 1244.498 830.001 1228.503 819.338 - -
G1 1325.524 884.019 1309.529 873.356a1 - -
G2 1406.551 938.036 1390.556 927.373a2 - -
G0N 1346.038 897.694 1330.043 887.031 - -
G1N 1427.064 951.712 1411.069 941.049a3 - -
G2N 1508.090 1005.730 1492.096 995.066a4 - -
G1S 1471.072 981.051 1455.077 970.387 - -
G2S 1552.098 1035.068 1536.104 1024.405a5 - -
a1 – a5isomeric glycopeptide species of IgG4 and IgG2.
bSwissProt entry number
ctryptic IgG glycopeptide sequence
dglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
Results 
To evaluate IgG Fc N-glycosylation changes upon vaccination tryptic IgG glycopeptides 
prepared from human plasma or serum were analyzed using a recently established fast 
nanoLC-ESI-MS method.217 An optimized tryptic cleavage procedure was applied, 
and no missed tryptic cleavages were observed. On the basis of literature knowledge 
of IgG N-glycosylation3,4,9,10,79 the nanoLC-ESI-MS method allowed unambiguous 
assignment of 46 IgG glycopeptides species (18 glycoforms of IgG1, 10 of IgG4, and 18 
of IgG2; Table 2). Glycoforms having 5 N-acetylhexosamine residues were interpreted 
as bisected species.3,4,9,10,79 In agreement with literature data, N-acetylneuraminic acid 
was the only form of sialic acids observed in our analysis.3,4,9,10,79 The fast nanoHPLC 
separation together with the integration and summation of multiple isotopic peaks for 
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each assigned IgG Fc N-glycopeptide species provides subclass-specific glycosylation 
information with good precision.217 No indications for the presence of trypsin missed 
cleavages were obtained as a result of the optimized digestion protocol and were 
therefore not included in the data.
Fc N-glycosylation profiles of total IgG and antigen affinity captured IgG were 
evaluated for 10 Caucasian adults and 10 African children prior to vaccination and 
at several time points after vaccination. For each individual similar total IgG1 Fc 
N-glycopeptide profiles were observed at all vaccination time points (typical example 
Figure 1A-C; Figure S-1A-C). By contrast, antigen affinity-purified IgG1 showed 
changes in Fc N-glycopeptide profiles with time (typical example Figure 1D-F; Figure 
S-1D-I). Higher intensities for galactosylated glycoforms were observed for Caucasian 
adults at day 21 and 56 of influenza vaccination as compared to day 0 (Figure 1E-F). 
Similarly, in African children galactosylated glycoforms for influenza and tetanus 
affinity-purified IgG1 were higher at day 14 and 28 than before vaccination (Figure 
S-1). Only very low signals were obtained for IgG4 and IgG2 Fc N-glycopeptides in 
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Figure 1. Nano-RPLC-ESI-MS profiles (sum spectra of 1 min) of tryptic IgG1 glycopeptides 
purified from Caucasian plasma by protein A (A-C) and influenza vaccine (D-F) affinity 
chromatography at day 0 (A and D), day 21 (B and E), and day 56 (C and F) after vaccination. 
Glycan code as in Figure 1 of Chapter 1.
122
time. We, therefore, excluded IgG4 and IgG2 glycosylation from further analysis. In the 
following, the vaccination-associated changes in IgG1 fucosylation, galactosylation, 
sialylation, and the incidence of bisecting GlcNAc are described.
Fucosylation. Differences between total and antigen affinity-purified IgG1 were 
evaluated using the Wilcoxon Signed Rank test. Only the day 0 time point of Begrivac 
affinity-purified IgG1 of African children showed a significantly lower fucosylation 
compared with total IgG1 (p-value = 0.007; Table S-1, medians available in Table 3 and 
4). Next we looked for longitudinal changes in IgG1 Fc fucosylation by evaluating the 
three time points with the Friedman test. Total and antigen affinity-purified IgG1 of 
Caucasian adults (Figure 2A, F) and African children (Figure 3A, F, K) did not show 
any changes in Fc fucosylation during the influenza or tetanus vaccination time courses.
Galactosylation. In Caucasians and Africans the median level of galactosylation for 
total IgG1 at day 0 (medians available in Table 3 and 4) was significantly lower than 
for the influenza affinity purified IgG1 (p-values = 0.005; Table S-1). At the two time 
points after vaccination (day 21 and 56 for Caucasians, day 14 and 28 for Africans) 
the level of galactosylation for total IgG1 remained significantly lower compared 
with the corresponding time points of influenza specific purified IgG1 (p-values = 
0.005; Table S-1). For the difference in galactosylation between total IgG1 and tetanus 
affinity-purified IgG1 p-values of 0.028 were observed which were considered to be 
non-significant after correction for multiple testing. The Friedman test showed changes 
in galactosylation upon vaccination of Caucasian adults (Figure 2B, G) and African 
children (Figure 3B, G, L): antigen affinity-purified IgG1 showed a significant increase 
in the level of Fc galactosylation (p-value < 0.01; Tables 3 and 4) while no change was 
observed for total IgG. More specifically the level of galactosylation of influenza affinity 
purified IgG1 of Caucasians was significantly increased from 62.1% (median) at day 0 
to 72.9% (median) at day 21 (p-value = 0.005). At day 56 the level of galactosylation 
(median = 68.9%) remained significantly elevated compared with day 0 (p-value = 
0.005) and showed a tendency towards lower IgG1 galactosylation levels than at day 
21 (p-value = 0.047). For African children the median levels of galactosylation of 
influenza affinity purified IgG1 significantly increased from 56.0% at day 0 to 74.3% at 
day 14 (p-value = 0.005) and 67.9% at day 28 (p-value = 0.007). At day 28 the level of 
IgG1 galactosylation was significantly lower compared with day 14 (p-value = 0.005). 
For tetanus specific purified IgG1 the Friedman test showed a significant change in 
time for the level of galactosylation (p-value = 0.006; Table 4). Evaluation of the specific 
differences between the time points with the Wilcoxon Signed Rank test showed a 
trend towards higher levels of galactosylation upon vaccination of the 6 children with 
the tetanus booster (median at day 0 = 51.3%, day 14 = 64.7% and day 28 = 62.1%; 
p-value = 0.028). In accordance, at the level of the individual glycoforms influenza and 
tetanus vaccination resulted in a significant decrease of the G0F species, while the G2F 
and G2FS species were significantly increased (p-values < 0.01; Table S-2 and 3).
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Figure 2. Change in IgG1 glycosylation upon influenza vaccination of Caucasian adults. For total 
IgG1 (A-E) and antigen (F-J) affinity-purified IgG1 the levels of fucosylation (A, F), galactosylation 
(B, G) sialylation (C, H), SA/Gal (D, I) and bisecting N-acetylglucosamine (E, J) are given.
Figure 3. Change in IgG1 glycosylation upon influenza and tetanus vaccination of African 
children. For total IgG1 (A-E), and influenza (F-J) and tetanus (K-O) affinity-purified IgG1 the 
levels of fucosylation (A, F, K), galactosylation (B, G, L) sialylation (C, H, M), SA/Gal (D, I, N) 
and bisecting N-acetylglucosamine (E, J, O) are given.
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Sialylation. At day 0 total IgG1 of African children showed a lower median level of 
sialylation (medians available in Table 4) than influenza affinity-purified IgG1 (p-value 
< 0.01; Table S-1). For both Africans and Caucasians the median levels of sialylation 
for influenza affinity-purified IgG1 at time points 2 and 3 were significantly higher 
compared with total IgG1 (p-value < 0.01; Table S-1).  Influenza affinity-purified IgG1 
showed a change in the level of sialylation during vaccination for Caucasian (Figure 
3C, H) and African (Figure 3C, H, M) individuals (Friedman test p-value < 0.001; 
Table 3 and 4). The Wilcoxon Signed Rank test revealed a significant increase in the 
median level of sialylation of influenza affinity purified IgG1 from 16.7% at day 0 to 
24.9% at day 21 (p-value = 0.005) in Caucasian adults, which remained elevated with 
23.6% at day 56 (p-value = 0.005). No significant difference was observed in the level 
of sialylation between day 28 and 56. For the African children a significant increase in 
the median level of sialylation of influenza affinity purified IgG1 was observed between 
day 0 (median = 20.1%) and day 14 (median = 30.4%; p-value = 0.005), while day 28 
(median = 25.9%) only showed a tendency towards higher levels (p-value = 0.022). The 
level of IgG1 sialylation at day 28 was significantly decreased compared with day 14 
(p-value = 0.005). For the 6 African children with additional tetanus boost vaccination 
the Friedman test showed a tendency towards changed levels of sialylation of the 
tetanus affinity purified IgG1 (p-value = 0.06; Table 4). 
Next we evaluated the number of sialic acids per galactose moiety (SA/Gal; medians 
available in Table 3 and 4). At day 0 the number of SA/Gal did not significantly differ 
between total IgG1 and antigen affinity purified IgG1 (influenza and tetanus) (Table 
S-1). By contrast, at the time points after vaccination the number of SA/Gal was 
significantly higher for influenza affinity-purified IgG1 than for total IgG1 (p-values 
< 0.01; Table S-1). No significant difference in the number of SA/Gal was reached 
for the corresponding time points of total IgG1 and tetanus affinity-purified IgG1. 
Changes in the number of SA/Gal during the vaccination time course were evaluated 
with the Friedman test. Upon vaccination more sialic acid moieties were found per 
galactose independent of the ethnicity (Figure 2D, I, Figure 3D, I, N, Table 3 and 
Table 4). In depth analysis of the data for Caucasions adults with the Wilcoxon Signed 
Rank test showed increased ratios at days 28 and 56 as compared with day 0 (p-value 
= 0.005). For influenza affinity purified IgG1 of African children this increase was 
significant between day 0 and day 14 (p-value = 0.005), but not between day 0 and 
day 28. Likewise, for the six African children additionally vaccinated against tetanus 
Friedman’s test indicated that there was a significant change in the amount of SA/Gal 
(Table 4). However, significance was not reached for the comparison of the different 
time points with the Wilcoxon Signed Rank test.
Incidence of bisecting N-acetylglucosamine. Finally we evaluated the level of 
bisecting N-acetylglucosamine and compared the obtained medians of total IgG1 for 
each time point (medians available in Tables 3 and 4) with the corresponding time 
IgG glycosylation with vaccination
6
125
points after vaccine affinity purification. At day 0 no significant differences were 
observed between total IgG1 and antigen affinity-purified IgG1 (Table S-1). After 
vaccination, influenza affinity-purified IgG1 showed a significantly lower level of 
bisecting N-acetylglucosamine compared with total IgG1 at the corresponding time 
points (p-value < 0.01; Table S-1). By contrast, significance was not reached when 
we compared the corresponding time points between total IgG1 and tetanus affinity-
purified IgG1. After influenza vaccination all individuals showed a decrease in the 
level of bisecting N-acetylglucosamine on influenza affinity-purified IgG1 (Figure 2E, 
J and Figure 3E, J, O) (Friedman test p-value < 0.001; Table 3 and 4). This decrease 
did not reach statistical significance for tetanus affinity-purified IgG1. The Wilcoxon 
Signed Rank test revealed that in Caucasian adults the median level of bisecting 
N-acetylglucosamine on influenza affinity purified IgG1 decreased from 17.6% at day 0 
to 12.2% at day 21 (p-value = 0.005). The median level at day 56 was comparable (12.5%) 
to the level at day 21. For the African children the level of bisecting N-acetylglucosamine 
on influenza affinity purified IgG1 decreased from a median of 11.9% at day 0 to 7.5% 
at day 14 (p-value = 0.005). The level of bisecting N-acetylglucosamine at day 28 were 
significantly lower than at day 28 (median = 10.0%) than at day 0 (p-value = 0.005) yet 
higher than at day 14 (p-value = 0.005).
Discussion
IgG effector mechanisms are influenced by the attached Fc N-glycans. Here we studied 
changes in IgG Fc N-glycosylation upon vaccination of 10 Caucasian adults and 10 
African children. To our knowledge, glycosylation of the constant region of human 
plasma IgG1 is restricted to N-glycosylation at Asn297, and no literature reports on 
O-glycosylation of the constant region are available. IgG Fc N-glycosylation profiles 
were determined using a recently described fast nanoLC-ESI-MS method, which 
allows accurate registration of tryptic IgG1, IgG2 and IgG4 Fc N-glycopeptides in 
Table 3. Friedman test for the IgG1 glycosylation features of Caucasian adults.
Glycosylation feature
Medians
p-values*Protein A Focetria 09
Day 0 Day 21 Day 56 Day 0 Day 21 Day 56 Protein A Focetria 09
Fucosylation 91.6 91.6 91.5 91.0 90.7 91.9 0.061 0.061
Bisecting N 16.2 15.8 16.2 17.6 12.2 12.5 0.150 < 0.001
Galactosylation 56.9 57.7 57.1 62.1 73.0 68.9 0.082 < 0.001
Sialylation 14.0 13.6 14.7 16.7 24.9 23.6 0.905 < 0.001
SA/Gal 12.6 12.6 13.4 13.5 17.4 17.2 0.670 < 0.001
*Friedman test p-value < 0.05 are considered to be significant and are highlighted in bold.
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a single analysis.217 The relative expression levels were determined for a total of 46 
IgG Fc N-glycopeptides (Table 2) which were assigned unambiguously on the basis 
of literature knowledge of IgG N-glycosylation.3,4,9,10,79 From these data a set of IgG Fc 
N-glycosylation features, namely fucosylation, galactosylation, sialylation, SA/Gal and 
the level of bisecting N-acetylglucosamine were determined.217
There were no vaccine related longitudinal changes in glycosylation of total 
IgG1, IgG2, and IgG4. We did detect glycosylation changes of vaccine-specific IgG1 
in time. Active immunization with influenza or tetanus toxoid induced higher levels 
of galactosylation and sialylation and decreased the bisecting GlcNAc of antigen-
directed IgG1. Interestingly, we observed an increase in the number of SA/Gal upon 
vaccination which might indicate a differential regulation of β4-galactosyltransferase 
and sialyltransferase activities involved in IgG Fc N-glycosylation during biosynthesis 
in B-lymphocytes.57 We did not observe significant changes in the level of fucosylation 
for total IgG and antigen-directed IgG1. No further changes in the glycosylation profiles 
were observed upon the second immunization of the Caucasians with influenza (day 
21) which was possibly due to the large time difference (35 days) between the boost 
vaccination and sampling. 
Our results are in contrast to the results of murine immunization studies: active 
immunization of specific pathogen free CBA/Ca mice with BSA causes a decrease 
in the galactosylation level for anti-BSA IgG.34 In a murine serum nephritis model, 
immunization caused a drastic reduction of the IgG sialic acid content.35 Upon 
repeated immunization with ovalbumin, increased levels of IgG fucosylation have been 
observed for male ICR mice.211 Specific pathogen free mice transferred from a sterile 
to a conventional environment showed an initial increase in the total IgG galactose 
content up to day 17 after which it decreased.34 This galactosylation effect on the level of 
total IgG is similar to our observation of an initial galactosylation increase on vaccine-
specific directed IgG1. However, specific pathogen free control mice remaining in 
the sterile environment revealed a similar galactosylation change, suggesting that the 
Table 4. Friedman test for the IgG1 glycosylation features of African children.
Glycosylation feature
Medians
p-values*Protein A Begrivac 04/05 Tetanus
Day 0 Day 14 Day 28 Day 0 Day 14 Day 28 Day 0 Day 14 Day 28 Protein A Begrivac Tetanus
Fucosylation 95.1 94.8 94.8 94.2 93.8 93.0 93.1 94.7 94.7 0.497 0.741 0.135
Bisecting N 11.8 11.5 11.6 11.9 7.5 10.0 13.4 10.3 10.8 0.122 < 0.001 0.160
Galactosylation 47.5 49.0 48.2 56.0 74.3 67.9 51.3 64.7 62.1 0.027 < 0.001 0.006
Sialylation 15.1 16.1 15.3 20.1 30.4 25.9 16.6 26.5 24.4 0.122 < 0.001 0.060
SA/Gal 15.4 16.8 15.8 17.3 20.8 19.7 16.0 19.5 18.8 0.202 < 0.001 0.002
*Friedman test p-values < 0.05 are considered to be significant and are highlighted in bold.
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observed effect was caused by aging of the mice rather than due to infection. Murine 
and human IgG subclasses/isotypes are different in various respects including their 
glycosylation, as murine IgG Fc N-glycans contain no bisecting GlcNAc and may carry 
N-glycolylneuraminic acid which is not found on human IgG.218-220 In addition, lectins 
expressed on murine effector cells differ from those expressed in humans (e.g. SIGN-R1 
an orthologue of the human DC-SIGN).47,48 Furthermore, murine glycoproteins and 
glycoproteins expressed in murine cell lines contain Galα1,3-Gal epitopes.221-223 Hence, 
the study of specific glycosylation changes in murine models might not translate 
directly to the situation in humans. 
IgG1 Fc N-glycans containing a bisecting N-acetylglucosamine have been shown 
to exhibit increased ADCC potency in in-vitro assays.213,214 The decrease in the level 
of bisecting N-acetylglucosamine on antigen-directed IgG1 upon vaccination might, 
therefore, suggest a lower ADCC potency of the anti-vaccine IgG1. While the high level 
of IgG1 Fc galactosylation found in our study is likewise expected to result in rather 
weak interactions with activating Fcγ-receptors and, consequently, ADCC,35 high levels 
of Fc galactosylation have been found to lead to enhanced complement-dependent 
cytotoxicity (CDC).181,224 Tetanus toxoid225 and influenza envelope glycoprotein 
(hemagglutinin and neuraminidase)226-228 vaccines elicit high neutralizing antibody 
responses which have been correlated to vaccine-induced protective immunity. 
Influenza vaccine induced effector functions by non-neutralizing antibodies have also 
been shown to be involved in influenza clearance,229-233 and these effector functions are 
expected to be modulated by the glycosylation changes described here. The precise 
effector mechanisms involved in vaccine-mediated protection are far from clear and 
different mechanisms might apply for different viruses under different conditions.234 
B-lymphocytes may produce IgGs with distinct Fc N-glycosylation profiles as is 
exemplified by the glycosylation differences between vaccine-specific IgG1 and total 
serum/plasma IgG1. First steps towards elucidating the underlying regulatory IgG 
glycosylation mechanisms in B-cells have recently been performed.57 The glycosylation 
of IgG1 produced by B lymphocytes in-vitro is influenced by environmental 
factors (all-trans retinoic acid) and factors known to stimulate the innate (i.e. CpG 
oligodeoxynucleotide) or adaptive (i.e. interleukin 21) immune system.57 Interestingly, 
the reported short-term increase in galactosylation and decrease in bisecting GlcNAc 
of IgG1 in oligodeoxynucleotide or interleukin 21 stimulated B-cells is in agreement 
with our observations during vaccination of humans. Modern vaccines such as those 
used in this study often contain adjuvants to enhance the immunogenicity of subunit 
(microbe strains and purified proteins) and DNA vaccines. Adjuvants can modify the 
outcome of epitope presentation to the immune system by specific TH1 versus TH2 
polarization efficacy.235 The observed IgG Fc N-glycosylation changes, therefore, might 
be a result of a combined immune response towards the antigens and the adjuvant.
One may expect that prior to vaccination the individuals have had several 
encounters with cross reactive influenza strains via infections or previous vaccinations 
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resulting in the resting state IgG glycosylation profile at day 0. While glycosylation 
changes were observed within weeks after vaccination, IgG1 Fc glycosylation profiles 
obtained 9 months after influenza vaccination (determined for four African children, 
data not shown) were very similar to the profiles at day 0 and are likewise interpreted 
as resting state profiles.
Seasonal flu (influenza) vaccination usually precedes the encounter with the 
virus by weeks or months (prophylactic). Hence antibodies with high galactosylation 
and sialylation but with low incidence of bisecting GlcNAc are expected to be the 
ones involved in the defence against seasonal flu. Tetanus vaccination provides two 
scenarios as it is often performed directly after a wound (curative), and as preventive 
vaccination (prophylactic) which protects the individual 10-15 years. Our data indicate 
that depending on the vaccination time point the infectious agent will encounter IgGs 
with different glycosylation profiles (acute, high galactosylation, high sialylation versus 
resting state, low galactosylation, low sialylation) which might influence the antibody 
effector functions relevant in immunity. Interestingly, the observed switching points in 
the glycosylation features follow the antibody titers (data not shown).215,216
In conclusion, analysis of different populations and races shed some light on natural 
effects of vaccination on antibody glycosylation profiles. Obviously, glycosylation 
patterns observed by us upon vaccination can not be easily explained from a teleological 
point of view, but it should be stressed that the regulatory aspects and functional 
implications of human IgG glycosylation features are still largely unknown, and that 
further research is required.
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Figure S-1. Nano-RPLC-ESI-MS profiles (sum spectra of 1 min) of tryptic glycopeptides of 
IgG1 purified from African plasma by affinity chromatography with protein A (A-C), influenza 
vaccine (D-F) and tetanus toxoid (G-I) beads at day 0 (A, D, G), day 14 (B, E, H), and day 28 (C, 
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Caucasians Focetria - 
Protein A
Africans Begrivac - 
Protein A
Africans Tetanus - 
Protein A
Day 0 Day 21 Day 56 Day 0 Day 14 Day 28 Day 0 Day 14 Day 28
Fucosylation 0.022 0.017 0.575 0.007 0.074 0.093 0.028 0.753 0.600
Galactosylation 0.005 0.005 0.005 0.005 0.005 0.005 0.028 0.028 0.028
Sialylation 0.022 0.005 0.005 0.005 0.005 0.009 0.046 0.028 0.028
SA/Gal 0.203 0.005 0.005 0.037 0.005 0.005 0.116 0.028 0.028
Bisecting GlcNAc 0.333 0.005 0.005 0.093 0.005 0.007 0.249 0.075 0.075
G0Fa 0.005 0.005 0.005 0.005 0.005 0.005 0.028 0.028 0.028
G1F 0.009 0.005 0.005 0.114 0.005 0.007 0.028 0.046 0.075
G2F 0.007 0.005 0.005 0.059 0.005 0.005 0.345 0.028 0.028
G0FN 0.074 0.005 0.005 0.005 0.005 0.005 0.046 0.028 0.028
G1FN 0.203 0.005 0.005 0.013 0.013 0.203 0.463 0.116 0.173
G2FN 0.007 0.575 0.093 0.005 0.005 0.005 0.028 0.075 0.116
G1FS 0.285 0.007 0.009 0.169 0.005 0.022 0.116 0.249 0.116
G2FS 0.013 0.005 0.005 0.007 0.005 0.007 0.075 0.028 0.028
G1FNS 0.575 0.241 0.333 0.005 0.013 0.093 0.028 0.028 0.028
G2FNS 0.047 0.017 0.028 0.005 0.007 0.005 0.028 0.028 0.028
G0 0.059 0.241 0.139 0.575 0.028 0.005 0.249 0.345 0.046
G1 0.017 0.047 0.959 0.059 0.139 0.241 0.028 0.917 0.463
G2 0.005 0.013 0.093 0.114 0.028 0.037 0.028 0.173 0.463
G0N 0.799 0.093 0.028 0.646 0.007 0.114 0.345 0.917 0.345
G1N 0.646 0.009 0.017 0.386 0.017 0.059 0.075 0.917 0.753
G2N 0.005 0.007 0.114 0.007 0.017 0.022 0.028 0.028 0.046
G1S 0.575 0.169 0.093 0.005 0.114 0.203 0.116 0.345 0.028
G2S 0.037 0.013 0.074 0.022 0.093 0.093 0.028 0.173 0.075
G1NS 0.508 0.017 0.022 0.007 0.013 0.022 0.028 0.028 0.075
G2NS 0.386 0.005 0.059 0.017 0.017 0.028 0.028 0.028 0.046
*Wilcoxon Signed Ranks Test p-value < 0.013 are considered to be significant and are highlighted in bold.
aglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
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Table S-2. Friedman test for IgG1 glycosylation features of European adults.
Glycosylation feature
Medians
p-values*Protein A Focetria 09
Day 0 Day 21 Day 56 Day 0 Day 21 Day 56 Protein A Focetria 09
G0Fa 15.3 15.4 14.8 12.1 6.4 9.4 0.273 < 0.001
G1F 32.0 31.6 31.4 28.4 23.1 23.6 0.007 < 0.001
G2F 17.4 18.1 17.4 18. 873 26.7 24.0 < 0.001 < 0.001
G0FN 3.8 3.8 3.8 3.7 2.3 2.3 0.014 < 0.001
G1FN 8.4 8.2 8.3 8.8 5.9 6.3 0.301 < 0.001
G2FN 1.7 1.8 1.8 2.1 1.6 1.9 0.497 0.202
G1FS 1.8 1.8 1.8 1.8 1.5 1.6 0.082 0.007
G2FS 10.1 9.9 11.1 12.2 20.6 19.2 0.273 < 0.001
G1FNS 0.5 0.5 0.5 0.5 0.5 0.5 0.150 0.905
G2FNS 0.4 0.4 0.4 0.5 0.4 0.4 0.067 0.122
G0 1.0 0.9 1.0 1.3 0.7 0.7 0.003 0.067
G1 2.5 2.5 2.6 2.7 3.0 2.4 0.905 0.027
G2 1.9 1.9 2.0 2.3 2.7 1.9 0.497 0.014
G0N 0.3 0.3 0.3 0.3 0.2 0.2 0.014 0.741
G1N 0.6 0.6 0.6 0.7 0.4 0.4 0.273 0.122
G2N 0.3 0.3 0.3 0.4 0.4 0.4 0.150 0.273
G1S 0.2 0.2 0.2 0.2 0.2 0.2 0.067 0.670
G2S 0.8 0.8 0.8 0.9 1.2 0.8 0.273 0.008
G1NS 0.1 0.1 0.2 0.2 0.3 0.2 0.741 0.497
G2NS 0.2 0.1 0.2 0.2 0.2 0.2 0.061 0.301
*Friedman test p-values < 0.05 are considered to be significant and are highlighted in bold.
aglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
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p-values*Protein A Begrivac 04/05 Tetanus
Day 0 Day 14 Day 28 Day 0 Day 14 Day 28 Day 0 Day 14 Day 28 Protein A Infuvac Tetanus
G0Fa 27.4 26.8 26.5 19.1 7.4 11.6 25.1 13.4 14.9 0.082 < 0.001 0.006
G1F 29.5 29.3 29.4 28.4 24.1 26.6 27.6 27.2 27.9 0.497 0.002 0.042
G2F 13.2 14.1 13.3 16.8 26.5 23.8 13.3 20.1 20.1 0.061 < 0.001 0.006
G0FN 5.1 4.7 5.0 4.1 1.4 2.5 4.9 2.5 2.7 0.007 < 0.001 0.006
G1FN 4.4 4.2 4.4 4.9 3.3 4.2 5.0 4.2 4.5 0.061 < 0.001 0.069
G2FN 0.7 0.8 0.7 1.0 1.1 1.1 1.1 1.2 1.1 0.741 0.407 0.846
G1FS 2.0 2.1 2.1 2.1 1.6 1.8 2.0 2.1 2.1 0.670 0.007 0.513
G2FS 11.1 12.0 11.1 14.9 26.6 20.8 11.9 21.4 20.0 0.061 < 0.001 0.006
G1FNS 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.5 0.5 0.497 0.741 0.311
G2FNS 0.2 0.2 0.2 0.4 0.3 0.3 0.3 0.4 0.4 0.202 0.273 0.846
G0 0.6 0.6 0.8 0.7 0.4 0.5 0.8 0.5 0.5 0.150 < 0.001 0.069
G1 1.5 1.4 1.4 1.6 1.9 2.0 1.9 1.5 1.4 0.301 0.407 0.115
G2 1.1 1.1 1.2 1.3 2.0 2.0 1.6 1.4 1.1 0.741 0.273 0.223
G0N 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.905 < 0.001 0.513
G1N 0.3 0.2 0.3 0.3 0.2 0.2 0.4 0.2 0.3 0.301 0.014 0.069
G2N 0.2 0.2 0.2 0.3 0.2 0.3 0.3 0.4 0.3 0.670 0.150 0.311
G1S 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.3 0.273 0.273 0.223
G2S 0.5 0.5 0.6 0.6 1.0 1.0 0.7 0.6 0.8 0.741 0.150 0.135
G1NS 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.273 0.122 0.311
G2NS 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.905 0.741 0.607
*Friedman test p-values < 0.05 are considered to be significant and are highlighted in bold.
aglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
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Abstract
N-glycosylation of the immunoglobulin Fc moiety influences its biological activity by 
e.g. modulating the interaction with Fcγ-receptors. Changes in IgG glycosylation have 
been found to be associated with various inflammatory diseases. Here we evaluated 
for the first time IgG Fc N-glycosylation changes in well-defined antibody-mediated 
autoimmune diseases, i.e. the neurological disorders Lambert-Eaton myasthenic 
syndrome, and myasthenia gravis with antibodies to muscle nicotinic acetylcholine 
receptors or muscle-specific kinase. IgGs were purified from serum or plasma by 
protein A affinity chromatography and digested with trypsin. Glycopeptides were 
purified and analyzed by MALDI-FTICR-MS. Glycoform distributions of both IgG1 
and IgG2 were determined for 229 patients and 56 controls. We observed an overall age 
and sex dependency of IgG Fc N-glycosylation which was in accordance with literature. 
All three disease groups showed lower levels of IgG2 galactosylation compared to 
controls. In addition, LEMS patients showed lower IgG1 galactosylation. Notably, 
the galactosylation differences were not paralleled by a difference in IgG sialylation. 
Moreover, the level of IgG core-fucosylation and bisecting N-acetylglucosamine were 
evaluated. The control and disease groups revealed similar levels of IgG Fc core-
fucosylation. Interestingly, LEMS patients below 50 years showed elevated levels of 
bisecting N-acetylglucosamine on IgG1 and IgG2, demonstrating for the first time the 
link of changes in the level of bisecting N-acetylglucosamine with disease.
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Introduction
Immunoglobulins (Igs) represent an important part of the human immune system and 
can adapt to many different antigenic challenges. Structural variety of Igs is achieved 
by the expression of a multitude of hypervariable regions which create the antigen 
binding site and define the antigen specificity and affinity. Moreover, multiple classes 
(i.e. IgM, IgD, IgG, IgA, IgE) and subclasses (e.g. IgG1-4) of immunoglobulins are 
present in humans, differing in temporal expression patterns as well as in function. 
Igs are glycosylated, and the attached glycans have been implicated in modulating 
antibody function.19,35,43,44,146 IgG represents the most abundant antibody class in the 
human circulation, being present at a concentration of approximately 10 mg/ml.1,2 They 
consist of two heavy chains and two light chains. Parts of the heavy chains, together 
with the light chains, form two fragment antigen binding (Fab) moieties, whilst the 
remainders of the two heavy chains form the fragment crystallizable (Fc) moiety. A 
single biantennary complex-type N-glycan is attached to the asparagine residue at 
position 297 in the CH2 domain of each heavy polypeptide chain of the Fc part. As a 
result of the glycosylation machinery a variety of biantennary complex-type N-glycans 
can be present (N-glycan microheterogeneity) which often carry a core-fucose and 
vary in the number of antenna galactose residues.3,4,147 Biantennary, core-fucosylated 
IgG Fc N-glycoforms with no, one, or two galactoses are referred to as G0F, G1F, and 
G2F, respectively. Moreover, these complex-type N-glycans may contain a bisecting 
N-acetylglucosamine and a sialic acid residue attached to an antenna galactose. 
In healthy individuals IgG glycosylation features are reflected in age, gender and 
pregnancy.8-10 For both males and females it has been shown that the percentage of 
galactosylated complex-type N-glycans on IgG decrease with increasing age. Compared 
to males of similar age, young females (<30 years) were found to express higher levels 
of galactosylated species, and galactosylation showed a more pronounced decrease 
with increasing age for females than for males.10 During pregnancy an increase in IgG 
galactosylation is observed, reaching the highest levels towards the end of the gestation 
period. After delivery IgG galactosylation decreases to the levels observed before 
pregnancy.14 
The biological activity of IgGs is modulated by Fc N-glycosylation. IgG sialylation 
has been shown to decrease in mice upon antigenic challenge, and it has been 
suggested that this change may provide a switch from innate anti-inflammatory 
activity in the steady state to an adaptive pro-inflammatory response.35 Moreover, in 
a mouse arthritis model it has been shown that the anti-inflammatory properties of 
intravenous immunoglobulin depends on α2,6-sialic acid linkages on IgG Fc N-glycans 
recognized by the C-type lectin SIGN R1 (an orthologue of the human DC-SIGN) 
expressed on murine macrophages in the splenic marginal zone.47,48 The lack of core-
fucosylation of IgG1 Fc N-glycans has been shown to result in an enhanced binding to 
Fcγ-receptor IIIa expressed on macrophages leading to increased antibody-dependent 
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cellular cytotoxicity (ADCC).43,44 Enhanced ADCC activity of afucosylated IgG1 may 
have profound effects on the severity of antibody-mediated autoimmune diseases.43-
45 Moreover, antibodies lacking core-fucosylation show enhanced efficacy in in-vitro 
ADCC assays and represent a potent new generation of anti-cancer therapeutics.44,46 
Enhanced ADCC has also been related to an increased expression of bisecting 
N-acetylglucosamine on complex type Fc N-glycans.213,214 However, this was shown 
in-vitro and studies to confirm these findings in-vivo are required. 
A decrease of IgG galactosylation has been shown to occur with various infectious 
diseases, autoimmune diseases, and cancer.3,32,147,236 IgGs with lowered galactosylation 
have been shown to exhibit increased potency in causing collagen-induced arthritis in 
a mouse model.19 Moreover, low degrees of IgG Fc galactosylation have been associated 
with high disease activity in rheumatoid arthritis.15,18,146 
The hitherto studied autoimmune diseases for which lowered IgG galactosylation 
has been demonstrated are characterized by both cellular and humoral autoimmunity. 
We here study IgG Fc N-glycosylation in autoimmune diseases, for which the role 
of pathogenic antibodies against well known target antigens has been described in 
detail. In the Lambert-Eaton myasthenic syndrome (LEMS) antibodies are directed 
against presynaptic voltage-gated calcium channels (VGCC), and in myasthenia 
gravis (MG) antibodies are found against either the postsynaptic muscle nicotinic 
acetylcholine receptors (AChR) or muscle-specific kinase (MuSK). The antibodies 
against these antigens impair the function of the neuromuscular junction resulting 
in fatigable weakness.237 Half of the patients with LEMS have a small-cell lung 
carcinoma238, which is known to express VGCC, while about 15% of the patients with 
MG have a thymoma.
Shifts in IgG Fc N-glycosylation features in well-defined antibody-mediated 
autoimmune diseases could provide valuable insights into which IgG Fc N-glycosylation 
features potentially influence antibody pathogenicity. In this study we, therefore, 
compared IgG Fc N-glycosylation features in LEMS and MG patients with presumably 
healthy controls by registering tryptic IgG1 and IgG2 glycopeptides with MALDI-
FTICR-MS using a recently described protocol.148 In addition, the effect of tumor on 
IgG Fc N-glycosylation was analyzed for LEMS patients.
Experimental section
Study cohort. The study cohort is described in Table 1. For the control group 27 human 
sera (15 male, 12 female) and 29 human citrate plasma samples (10 male, 19 female) 
were obtained from presumably healthy individuals. As no selection on the health 
status in the control cohort was performed, prevalence of diseases which are known to 
interfere with IgG Fc N-glycosylation is assumed to be low. Patients with LEMS with 
or without a small-cell lung carcinoma, non-thymoma AChR MG and MuSK MG were 
obtained from nationwide studies described previously.239,240
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IgG glycopeptide profiling. IgG capturing, tryptic cleavage, glycopeptide purification, 
and MALDI-FTICR-MS analysis were performed as described elsewhere.148 Briefly, 
human polyclonal IgGs were captured from 2 µl plasma or serum by affinity 
chromatography with Protein A-SepharoseTM Fast Flow beads (GE Healthcare, 
Uppsala, Sweden), and digested overnight at 37˚C with 200 ng sequencing grade 
trypsin (Promega, Madison, WI). Glycopeptides were purified and desalted by 
hydrophilic interaction liquid chromatography (HILIC) solid phase extraction (SPE) 
using Sepharose® Cl-4B beads (GE Healthcare, Uppsala, Sweden). The entire procedure 
was performed in a 96-well plate format to allow high-throughput sample preparation. 
The purified and desalted IgG glycopeptides were spotted onto a polished stainless steel 
MALDI target plate (Bruker Daltonics, Bremen, Germany), overlaid with α-cyano-4-
hydroxycinnamic acid matrix (CHCA, 5 mg/ml 50% ACN) and analyzed on an APEX-
ultra 9.4 tesla FTICR mass spectrometer equipped with a intermediate pressure dual 
ESI/MALDI ion source (Apollo II), a Smartbeam™ laser system and a quadrupole 
mass filter (Bruker Daltonics). IgG glycopeptide profile spectra were generated by 
summation of 8 scans each performed after 9 ion accumulation cycles with 50 laser 
shots, effectively summing the ions of 3600 laser shots per spectrum. All data were 
acquired using Bruker ApexControl 3.0.0 software in expert mode. Mass spectra were 
internally calibrated using a list of known glycopeptides and Bruker DataAnalysis 3.4 
in batch mode. Data processing was performed with the in-house developed software 
“Xtractor” (freely available at www.ms-utils.org/Xtractor) and Microsoft Excel. Relative 
intensities for twenty-six unambiguously assigned IgG Fc N-glycopeptides4,148 (15 IgG1 
and 11 IgG2; Table 2) were obtained by integrating and summing four isotopic peaks 
followed by normalization to the total subclass-specific glycopeptide intensities. As 
part of the data processing, the level of non-detects within the dataset was determined. 
Non-detects were observed for some of the low abundant IgG Fc N-glycopeptides and 
Table 1. Human sample cohort
Group Sex NTa Tb ISc Youngest Oldest Mean age STD age
Controls Female 31 22 66 48.2 15.3
Male 25 23 79 49.2 17.6
LEMS Female 28 14 6 24 90 55.4 13.7
Male 21 30 5 30 82 61.2 11.0
AChR MG Female 64 19 11 84 40.8 17.7
Male 34 7 33 90 51.2 20.4
MuSK MG Female 27 16 15 86 52.3 18.5
Male 11 8 18 79 63.5 15.7
aNon-tumor 
bTumor
cImmune suppression (i.e. prednisone, azathioprine or ciclosporin)
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comprised less than 5% for each of these glycoforms (response variables). It is known 
that the bias generated by substitution of non-detects will be neglectable if less than 
10% non-detects are present for each separate variable (i.e., glycoforms).241,242 Therefore, 
non-detects were substituted for the limit of detection (LOD) of the specific glycoform.
The level of galactosylation was calculated on the basis of the normalized intensities 
for the various Fc N-glycoforms according to the formula (G1F + G1FN + G1FS + G1 
+ G1N + G1S) * 0.5 + G2F + G2FN + G2FS + G2 + G2N + G2S for the IgG1 subclass 
and (G1F + G1FN + G1FS + G1S) * 0.5 + G2F + G2FN + G2FS for the IgG2 subclass. 
The prevalence of IgG sialylation was determined by summation of all sialylated Fc 
N-glycopeptide species (G1FS, G2FS, G1S and G2S for IgG1 and G1FS, G2FS, and G1S 
for IgG2). The level of bisecting N-acetylglucosamine was evaluated by summation of all 
bisected Fc N-glycopeptide species (G0FN, G1FN, G2FN, G0N, G1N, and G2N for the 
IgG1 subclass or G0FN, G1FN, G2FN, and G0N for the IgG2 subclass). The incidence 
of IgG1 and IgG2 N-acetylglucosamine is given as (G0FN + G1FN + G2FN + G0N + 
G1N + G2N) / (G0F + G1F + G2F + G0 + G1 + G2 + G0FN + G1FN + G2FN + G0N + 
Table 2. Tryptic glycopeptides of human IgG subclasses 1 and 2.
Glycan species IgG1 P01857a IgG2 P01859a

















aSwissProt entry number 
bIsomeric glycopeptide species of IgG1 and IgG4.
*Not determined
dglycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose (F), bisecting 
N-acetylglucosamine (N), and N-acetylneuraminic acid (S).
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G1N + G2N) and (G0FN + G1FN + G2FN + G0N) / (G0F + G1F + G2F + G0 + G0FN + 
G1FN + G2FN + G0N), respectively. The percentage of afucosylation is represented by 
summing the relative intensities of all non-fucosylated IgG Fc N-glycopeptide species 
(G0, G1, G2, G0N, G1N, G2N, G1S, and G2S for the IgG1 subclass and G0, G0N, and 
G1S for the IgG2 subclass). 
Statistical analysis. The total subclass-specific normalized glycopeptide intensities 
were Log 10 transformed to obtain normally distributed IgG Fc N-glycosylation 
variables. Non-detects were included in the statistical analysis by substitution for the 
limit of detection (LOD). To determine possible associations two tailed Pearson and 
Spearman rank correlations were evaluated. Linear regression analysis was used to 
explore relationships between the response variables (IgG Fc N-glycopeptide values), 
and covariates (age and sex). Next, an interaction term between age and sex was 
included in the linear regression model. p-Values obtained by analysis of variance 
(ANOVA) were adjusted for multiple comparisons by Bonferroni correction, and 
p-values ≤ 0.05 were considered statistically significant. Data evaluation and statistical 
analysis were performed with Microsoft Excel and SPSS 16.0, respectively.
Results
IgG glycopeptide profiling by MALDI-FTICR-MS. In order to evaluate IgG 
Fc N-glycosylation changes in LEMS, AChR MG, and MuSK MG tryptic IgG Fc 
N-glycopeptides prepared from serum or plasma of control individuals and patients, 
were analyzed using a recently described MALDI-FTICR-MS method.148 On the basis 
of published structural information on human IgG glycosylation3,4,9,10 the obtained 
high resolution mass spectra (an example is given in Figure 1) allowed unambiguous 
assignment of 15 IgG1 Fc N-glycopeptides and 11 IgG2 Fc N-glycopeptides (Table 2). 
Moreover, the integration and summation of four isotopic peaks for each assigned IgG Fc 
N-glycopeptide species provided very accurate relative quantification. Due to relatively 
low abundance of the signals and overlap with other signals, Fc N-glycopeptides of the 
human IgG4 subclass were not determined.
Age- and sex-dependency of IgG Fc N-glycosylation. To determine the effect of 
age and gender on IgG galactosylation within our cohort, we graphically evaluated IgG 
Fc galactosylation as a function of age. For all groups (controls, LEMS, AChR MG, 
and MuSK MG) the relative abundances of agalactosylated IgG species increased at 
higher age, as is represented for the G0F and G0FN species of IgG1 (Figure 2A and 
C) and IgG2 (Figure S-1A and D) of control and LEMS individuals. On the contrary, 
glycoforms exhibiting two galactoses decreased with age, which is shown for the G2F 
and G2 species of IgG1 (Figure 2B and D) and for the G2F glycoform of IgG2 (Figure 
S-1C). Interestingly, the IgG2 G1F glycoform (Figure S-1B) showed an age-dependency 
which was similar to that of the IgG2 G2F glycoform.
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In control individuals as well as LEMS, AChR MG and MuSK MG patients, 
differences in IgG galactosylation were observed between females and males, with 
the younger females (< 30 years) showing higher levels of IgG galactosylation than 
males of the same age (data not shown). Moreover, linear regression analysis of IgG 
galactosylation with age showed for females within each group a steeper drop (p-value 
< 0.01) in the level of IgG galactosylation with increasing age than for males, reaching 
similar levels as males between the ages of 60 to 70 years.
Next to changes in galactosylation we evaluated age and sex dependent variations in 
IgG Fc sialylation, incidence of bisecting N-acetylglucosamine and core-fucosylation. 
The G2F glycan structure represents the substrate of the sialyltransferase reaction 
which results in G2FS. For the controls and the three disease groups our data revealed 
a G2FS age and sex dependency similar to that observed for the G2F species (data not 
shown). Linear regression analysis of the total level of IgG sialylation with age showed 
a decrease in IgG sialylation with increasing age for each group. Moreover, younger 
females showed higher levels of IgG sialylation than males of similar age. For females 
Figure 1. MALDI-FTICR-MS spectrum of tryptic IgG Fc N-glycopeptides. Continued arrows, 














































































a more pronounced decrease in IgG sialylation levels with increasing age was observed 
than for males (p-value < 0.01), reaching similar levels as males between the age 60 to 
70 years. 
The incidence of bisecting N-acetylglucosamine species increased at higher age 
for the control group and the AChR MG and MuSK MG patients, as shown for IgG1 
(Figure 3) and IgG2 (Figure S-2). Within all groups (control, LEMS, AChR MG and 




































































Figure 2. Age dependency of IgG1 Fc galactosylation. Tryptic IgG glycopeptides were desalted 
and purified by Sepharose SPE, spotted on a stainless steel MALDI target plate, overlaid with 
CHCA, and analyzed by MALDI-FTICR-MS. Signal intensities of individual glycoforms were 
normalized to the total subclass-specific glycopeptide intensities. Circles represent IgG1 Fc 
N-glycopeptides of control individuals, and crosses represent IgG1 Fc N-glycopeptides of LEMS 
patients.
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Linear regression analysis of the level of IgG1 and IgG2 Fc core-fucosylation with 
age revealed a significant age effect for MG patients producing MuSK autoantibodies 
(p-value < 0.01). Although controls as well as LEMS and AChR MG patients showed 
a trend towards increasing levels of non-fucosylated species at higher age this was not 
statistically significant. Within the cohort, no clear sex effects were observed for the 
fucosylated glycopeptide species. 
Statistical analysis of disease-associated IgG Fc N-glycosylation features. Because 
of the age- and sex-dependency of various IgG glycosylation features observed in our 
cohort (see above) as well as by others,8-10 correction for these confounding factors 
was performed to allow statistical comparison of IgG Fc N-glycosylation features from 
controls, LEMS, AChR MG and MuSK MG by linear regression. Models generated 
by regression analysis, however, may be biased or misleading if the variables are not 






















































































































Figure 3. Age-related changes in the incidence of IgG1 Fc bisecting N-acetylglucosamine in 
control individuals, and patients suffering from LEMS, AChR MG or MuSK MG.
144
for each IgG Fc N-glycopeptide within the separate groups prior to statistical data 
analysis. This revealed a skewed distribution for most IgG Fc N-glycopeptides, which 
could be restored to normality by Log 10 transformation. The Log 10 transformed 
relative abundances were corrected for age, sex and the interaction between age and sex 
using linear regression analysis.
Pair wise comparison (post-hoc analysis) of IgG Fc N-glycosylation for controls, 
LEMS, AChR MG and MuSK MG was performed for the specific glycosylation features 
galactosylation, level of bisecting N-acetylglucosamine, sialylation, and afucosylation 
(Figure 4A; Figure S-3A) as well as for the individual glycoforms (Figure 4B and C; 
Figure S-3B and C). This revealed that IgG1 and IgG2 of LEMS patients had a lower 
degree of galactosylation compared to IgGs of controls (p-value < 0.01). Moreover, 
higher levels of agalactosylated IgG1 (G0F, G0FN, G0 and G0N) and IgG2 (G0F, 
G0FN and G0N) species (p-value < 0.01) were observed in the LEMS patients. On 
the contrary, several of the digalactosylated glycoforms were decreased. Notably, the 
lowered IgG1 and IgG2 Fc galactosylation of LEMS patients was already indicated by 
the data presented in Figure 2 and Figure S-2, which over the whole age range showed a 
tendency towards lower IgG1 and IgG2 Fc galactosylation of LEMS patients compared 
to control individuals. 
While LEMS patients compared to the control individuals showed a lower degree 
of galactosylation for both IgG1 and IgG2, galactosylation in AChR MG and MuSK 
MG patients was only lowered for IgG2 (p-value < 0.05; Figure S-3A). At the level of 
individual IgG2 glycoforms, the G0F species were increased, whilst both G1F and G2F 
were lowered for all disease groups. As already mentioned previously, the acceptor 
structure for the sialyltransferase reaction resulting in G2FS is represented by the G2F 
glycan structure. Although diseased individuals expressed lower G2F species compared 
to control individuals, no differences were observed for the level of IgG1 and IgG2 Fc 
sialylation. At the individual IgG glycoform level, however, higher prevalence of IgG1 
G1FS and IgG2 G1FS species (p-value < 0.05) were observed for the LEMS and AChR 
MG patients compared to the control individuals. Moreover, IgG1 G2FS was lowered 
in LEMS patients compared to the control individuals. For the MuSK MG patients only 
the IgG2 G1FS species was higher (p-value < 0.05) than for the control group. As no 
overall change in sialylation was observed (Figure 4A and Figure S-3A), the differences 
in G1FS levels are considered to predominantly reflect changes in galactosylation 
rather than specific sialylation changes.
A higher level of IgG1 and IgG2 Fc bisected N-acetylglucosamine (p-value < 0.01) 
was observed for the LEMS patients in comparison to the controls. Evaluation of the 
individual bisected glycopeptides revealed a higher prevalence of the G0FN and G0N 
species for IgG1 as well as IgG2 (p-value < 0.01). LEMS patients tended to have elevated 
levels of bisecting N-acetylglucosamine already at younger age, which remained at 
the same level over the whole age range. Yamada et al. described that the incidence 
of bisecting N-acetylglucosamine in healthy individuals increased until the age of 
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50 years at which it reached a plateau.9 Therefore, we divided the LEMS patients and 
control individuals in two groups; i.e. younger than 50 years and older than 50 years, 
and reevaluated the level of bisecting N-acetylglucosamine within these age groups. 
This revealed a higher incidence of IgG1 and IgG2 bisecting N-acetylglucosamine 
level (p-value < 0.01) for LEMS patients younger than 50 years compared with control 
individuals of similar age and gender. Notably, female LEMS patients below 50 years 
showed a higher level of IgG2 bisecting N-acetylglucosamine than male LEMS patients 
of similar age (p-value < 0.05). No statistically significant differences were observed 
for the level of bisected N-acetylglucosamine between LEMS patients and control 
individuals above 50 years. Evaluation of the individual bisecting N-acetylglucosamine 
species revealed a higher prevalence for the IgG1 and IgG2 G0FN species in LEMS 
patients younger than 50 years compared with age matched control individuals (p-value 
< 0.01). By contrast, LEMS patients older than 50 years showed a higher prevalence of 
the IgG1 G0N and G2N species compared with the age matched control individuals 
(p-value < 0.05). 
Figure 4. Statistical comparison of IgG1 Fc N-glycosylation for control and diseased individuals. 
A and D represent the statistical comparison of different IgG1 Fc N-glycosylation features, while 
B, C, E and F represent the statistical comparison of the individual IgG1 Fc N-glycopeptides. 































































































































































































































Statistical comparison of the total level of IgG1 Fc afucosylation revealed no 
difference between controls and diseased (LEMS, AChR MG and MuSK MG) for IgG1. 
Moreover, AChR MG and MuSK MG patients showed levels of IgG2 afucosylation 
which were similar to those of controls. By contrast, higher levels of IgG2 afucosylation 
were observed for LEMS patients (p-value < 0.05). Evaluation at the individual IgG 
glycoform level revealed that only for the LEMS patients some non-fucosylated species 
(IgG1 G0, IgG1 G0N, and IgG2 G0N) differed statistically significant from the controls. 
Analysis of the role of confounding factors such as tumors and immune 
suppression. To determine potential tumor-related IgG Fc N-glycosylation differences, 
LEMS patients with and without tumor were compared with the controls group (Figure 
4D-F and Figure S-3D-F). The overall IgG1 and IgG2 Fc N-glycosylation of both LEMS 
groups (tumor, non-tumor) was comparable to the IgG Fc N-glycosylation observed 
for LEMS patients prior splitting. In addition to the IgG Fc N-glycosylation features 
already described in the previous sections, LEMS patients with a tumor showed a higher 
level of IgG2 sialylation compared to the controls (p-values < 0.05) and compared to 
LEMS patients without tumor (p-values < 0.05). No significant changes were observed 
for the degrees of IgG1 sialylation in LEMS tumor versus controls and versus LEMS 
non-tumor. 
Next to tumor-related IgG Fc N-glycosylation differences, we evaluated potential 
associations of IgG Fc N-glycosylation with the use of oral immune suppressants (i.e. 
prednisone, azathioprine or ciclosporin). The use of immune suppressants could not be 
associated with changes in IgG Fc N-glycosylation features. 
Discussion
IgG glycosylation changes have been shown to occur in various infectious diseases, 
autoimmune diseases, and cancer.3,15,18,32,146,147 Here we studied IgG Fc N-glycosylation 
in the context of well-defined autoantibody-mediated autoimmune diseases. Our results 
show that LEMS and MG subtypes are associated with changes in IgG1 and IgG2 Fc 
N-glycosylation (e.g. decrease in galactosylation). Experiments were performed using a 
recently described high-throughput IgG glycosylation profiling method which registers 
IgG1 and IgG2 tryptic Fc N-glycopeptides by MALDI-FTICR-MS.148 The analyzed cohort 
comprised a total of 285 samples from four groups, namely (1) presumably healthy control 
individuals, (2) patients with LEMS, (3) non-thymoma MG patients with autoantibodies 
directed against the muscle nicotinic acetylcholine receptor and (4) MG patients with 
autoantibodies against muscle-specific kinase. Information was obtained on the relative 
expression levels of 15 IgG1 Fc N-glycan structures and 11 IgG2 Fc N-glycan structures. 
In order to give a simplified and informative overview on the IgG Fc N-glycosylation 
status, next to the expression levels of the individual glycoforms, the overall incidence of 
the glycosylation features galactosylation, sialylation, fucosylation, and level of bisecting 
N-acetylglucosamine were determined (Figure 4).
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IgG glycosylation profiles are known to be influenced by age and gender.8-10 Our 
results showed in all groups a higher degree of IgG1 and IgG2 galactosylation for young 
females (<30 years) than for males of similar age, which is in agreement with previous 
findings.10 We observed a decrease of IgG1 and IgG2 Fc galactosylation with age which 
is in accordance with literature reports on age dependent changes of the glycosylation 
of total human IgG.8-10 This decrease was more pronounced in females than in males. 
Above age 60 years an equally low plateau of low levels of IgG1 and IgG2 galactosylation 
and sialylation was reached in males and females. In contrast to literature data, which 
are mostly based on the combined analysis of Fc and Fab N-glycosylation of total IgG, 
our results reflect the specific Fc N-glycosylation analysis of IgG1 and IgG2 subclasses.
IgG Fc N-glycosylation results obtained for the four groups (controls, LEMS, 
AChR MG, and MuSK MG) were compared after log-transformation and correction 
for age, sex, and the interaction of age and sex giving the following findings: IgG2 
galactosylation was found to be lower in all three disease groups than in controls. IgG1 
galactosylation was found to be significantly lowered in LEMS patients only, while 
the other two disease groups showed a similar trend. Notably, no difference in the 
overall degree of IgG1 and IgG2 sialylation was found. Thus, the observed differences 
in IgG galactosylation between the controls and the disease groups are not paralleled 
by a difference in IgG sialylation. This indicates that different factors are influencing 
IgG galactosylation and sialylation in different ways: while age-associated decrease 
of IgG galactosylation and sialylation appear to go in parallel, the disease-associated 
decrease in IgG galactosylation is not paralleled by a sialylation decrease. This might 
reflect changes in the regulation of the involved glycosyl transferases which could be 
assumed to be considerably different in ageing and in disease. Another indication for 
the distinct regulation of IgG galactosylation and sialylation has been reported by 
Kaneko et al. (2006), who described that antigenic challenge leads to a specific change 
in IgG sialylation in mice, which was not reflected in a corresponding change in IgG 
galactosylation.35 Hence, comprehensive analysis of IgG Fc N-glycosylation for mice 
as well as humans should involve registration of both galactosylation and sialylation 
levels.
The only partially linked regulation of IgG sialylation and galactosylation is 
paralleled by presumably distinct functions of these two IgG glycosylation features: 
IgG Fc sialylation has been indicated as an anti-inflammatory signal which acts via 
the receptor SIGN-R1 (an orthologue of the human lectin DC-SIGN) on murine 
macrophages.35,48 The degree of IgG galactosylation has been reported to influence the 
pathogenicity of IgGs.19 In a murine collagen-induced arthritis model anti-collagen 
IgG which had been treated with b-galactosidase (resulting in elevated levels of IgG 
G0F) was found to be more potent in inducing arthritis than non-treated control IgG. 
Moreover, agalactosylated IgG has been shown to have a higher efficacy in complement 
activation than galactosylated IgG, though the in-vivo relevance of this finding has not 
been demonstrated.20,243
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Changes in overall IgG galactosylation have been reported for many other 
autoimmune and inflammatory diseases. Rheumatoid arthritis and osteoarthritis have 
been reported to result in an increase of the level of agalactosylated IgG N-glycans 
of approximately 25% and 10%, respectively: rheumatoid arthritis patients showed an 
average of 50% agalactosylated IgG, which was 35% for osteoarthritis patients and 25% 
for control individuals.3 These data were obtained by analyzing released N-glycans of 
total serum IgG and, therefore, refer to the combined Fc and Fab glycosylation of all 
IgG subclasses. Fab glycosylation contributes approximately 20% to the overall IgG 
N-glycosylation profile and shows only minor changes in rheumatoid arthritis.244 
By contrast, Fc N-glycosylation of all IgG subclasses is known to be affected by 
rheumatoid arthritis.4 As both changes in total IgG N-glycosylation profiles (Fab and 
Fc) in rheumatoid arthritis will predominantly reflect Fc N-glycosylation changes, it 
seems legitimate to us to compare combined Fab and Fc N-glycosylation data from 
literature with the Fc N-glycosylation results we obtained here. 
The total level of agalactosylated IgG1 and IgG2 Fc N-glycans (sum of G0F, G0, 
G0FN, and G0N) found in our study was 33% (IgG1) and 44% (IgG2) for LEMS while 
in controls this was 26% (IgG1) and 37% (IgG2). Thus, for both IgG1 and IgG2 the 
LEMS-associated decrease in Fc galactosylation was 7%. For AChR MG and MuSK MG 
the disease-associated decrease in IgG2 Fc galactosylation was approximately 4% and 
5%, respectively. Clearly, the galactosylation changes associated with LEMS and MG 
are less pronounced than those described for arthritis and osteoarthritis. While the 
immunological relevance of the observed IgG galactosylation changes in LEMS and 
MG is still unclear, a decrease of IgG Fc galactosylation is generally leading to a less 
efficient complement activation by IgG.181 Moreover, lowered IgG Fc galactosylation 
enhanced the potency of IgG autoantibodies in a murine arthritis model19 and has been 
shown to correlate with high disease activity and progressive disease for rheumatoid 
arthritis.15,18 
Next to galactosylation and sialylation, we monitored the incidence of bisecting 
N-acetylglucosamine as well as the degree of core-fucosylation of IgG Fc N-glycans. 
The incidence of IgG1 and IgG2 bisecting N-acetylglucosamine was found to increase 
with age for controls, AChR MG, and MuSK MG, which is in accordance with previous 
findings for total IgG of healthy individuals.8-10 No difference was found in the levels 
of bisecting N-acetylglucosamine between controls, AChR MG, and MuSK MG. 
Interestingly, LEMS patients of age below 50 years showed elevated levels of bisecting 
N-acetylglucosamine on both IgG1 and IgG2, while these levels were not elevated for 
LEMS patients of age above 50 years. Elevated levels of bisecting N-acetylglucosamine 
have been associated with increased ADCC.213 However, in-vivo relevance has not been 
shown yet. To the best of our knowledge, our study for the first time shows the link of 
changes in the level of bisecting N-acetylglucosamine with disease. 
Human IgGs from various body fluids has consistently been found to exhibit 
a low degree of non-fucosylated Fc N-glycans,146 which is in accordance with our 
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findings. Increasing levels of non-fucosylated species at higher age were observed for 
MuSK MG patients (p-value < 0.01), while controls, LEMS and AChR MG patients 
only showed a similar trend. In juvenile chronic arthritis and rheumatoid arthritis, a 
disease-associated increase in IgG Fc fucosylation has been observed.23,25 By contrast, 
we observed a small decrease in the core-fucosylation of IgG2 Fc N-glycans of LEMS 
patients, while no disease-associated changes were observed for AChR MG and MuSK 
MG patients. 
In approximately half of the LEMS group a small-cell lung carcinoma was present, 
which is strongly associated with the development of the disease.237,238 Interestingly, 
all LEMS patients revealed similar IgG Fc N-glycosylation profiles independent of the 
presence of a tumor. 
Pathogenic autoantibodies in AChR MG are mainly of the IgG1 subclass and 
trigger complement mediated damage to the neuromuscular synapse.245 By contrast, 
disease severity in MUSK MG appears to be related to autoantibodies of the IgG4 
subclass.246 Remissions and exacerbations in these autoimmune disorders are related to 
autoantibody titers in individual patients.247 However, the inter-individual relationship 
is weak meaning that patients can be severely affected while having very low 
autoantibody titers and vice versa. Besides the autoantibody titers, differences in IgG 
Fc N-glycosylation may also be related to the fluctuating muscle weakness. For MUSK 
MG and AChR MG, we did not find a correlation between disease severity scores 
(DSS) and IgG Fc N-glycosylation, while DSS were not available for the LEMS patients. 
As an alternative attempt to correlate clinical disease severity with overall IgG Fc 
N-glycosylation, longitudinal studies (repeated observations of the same patients over 
long periods of time) should be performed. Notably, the overall IgG Fc N-glycosylation 
as studied here may not reflect the characteristics of antigen-specific IgG.22,24 Future 
studies of autoantigen-specific IgG Fc N-glycosylation will possibly reveal associations 
between disease severity and glycosylation features.
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Supporting Figure 1
Figure S-1. Age dependency of IgG2 Fc galactosylation. Tryptic IgG glycopeptides were desalted 
and urified by Sepharose SPE, spotted on a stainless steel MALDI target plate, overlaid with 
CHCA, and analyzed by MALDI-FTICR-MS. Signal intensities of individual glycoforms were 
normalized to the total subclass-specific glycopeptide intensities. Circles represent IgG2 Fc 
N-glycopeptides of control individuals, and crosses represent IgG2 Fc N-glycopeptides of LEMS 
patients.
























































































































Figure S-2. Age-related changes in the incidence of IgG2 Fc bisecting N-acetylglucosamine in 

























































































































































































Figure S-3. Statistical comparison of IgG2 Fc N-glycosylation for control and diseased individuals. 
A and D represent the statistical comparison of different IgG2 Fc N-glycosylation features, while 
B, C, E and F represent the statistical comparison of the individual IgG1 Fc N-glycopeptides. 
*, Significant from controls with p-value < 0.05; **, Significant from controls with p-value < 0.01.
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Over the last decade the number of approved biopharmaceuticals harboring 
glycosylation has been rapidly growing. Glycans attached to therapeutic proteins affect 
their physical properties, stability and efficacy, and aberrant glycoforms may cause 
serious adverse effects. Detailed characterization of protein glycosylation is of utmost 
importance in pharmaceutical industry in order to maintain product quality and 
safety. Therapeutic immunoglobulins received much attention over the last years due 
to drastic enhancement of ADCC observed for antibodies lacking the core-fucoses on 
the Fc N-glycan.43,44 Therefore, IgG Fc N-glycosylation of biotechnologically produced 
IgGs is being designed in order to maximize the efficacy in e.g. anti-cancer therapy 
(next generation therapeutic antibodies).5,46 
Glycan structural and linkage information of human IgG Fc N-glycans is well 
characterized and has been shown to be influenced by age, sex, pregnancy and 
health state.8-10,147 For a variety of infectious and autoimmune diseases, and cancer 
aberrant glycosylation has been reported.3,21,30-32 A common observation for many of 
these diseases is the lowered IgG Fc galactosylation and sialylation.147 Fc N-glycans 
have been shown to influence the biological activity of IgG by e.g. modulating Fcγ-
receptor binding.19,35,38,39,43,44,146 Sensitive and detailed characterization of aberrant IgG 
Fc N-glycosylation profiles could provide valuable information on the regulatory 
mechanisms involved in a broad range of antibody mediated diseases. By implementing 
this knowledge into sensitive enzyme-linked immunosorbent assays capable of 
discriminating IgG with different glycosylation (e.g IgG with various levels of 
galactosylation but lacking the core-fucose), it might become possible to discriminate 
pathogenic from non-pathogenic situations. This would open the door for treating 
potentially harmful changes in glycosylation such as the decreased levels of core-
fucosylation observed during pregnancy on IgG1 alloantibodies against the human 
platelet antigens of the fetus (causing fetoneonatal alloimmune thrombocytopenia)45 
already in an early stage prior to the actual harm/damage.
Clearly, in view of the above mentioned interest in antibody glycosylation in the 
biopharmaceutical as well as in the clinical setting, analytical methods are needed to 
study these glycans. Detailed analysis of protein glycosylation is a challenging and 
time-consuming task due to the large structural variety in the attached glycans even 
for a single glycosylation site (microheterogeneity). In this thesis novel approaches 
for fast, miniaturized and high-throughput analysis of IgG Fc N-glycosylation are 
presented, and the utility of these methods has been demonstrated for clinically 
relevant research questions. Due to the complexity of human polyclonal IgG, Fc 
N-glycopeptide MS profiles might contain glycan information from a mixture of 
IgG subclasses. This is especially occurring with MALDI-MS approaches while 
obviously for LC-MS approaches it is a much less relevant issue. When analyzing 
biotechnologically produced therapeutic monoclonal antibodies, MALDI-MS and 
LC-MS both provide similar IgG Fc N-glycosylation information but differ in analysis 




for accurate high-throughput IgG Fc N-glycosylation analysis. By contrast, LC-MS 
is better suited for accurate IgG Fc N-glycosylation analysis in complex biological 
samples such as plasma and serum. In general, LC-MS is less prone to in-source and 
metastable decay of highly sialylated glycopeptides than MALDI-MS. Nevertheless, the 
labile nature of glycoconjugates under standard ESI-MS proteomics settings requires 
several optimizations. Decay of glycoconjugates commonly occurs in the source and 
during the ion-transfer. Thus lowering of the potential differences during ESI (sprayer 
and MS inlet) and the ion-transfer (capillary and skimmer or lenses) is a good start to 
reduce glycan decay. Which potential differences have to be lowered, however, strongly 
depend on the type of mass spectrometer. 
The IgG glycosylation analysis methods described in Chapter 2 and Chapter 4 of 
this thesis are robust, can handle large sample cohorts, reveal glycosylation features 
such as galactosylation, sialylation, fucosylation, and the incidence of bisecting 
N-acetylglucosamine at an IgG subclass-specific level, and can be applied to analyze 
the Fc N-glycosylation of recombinantly produced IgG in great detail. Fast or high-
throughput analysis was achieved by optimizing the entire analytical process, including 
sample preparation, glycopeptide detection and data processing. These techniques 
were then successfully applied for specific clinical research questions where IgG Fc 
N-glycosylation is believed to play a role (e.g. vaccination, autoimmune diseases). 
Other applications that one may envision involve longitudinal studies where total 
and autoantigen-specific IgG Fc N-glycosylation changes are evaluated to reveal 
associations between glycosylation features and e.g. disease severity. Furthermore, 
these sensitive fast profiling techniques are expected to prove their use for monitoring 
IgG Fc N-glycosylation changes during treatment. This would potentially provide 
information on the effectiveness of the treatment and offer the possibility to adjust the 
dose or treatment frequency for a specific patient. Within the pharmaceutical industry 
high-throughput glycopeptide profiling may prove its value during quality control 
and might be particularly useful for monitoring the fermentation process. This then 
allows early identification of harmful glycosylation changes and offers the possibility 
to interfere with the production process and restore product quality without losing an 
entire harvest. 
As already mentioned the glycosylation of therapeutic proteins has to be human-
like to prevent adverse effects. Therefore, prior to marketing complete structural 
characterization of protein glycosylation is mandatory for every biopharmaceutical. 
Here, a strategy based on MS can be problematic as no glycan linkage information 
is obtained and discrimination of isomers is virtually impossible even when cross 
ring fragment information is obtained.191,248 To obtain such structural and linkage 
information MS may be combined with lectin chromatography, and/or endo- and 
exoglycosidase treatment. High-throughput protein glycosylation analysis by MS with 
analysis techniques such as those developed in this thesis is, therefore, only useful with 
sufficient pre-knowledge on the glycosylation features of the specific protein. It should 
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be kept in mind that hitherto no technique is available which is capable of elucidating 
the entire structural complexity of protein glycosylation in a single analysis, and for 
detailed structural analysis the information from several (complementary) strategies 
has to be combined. 
To our knowledge, the Fc N-glycosylation sites of human polyclonal IgG are fully 
occupied. In cases where only partial occupation of N-glycosylation sites occurs (e.g. 
recombinant expressed proteins)189 it might be required to monitor both glycosylated 
peptides and non-glycosylated variants of the peptides carrying the N-glycosylation 
consensus sequence. For these situations RP-SPE is the most suitable purification 
method as glycosylated and non-glycosylated variants of the peptides tend to co-elute. 
However, care should be taken with such an approach as MS glycopeptide signals are 
easily suppressed by co-eluting peptides which often possess higher proton affinities. 
Moreover, the acidic conditions applied during elution of (glyco)peptides from reversed 
phase stationary phases can quickly lead to partial desialylation of the glycopeptides. By 
contrast, HILIC-SPE is highly suited for glycoproteins with a high level of sialylation as 
elution from HILIC stationary phases can be performed with water. Moreover, HILIC 
purifications such as those described in Chapter 3 and Chapter 4 of this thesis allow 
very selective glycoconjugate enrichment and at the same time the removal of salts, 
most non-glycosylated peptides, and detergents from glycoconjugate samples. 
In this thesis we predominantly performed targeted analyses where we selectively 
studied Fc N-glycosylation of purified IgG samples and did not gather other potentially 
useful information. With this strategy we effectively determined IgG Fc N-glycosylation 
changes occurring during pregnancy (Chapter 2), aging (Chapter 4), vaccination 
(Chapter 6) and two autoimmune diseases (Chapter 7). Our results of clinical cohorts 
confirmed the previously reported IgG glycosylation changes with age, sex and 
pregnancy,4,8-10,13,14 and revealed specific glycosylation changes with vaccination and the 
two autoimmune diseases (i.e. LEMS and MG). However, no conclusive information 
on the regulatory mechanisms involved in IgG Fc N-glycosylation changes or on the 
immunological role and implications of these alterations have been obtained. While 
effector immune mechanisms of IgG are modulated by the Fc N-glycosylation, binding 
of the antigen is influenced by glycosylation of the Fab portion as has already been 
shown for asymmetric antibodies in pregnancy.212 By developing high-throughput 
techniques capable of simultaneously analyzing IgG Fc and Fab glycosylation more 
conclusive information might be obtained on the immune-regulatory and functional 
aspects of IgG glycosylation. Moreover, by broadening the range of simultaneously 
monitored blood glycoproteins (e.g. circulating lysosomal hydrolases,249 erythropoietin, 
fibrinogen, apolipoproteins, tissue plasminogen activator, fetuin, transferrin etc.) 
additional information on disease related glycosylation changes may be revealed. 
For complex biological samples the use of LC-MS is preferred over MALDI as the 
complexity of the mass spectra is reduced by the LC separation, and the retention time 




m/z. The more sophisticated ultra high pressure LC separation systems coupled to high 
resolution mass spectrometers are expected to improve chromatographic resolution 
and confidence with glycopeptide identification, and will allow analysis of more 
complex glycopeptide samples. 
With current technologies, targeted analysis and de novo glycan sequencing in 
complex biological samples remains a challenging and tedious task due to the lack of 
computational tools (e.g. algorithms, databases) capable of automated interpretation of 
high-throughput MS and MS/MS data from glycoconjugates. Hitherto, computational 
tools (e.g. GlycoPep DB,250 GlycoSpectrumScan,251 GlycoPeptideSearch) are 
available which facilitate compositional assignment for glycopeptides by comparing 
experimentally measured masses to calculated glycopeptide masses from carbohydrate 
databases. However, MS/MS spectra often do not reveal the complete structure 
information of the glycan. Furthermore, the quality of glycopeptide fragmentation 
spectra strongly depends on the experimental settings and can substantially differ 
between different MS instruments. Therefore, intensive manual evaluation remains 
required for correct assignment. To overcome these limitations a large database is 
required that contains good quality (high resolution) glycopeptide fragmentation 
mass spectra (preferably obtained with various instruments) of different biological and 
clinical samples. Together with a standardization of mass spectrometric procedures 
and settings, this would offer the possibility to match experimentally obtained MS/
MS spectra with spectra in the database and might allow the association of specific 





&Reference listSummarySamenvattingAbbreviationsAcknowledgements Curriculum VitaeList of publications

Reference List
1. Plebani, A.; Ugazio, A. G.; Avanzini, M. A.; 
Massimi, P.; Zonta, L.; Monafo, V.; Burgio, G. 
R. Eur.J.Pediatr. 1989, 149, 164-167.
2. Butler, M.; Quelhas, D.; Critchley, A. J.; 
Carchon, H.; Hebestreit, H. F.; Hibbert, R. G.; 
Vilarinho, L.; Teles, E.; Matthijs, G.; Schollen, 
E.; Argibay, P.; Harvey, D. J.; Dwek, R. A.; 
Jaeken, J.; Rudd, P. M. Glycobiology 2003, 13, 
601-622.
3. Parekh, R. B.; Dwek, R. A.; Sutton, B. J.; 
Fernandes, D. L.; Leung, A.; Stanworth, D.; 
Rademacher, T. W.; Mizuochi, T.; Taniguchi, 
T.; Matsuta, K.; Takeuchi, F.; Nagano, Y.; 
Miyamoto, T.; Kobata, A. Nature 1985, 316, 
452-457.
4. Wuhrer, M.; Stam, J. C.; van de Geijn, F. E.; 
Koeleman, C. A.; Verrips, C. T.; Dolhain, R. 
J.; Hokke, C. H.; Deelder, A. M. Proteomics 
2007, 7, 4070-4081.
5. Jefferis, R. Biotechnol.Prog. 2005, 21, 11-16.
6. Wang, W.; Singh, S.; Zeng, D. L.; King, K.; 
Nema, S. J Pharm.Sci. 2007, 96, 1-26.
7. Shim, H. Exp.Mol.Med. 2011.
8. Parekh, R.; Roitt, I.; Isenberg, D.; Dwek, R.; 
Rademacher, T. J.Exp.Med. 1988, 167, 1731-
1736.
9. Yamada, E.; Tsukamoto, Y.; Sasaki, R.; Yagyu, 
K.; Takahashi, N. Glycoconj.J. 1997, 14, 401-
405.
10. Shikata, K.; Yasuda, T.; Takeuchi, F.; Konishi, 
T.; Nakata, M.; Mizuochi, T. Glycoconj.J. 
1998, 15, 683-689.
11. Pucic, M.; Knezevic, A.; Vidic, J.; Adamczyk, 
B.; Novokmet, M.; Polasek, O.; Gornik, O.; 
Supraha-Goreta, S.; Wormald, M. R.; Redzic, 
I.; Campbell, H.; Wright, A.; Hastie, N. D.; 
Wilson, J. F.; Rudan, I.; Wuhrer, M.; Rudd, P. 
M.; Josic, D.; Lauc, G. Mol.Cell Proteomics. 
2011.
12. Ruhaak, L. R.; Uh, H. W.; Beekman, M.; 
Koeleman, C. A.; Hokke, C. H.; Westendorp, 
R. G.; Wuhrer, M.; Houwing-Duistermaat, J. 
J.; Slagboom, P. E.; Deelder, A. M. PLoS.ONE. 
2010, 5, e12566.
13. Pekelharing, J. M.; Hepp, E.; Kamerling, J. 
P.; Gerwig, G. J.; Leijnse, B. Ann.Rheum.Dis. 
1988, 47, 91-95.
14. Rook, G. A. W.; Steele, J.; Brealey, R.; 
Whyte, A.; Isenberg, D.; Sumar, N.; Nelson, 
J. L.; Bodman, K. B.; Young, A.; Roitt, I. M.; 
Williams, P.; Scragg, I.; Edge, C. J.; Arkwright, 
P. D.; Ashford, D.; Wormald, M.; Rudd, P. M.; 
Redman, C. W. G.; Dwek.R.A.; Rademacher, 
T. W. J.Autoimmun. 1991, 4, 779-794.
15. van de Geijn, F. E.; Wuhrer, M.; Selman, M. 
H.; Willemsen, S. P.; de Man, Y. A.; Deelder, 
A. M.; Hazes, J. M.; Dolhain, R. J. Arthritis 
Res.Ther. 2009, 11, R193.
16. Williams, P. J.; Arkwright, P. D.; Rudd, P.; 
Scragg, I. G.; Edge, C. J.; Wormald, M. R.; 
Rademacher, T. W. Placenta 1995, 16, 749-
756.
17. Tetsuya KIBE; Shinji FUJIMOTO; Chizu 
ISHIDA; Hajime TOGARI; Yoshiro WADA; 
Setsuo OKADA; Hiroaki NAKAGAWA; 
Yoshinori TSUKAMOTO; Noriko 
TAKAHASHI Journal of Clinical Biochemistry 
and Nutrition 1996, 21, 57-63.
18. van Zeben, D.; Rook, G. A.; Hazes, J. M.; 
Zwinderman, A. H.; Zhang, Y.; Ghelani, 
S.; Rademacher, T. W.; Breedveld, F. C. 
Br.J.Rheumatol. 1994, 33, 36-43.
19. Rademacher, T. W.; Williams, P.; Dwek, R. 
A. Proc.Natl.Acad.Sci.U.S.A. 1994, 91, 6123-
6127.
20. Malhotra, R.; Wormald, M. R.; Rudd, P. M.; 
Fischer, P. B.; Dwek, R. A.; Sim, R. B. Nat.
Med. 1995, 1, 237-243.
21. Bond, A.; Alavi, A.; Axford, J. S.; Bourke, B. 
E.; Bruckner, F. E.; Kerr, M. A.; Maxwell, J. D.; 
Tweed, K. J.; Weldon, M. J.; Youinou, P.; Hay, 
F. C. J Autoimmun. 1997, 10, 77-85.
22. Ercan, A.; Cui, J.; Chatterton, D. E.; Deane, K. 
D.; Hazen, M. M.; Brintnell, W.; O’Donnell, 
C. I.; Derber, L. A.; Weinblatt, M. E.; Shadick, 
N. A.; Bell, D. A.; Cairns, E.; Solomon, D. H.; 
Holers, V. M.; Rudd, P. M.; Lee, D. M. Arthritis 
Rheum. 2010.
23. Gornik, I.; Maravic, G.; Dumic, J.; Flogel, M.; 
Lauc, G. Clin.Biochem. 1999, 32, 605-608.
24. Scherer, H. U.; van der, Woude D.; Ioan-
Facsinay, A.; el Bannoudi, H.; Trouw, L. A.; 
Wang, J.; Haupl, T.; Burmester, G. R.; Deelder, 
A. M.; Huizinga, T. W.; Wuhrer, M.; Toes, R. 
E. Arthritis Rheum. 2010, 62, 1620-1629.
25. Flogel, M.; Lauc, G.; Gornik, I.; Macek, B. 
Clin.Chem.Lab Med. 1998, 36, 99-102.
26. Parekh, R. B.; Roitt, I. M.; Isenberg, D. A.; 
Dwek, R. A.; Ansell, B. M.; Rademacher, T. W. 
Lancet 1988, 331, 966-969.
27. Parekh, R.; Isenberg, D.; Rook, G.; Roitt, I.; 
Dwek, R.; Rademacher, T. J.Autoimmun. 
1989, 2, 101-114.
28. Bond, A.; Alavi, A.; Axford, J. S.; Youinou, P.; 
Hay, F. C. Clin.Exp.Immunol 1996, 105, 99-
103.
29. Dube, R.; Rook, G. A.; Steele, J.; Brealey, R.; 
Dwek, R.; Rademacher, T.; Lennard-Jones, J. 
Gut 1990, 31, 431-434.
30. Mehta, A. S.; Long, R. E.; Comunale, M. A.; 




R.; Marrero, J. A.; Dwek, R. A.; Block, T. M. 
J.Virol. 2008, 82, 1259-1270.
31. Moore, J. S.; Wu, X.; Kulhavy, R.; Tomana, 
M.; Novak, J.; Moldoveanu, Z.; Brown, R.; 
Goepfert, P. A.; Mestecky, J. AIDS 2005, 19, 
381-389.
32. Saldova, R.; Royle, L.; Radcliffe, C. M.; 
Hamid, U. M.; Evans, R.; Arnold, J. N.; Banks, 
R. E.; Hutson, R.; Harvey, D. J.; Antrobus, 
R.; Petrescu, S. M.; Dwek, R. A.; Rudd, P. M. 
Glycobiology 2007, 17, 1321-1332.
33. Perdivara, I.; Peddada, S. D.; Miller, F. W.; 
Tomer, K. B.; Deterding, L. J. J Proteome Res. 
2011, 10, 2969-2978.
34. Lastra, G. C.; Thompson, S. J.; Lemonidis, A. 
S.; Elson, C. J. Autoimmunity 1998, 28, 25-30.
35. Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. 
Science 2006, 313, 670-673.
36. Collin, Mattias; Olsen, Arne EMBO J 2001, 
20, 3046-3055.
37. Allhorn, M.; Olin, A. I.; Nimmerjahn, F.; 
Collin, M. PLoS.ONE. 2008, 3, e1413.
38. Collin, M.; Shannon, O.; Björck, L. Proc.Natl.
Acad.Sci.U.S.A 2008, 105, 4265-4270.
39. Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; 
Sondermann, P. J.Mol.Biol 2003, 325, 979-
989.
40. Kanda, Y.; Yamada, T.; Mori, K.; Okazaki, 
A.; Inoue, M.; Kitajima-Miyama, K.; Kuni-
Kamochi, R.; Nakano, R.; Yano, K.; Kakita, S.; 
Shitara, K.; Satoh, M. Glycobiology 2007, 17, 
104-118.
41. Mimura, Y.; Church, S.; Ghirlando, R.; 
Ashton, P. R.; Dong, S.; Goodall, M.; Lund, 
J.; Jefferis, R. Mol.Immunol 2000, 37, 697-706.
42. Mimura, Y.; Sondermann, P.; Ghirlando, R.; 
Lund, J.; Young, S. P.; Goodall, M.; Jefferis, R. 
J.Biol.Chem. 2001, 276, 45539-45547.
43. Shields, R. L.; Lai, J.; Keck, R.; O’Connell, 
L. Y.; Hong, K.; Meng, Y. G.; Weikert, S. H.; 
Presta, L. G. J.Biol.Chem. 2002, 277, 26733-
26740.
44. Iida, S.; Misaka, H.; Inoue, M.; Shibata, M.; 
Nakano, R.; Yamane-Ohnuki, N.; Wakitani, 
M.; Yano, K.; Shitara, K.; Satoh, M. Clin.
Cancer Res. 2006, 12, 2879-2887.
45. Wuhrer, M.; Porcelijn, L.; Kapur, R.; 
Koeleman, C. A.; Deelder, A.; de Haas, M.; 
Vidarsson, G. J.Proteome Res. 2009, 8, 450-
456.
46. Mori, K.; Iida, S.; Yamane-Ohnuki, N.; 
Kanda, Y.; Kuni-Kamochi, R.; Nakano, R.; 
Imai-Nishiya, H.; Okazaki, A.; Okazaki, A.; 
Natsume, A.; Niwa, R.; Shitara, K.; Satoh, M. 
Cytotechnology 2007, 55, 109-114.
47. Anthony, R. M.; Nimmerjahn, F.; Ashline, D. 
J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. 
V. Science 2008, 320, 373-376.
48. Anthony, R. M.; Wermeling, F.; Karlsson, M. 
C.; Ravetch, J. V. Proc.Natl.Acad.Sci.U.S.A 
2008, 105, 19571-19578.
49. Anthony, R. M.; Kobayashi, T.; Wermeling, F.; 
Ravetch, J. V. Nature 2011, 475, 110-113.
50. Stadlmann, J.; Weber, A.; Pabst, M.; Anderle, 
H.; Kunert, R.; Ehrlich, H. J.; Peter, Schwarz 
H.; Altmann, F. Proteomics. 2009, 9, 4143-
4153.
51. Stadlmann, J.; Pabst, M.; Altmann, F. J Clin.
Immunol. 2010.
52. Guhr, T.; Bloem, J.; Derksen, N. I.; Wuhrer, 
M.; Koenderman, A. H.; Aalberse, R. C.; 
Rispens, T. PLoS.ONE. 2011, 6, e21246.
53. Nimmerjahn, F.; Ravetch, J. V. J.Exp.Med. 
2007, 204, 11-15.
54. Katz, U.; Achiron, A.; Sherer, Y.; Shoenfeld, Y. 
Autoimmun.Rev. 2007, 6, 257-259.
55. Kuitwaard, K.; de Gelder, J.; Tio-Gillen, 
A. P.; Hop, W. C.; van Gelder, T.; van 
Toorenenbergen, A. W.; van Doorn, P. A.; 
Jacobs, B. C. Ann.Neurol. 2009, 66, 597-603.
56. Scherer, H. U.; Wang, J.; Toes, R. E.; van der, 
Woude D.; Koeleman, C. A.; de Boer, A. R.; 
Huizinga, T. W.; Deelder, A. M.; Wuhrer, M. 
Proteomics.Clin.Appl. 2009, 3, 106-115.
57. Wang, J.; Balog, C. I.; Stavenhagen, K.; 
Koeleman, C. A.; Scherer, H. U.; Selman, M. 
H.; Deelder, A. M.; Huizinga, T. W.; Toes, R. 
E.; Wuhrer, M. Mol.Cell Proteomics. 2011.
58. Wright, A.; Morrison, S. L. J Exp.Med. 1994, 
180, 1087-1096.
59. Wang, F.; Nakouzi, A.; Alvarez, M.; Zaragoza, 
O.; Angeletti, R. H.; Casadevall, A. Mol.
Immunol. 2006, 43, 987-998.
60. Ghirlando, R.; Lund, J.; Goodall, M.; Jefferis, 
R. Immunol.Lett. 1999, 68, 47-52.
61. Liu, H.; Bulseco, G. G.; Sun, J. Immunol.Lett. 
2006, 106, 144-153.
62. Gaza-Bulseco, G.; Hickman, K.; Sinicropi-
Yao, S.; Hurkmans, K.; Chumsae, C.; Liu, H. J 
Chromatogr.A 2009, 1216, 2382-2387.
63. Jones, A. J.; Papac, D. I.; Chin, E. H.; Keck, 
R.; Baughman, S. A.; Lin, Y. S.; Kneer, J.; 
Battersby, J. E. Glycobiology 2007, 17, 529-
540.
64. Goetze, A. M.; Liu, Y. D.; Zhang, Z.; Shah, 
B.; Lee, E.; Bondarenko, P. V.; Flynn, G. C. 
Glycobiology 2011, 21, 949-959.
65. Chen, X.; Liu, Y. D.; Flynn, G. C. Glycobiology 
2009, 19, 240-249.
66. Prahl, J. W.; Porter, R. R. Biochem.J 1968, 107, 
753-763.
166
67. Watson, M.; Rudd, P. M.; Bland, M.; Dwek, 
R. A.; Axford, J. S. Arthritis Rheum. 1999, 42, 
1682-1690.
68. Kuroda, Y.; Shikata, K.; Takeuchi, F.; Akazawa, 
T.; Kojima, N.; Nakata, M.; Mizuochi, T.; 
Goto, M. Exp.Gerontol. 2007, 42, 545-553.
69. Kuroda, Y.; Nakata, M.; Makino, A.; 
Matsumoto, A.; Ohashi, K.; Itahashi, K.; 
Takeuchi, F.; Goto, M.; Kojima, N.; Mizuochi, 
T. Glycoconj.J. 2002, 19, 23-31.
70. Lim, A.; Reed-Bogan, A.; Harmon, B. J. Anal.
Biochem. 2008, 375, 163-172.
71. Olivova, P.; Chen, W.; Chakraborty, A. B.; 
Gebler, J. C. Rapid Commun.Mass Spectrom. 
2008, 22, 29-40.
72. Qian, J.; Liu, T.; Yang, L.; Daus, A.; Crowley, 
R.; Zhou, Q. Anal.Biochem. 2007, 364, 8-18.
73. Schuster, M.; Jost, W.; Mudde, G. C.; 
Wiederkum, S.; Schwager, C.; Janzek, E.; 
Altmann, F.; Stadlmann, J.; Stemmer, C.; 
Gorr, G. Biotechnol.J. 2007, 2, 700-708.
74. Holland, M.; Yagi, H.; Takahashi, N.; Kato, 
K.; Savage, C. O.; Goodall, D. M.; Jefferis, R. 
Biochim.Biophys.Acta 2006, 1760, 669-677.
75. Omtvedt, L. A.; Royle, L.; Husby, G.; Sletten, 
K.; Radcliffe, C. M.; Harvey, D. J.; Dwek, R. A.; 
Rudd, P. M. Arthritis Rheum. 2006, 54, 3433-
3440.
76. Youings, A.; Chang, S. C.; Dwek, R. A.; 
Scragg, I. G. Biochem.J. 1996, 314, 621-630.
77. Wada, Y.; Azadi, P.; Costello, C. E.; Dell, A.; 
Dwek, R. A.; Geyer, H.; Geyer, R.; Kakehi, 
K.; Karlsson, N. G.; Kato, K.; Kawasaki, N.; 
Khoo, K. H.; Kim, S.; Kondo, A.; Lattova, 
E.; Mechref, Y.; Miyoshi, E.; Nakamura, K.; 
Narimatsu, H.; Novotny, M. V.; Packer, N. H.; 
Perreault, H.; Peter-Katalinic, J.; Pohlentz, 
G.; Reinhold, V. N.; Rudd, P. M.; Suzuki, A.; 
Taniguchi, N. Glycobiology 2007, 17, 411-
422.
78. Mechref, Y.; Muzikar, J.; Novotny, M. V. 
Electrophoresis 2005, 26, 2034-2046.
79. Stadlmann, J.; Pabst, M.; Kolarich, D.; 
Kunert, R.; Altmann, F. Proteomics 2008, 8, 
2858-2871.
80. Harazono, A.; Kawasaki, N.; Itoh, S.; Hashii, 
N.; Matsuishi-Nakajima, Y.; Kawanishi, T.; 
Yamaguchi, T. J.Chromatogr.B 2008, 869, 20-
30.
81. Kanoh, Y.; Mashiko, T.; Danbara, M.; 
Takayama, Y.; Ohtani, S.; Imasaki, T.; Abe, T.; 
Akahoshi, T. Oncology 2004, 66, 365-370.
82. Leibiger, H.; Wustner, D.; Stigler, R. D.; Marx, 
U. Biochem.J. 1999, 338, 529-538.
83. Harvey, D. J.; Crispin, M.; Scanlan, C.; Singer, 
B. B.; Lucka, L.; Chang, V. T.; Radcliffe, C. M.; 
Thobhani, S.; Yuen, C. T.; Rudd, P. M. Rapid 
Commun.Mass Spectrom. 2008, 22, 1047-
1052.
84. Taniguchi, T.; Mizuochi, T.; Beale, M.; 
Dwek, R. A.; Rademacher, T. W.; Kobata, A. 
Biochemistry 1985, 24, 5551-5557.
85. Ruhaak, L. R.; Zauner, G.; Huhn, C.; 
Bruggink, C.; Deelder, A. M.; Wuhrer, M. 
Anal.Bioanal.Chem. 2010.
86. Anumula, K. R. Anal.Biochem. 1994, 220, 
275-283.
87. Bigge, J. C.; Patel, T. P.; Bruce, J. A.; Goulding, 
P. N.; Charles, S. M.; Parekh, R. B. Anal.
Biochem. 1995, 230, 229-238.
88. Anumula, K. R. Anal.Biochem. 2006, 350, 1-
23.
89. Chen, X.; Flynn, G. C. Anal.Biochem. 2007, 
370, 147-161.
90. Takegawa, Y.; Deguchi, K.; Ito, S.; Yoshioka, 
S.; Nakagawa, H.; Nishimura, S. Anal.Chem. 
2005, 77, 2097-2106.
91. Royle, L.; Campbell, M. P.; Radcliffe, C. M.; 
White, D. M.; Harvey, D. J.; Abrahams, J. L.; 
Kim, Y. G.; Henry, G. W.; Shadick, N. A.; 
Weinblatt, M. E.; Lee, D. M.; Rudd, P. M.; 
Dwek, R. A. Anal.Biochem. 2008, 376, 1-12.
92. Takegawa, Y.; Deguchi, K.; Keira, T.; Ito, H.; 
Nakagawa, H.; Nishimura, S. J.Chromatogr.A 
2006, 1113, 177-181.
93. Kamoda, S.; Ishikawa, R.; Kakehi, K. 
J.Chromatogr.A 2006, 1133, 332-339.
94. Ruhaak, L. R.; Huhn, C.; Waterreus, W. J.; 
de Boer, A. R.; Neusüss, C.; Hokke, C. H.; 
Deelder, A. M.; Wuhrer, M. Anal.Chem. 
2008, 80, 6119-6126.
95. Kamoda, S.; Kakehi, K. Electrophoresis 2008, 
29, 3595-3604.
96. Fernández, L. E. M.; Kalume, D. E.; Calvo, L.; 
Fernández, M. M.; Vallin, A.; Roepstorff, P. 
J.Chromatogr.B 2001, 752, 247-261.
97. Majid, F. A.; Butler, M.; Al Rubeai, M. 
Biotechnol.Bioeng. 2007, 97, 156-169.
98. Hua, S.; An, H. J.; Ozcan, S.; Ro, G. S.; Soares, 
S.; Devere-White, R.; Lebrilla, C. B. Analyst 
2011.
99. Alley, W. R., Jr.; Madera, M.; Mechref, Y.; 
Novotny, M. V. Anal.Chem. 2010, 82, 5095-
5106.
100. Mimura, Y.; Ashton, P. R.; Takahashi, N.; 
Harvey, D. J.; Jefferis, R. J.Immunol.Methods 
2007, 326, 116-126.
101. Yamaguchi, Y.; Nishimura, M.; Nagano, M.; 
Yagi, H.; Sasakawa, H.; Uchida, K.; Shitara, 
K.; Kato, K. Biochim.Biophys.Acta 2006, 
1760, 693-700.





103. Songsrirote, K.; Li, Z.; Ashford, D.; Bateman, 
A.; Thomas-Oates, J. J Proteomics. 2010, 73, 
1479-1490.
104. Powell, L. D. Curr.Protoc.Mol.Biol 2001, 
Chapter 17, Unit17.
105. Nwosu, C. C.; Seipert, R. R.; Strum, J. S.; Hua, 
S. S.; An, H. J.; Zivkovic, A. M.; German, B. J.; 
Lebrilla, C. B. J Proteome Res. 2011, 10, 2612-
2624.
106. Hirayama, K.; Yuji, R.; Yamada, N.; Kato, K.; 
Arata, Y.; Shimada, I. Anal.Chem. 1998, 70, 
2718-2725.
107. Rehder, D. S.; Dillon, T. M.; Pipes, G. D.; 
Bondarenko, P. V. J.Chromatogr.A 2006, 
1102, 164-175.
108. Bongers, J.; Cummings, J. J.; Ebert, M. B.; 
Federici, M. M.; Gledhill, L.; Gulati, D.; 
Hilliard, G. M.; Jones, B. H.; Lee, K. R.; 
Mozdzanowski, J.; Naimoli, M.; Burman, S. 
J.Pharm.Biomed.Anal. 2000, 21, 1099-1128.
109. Schähs, M.; Strasser, R.; Stadlmann, J.; 
Kunert, R.; Rademacher, T.; Steinkellner, H. 
Plant Biotechnol.J. 2007, 5, 657-663.
110. Krokhin, O. V.; Ens, W.; Standing, K. G. Rapid 
Commun.Mass Spectrom. 2003, 17, 2528-
2534.
111. Janecki, D. J.; Broshears, W. C.; Reilly, J. P. 
Anal.Chem. 2004, 76, 6643-6650.
112. Jmeian, Y.; El Rassi, Z. J.Proteome.Res. 2007, 
6, 947-954.
113. Korecka, L.; Bilkova, Z.; Holeapek, M.; 
Kralovsky, J.; Benes, M.; Lenfeld, J.; Minc, 
N.; Cecal, R.; Viovy, J. L.; Przybylski, M. 
J.Chromatogr.B 2004, 808, 15-24.
114. Stigter, E. C.; de Jong, G. J.; van Bennekom, W. 
P. Anal.Bioanal.Chem. 2007, 389, 1967-1977.
115. Stigter, E. C.; de Jong, G. J.; van Bennekom, W. 
P. Anal.Chim.Acta 2008, 619, 231-238.
116. Ito, H.; Takegawa, Y.; Deguchi, K.; Nagai, S.; 
Nakagawa, H.; Shinohara, Y.; Nishimura, S. 
Rapid Commun.Mass Spectrom. 2006, 20, 
3557-3565.
117. Suzuki, N.; Lee, Y. C. Glycobiology 2004, 14, 
275-292.
118. Weitzman, S.; Portmore, J. J.Immunol. 1981, 
127, 2095-2101.
119. Zhang, Y.; Go, E. P.; Desaire, H. Anal.Chem. 
2008, 80, 3144-3158.
120. Strader, M. B.; Tabb, D. L.; Hervey, W. J.; Pan, 
C.; Hurst, G. B. Anal.Chem. 2006, 78, 125-
134.
121. Hervey, W. J.; Strader, M. B.; Hurst, G. B. 
J.Proteome.Res. 2007, 6, 3054-3061.
122. Rousseaux, J.; Rousseaux-Prevost, R.; Bazin, 
H. Mol.Immunol. 1989, 26, 27-32.
123. Suzuki, N.; Khoo, K. H.; Chen, C. M.; Chen, 
H. C.; Lee, Y. C. J.Biol.Chem. 2003, 278, 
46293-46306.
124. Kroon, D. J.; Freedy, J.; Burinsky, D. J.; 
Sharma, B. J.Pharm.Biomed.Anal. 1995, 13, 
1049-1054.
125. Perdivara, I.; Deterding, L.; Moise, A.; Tomer, 
K. B.; Przybylski, M. Anal.Bioanal.Chem. 
2008, 391, 325-336.
126. Wagner-Rousset, Elsa; Bednarczyk, Audrey; 
Bussat, Marie Claire; Colas, Olivier; 
Corvaïa, Nathalie; Schaeffer, Christine; Van 
Dorsselaer, Alain; Beck, Alain J.Chromatogr.B 
2008, In Press.
127. Huang, L.; Lu, J.; Wroblewski, V. J.; Beals, J. 
M.; Riggin, R. M. Anal.Chem. 2005, 77, 1432-
1439.
128. Chakraborty, A. B.; Berger, S. J. J.Biomol.Tech. 
2005, 16, 327-335.
129. Shou, W. Z.; Naidong, W. J.Chromatogr.B 
2005, 825, 186-192.
130. Huddleston, M. J.; Bean, M. F.; Carr, S. A. 
Anal.Chem. 1993, 65, 877-884.
131. Kilgore, B. R.; Lucka, A. W.; Patel, R.; 
Andrien, B. A., Jr.; Dhume, S. T. Methods Mol.
Biol. 2008, 446, 333-346.
132. Wuhrer, M.; Koeleman, C. A.; Hokke, C. H.; 
Deelder, A. M. Anal.Chem. 2005, 77, 886-
894.
133. Beck, A.; Bussat, M. C.; Zorn, N.; Robillard, 
V.; Klinguer-Hamour, C.; Chenu, S.; Goetsch, 
L.; Corvaïa, N.; Van Dorsselaer, A.; Haeuw, J. 
F. J.Chromatogr.B 2005, 819, 203-218.
134. Huang, L.; Biolsi, S.; Bales, K. R.; Kuchibhotla, 
U. Anal.Biochem. 2006, 349, 197-207.
135. Karnoup, A. S.; Kuppannan, K.; Young, S. A. 
J.Chromatogr.B 2007, 859, 178-191.
136. Gilar, M.; Yu, Y. Q.; Ahn, J.; Xie, H.; Han, H.; 
Ying, W.; Qian, X. Anal.Biochem. 2011, 417, 
80-88.
137. Neue, K.; Mormann, M.; Peter-Katalinic, J.; 
Pohlentz, G. J.Proteome Res. 2011.
138. Mysling, S.; Palmisano, G.; Hojrup, P.; 
Thaysen-Andersen, M. Anal.Chem. 2010, 82, 
5598-5609.
139. Wuhrer, M.; de Boer, A. R.; Deelder, A. M. 
Mass Spectrom.Rev. 2009, 28, 192-206.
140. Takegawa, Y.; Deguchi, K.; Ito, H.; Keira, T.; 
Nakagawa, H.; Nishimura, S. J.Sep.Sci. 2006, 
29, 2533-2540.
141. Boersema, P. J.; Mohammed, S.; Heck, A. J. 
Anal.Bioanal.Chem. 2008, 391, 151-159.
142. Takegawa, Y.; Ito, H.; Keira, T.; Deguchi, K.; 
Nakagawa, H.; Nishimura, S. J Sep.Sci. 2008, 
31, 1585-1593.
168
143. Yu, Y. Q.; Gilar, M.; Kaska, J.; Gebler, J. C. 
Rapid Commun.Mass Spectrom. 2005, 19, 
2331-2336.
144. O‘Connor, P. B.; Budnik, B. A.; Ivleva, V. B.; 
Kaur, P.; Moyer, S. C.; Pittman, J. L.; Costello, 
C. E. J.Am.Soc.Mass Spectrom. 2004, 15, 128-
132.
145. Zhang, B.; Yang, Y.; Yuk, I.; Pai, R.; McKay, 
P.; Eigenbrot, C.; Dennis, M.; Katta, V.; 
Francissen, K. C. Anal.Chem. 2008, 80, 2379-
2390.
146. Arnold, J. N.; Wormald, M. R.; Sim, R. B.; 
Rudd, P. M.; Dwek, R. A. Annu.Rev.Immunol. 
2007, 25, 21-50.
147. Huhn, C.; Selman, M. H.; Ruhaak, L. R.; 
Deelder, A. M.; Wuhrer, M. Proteomics. 2009, 
9, 882-913.
148. Selman, M. H. J.; McDonnell, L. A.; Palmblad, 
M.; Ruhaak, L. R.; Deelder, A. M.; Wuhrer, M. 
Anal.Chem. 2010, 82, 1073-1081.
149. Apffel, A.; Fischer, S.; Goldberg, G.; Goodley, 
P. C.; Kuhlmann, F. E. J.Chromatogr.A 1995, 
712, 177-190.
150. Kuhlmann, Frank E.; Apffel, Alex; Fischer, 
Steven M.; Goldberg, Gerson; Goodley, Paul 
C. Journal of the American Society for Mass 
Spectrometry 1995, 6, 1221-1225.
151. Liu, A.; Tweed, J.; Wujcik, C. E. J.Chromatogr.B 
Analyt.Technol.Biomed.Life Sci. 2009, 877, 
1873-1881.
152. Pedrioli, P. G.; Eng, J. K.; Hubley, R.; 
Vogelzang, M.; Deutsch, E. W.; Raught, 
B.; Pratt, B.; Nilsson, E.; Angeletti, R. H.; 
Apweiler, R.; Cheung, K.; Costello, C. E.; 
Hermjakob, H.; Huang, S.; Julian, R. K.; Kapp, 
E.; McComb, M. E.; Oliver, S. G.; Omenn, G.; 
Paton, N. W.; Simpson, R.; Smith, R.; Taylor, 
C. F.; Zhu, W.; Aebersold, R. Nat.Biotechnol. 
2004, 22, 1459-1466.
153. Nevedomskaya, E.; Derks, R.; Deelder, A. 
M.; Mayboroda, O. A.; Palmblad, M. Anal.
Bioanal.Chem. 2009, 395, 2527-2533.
154. Alfred V.Aho, B. W. K. a. P. J. W. The AWK 
programming Language, Addison-Wesley: 
Reading, Massachusetts, 1988.
155. Strittmatter, E. F.; Ferguson, P. L.; Tang, K.; 
Smith, R. D. J.Am.Soc.Mass Spectrom. 2003, 
14, 980-991.
156. Barbosa, Luis A. M. M.; van Santen, Rutger A. 
Journal of Catalysis 2000, 191, 200-217.
157. Hopmann, K. H.; Guo, J. D.; Himo, F. Inorg.
Chem. 2007, 46, 4850-4856.
158. Ma, Jun; Zhang, Xuelan; Zhao, Ning; Xiao, 
Fukui; Wei, Wei; Sun, Yuhan Journal of 
Molecular Structure: THEOCHEM 2009, 911, 
40-45.
159. Haselberg, R.; Brinks, V.; Hawe, A.; de Jong, 
G. J.; Somsen, G. W. Anal.Bioanal.Chem. 
2011, 400, 295-303.
160. Gritti, F.; Guiochon, G. J.Chromatogr.A 2010, 
1217, 8167-8180.
161. Destefano, J. J.; Langlois, T. J.; Kirkland, J. J. 
J.Chromatogr.Sci. 2008, 46, 254-260.
162. Marchetti, N.; Guiochon, G. J.Chromatogr.A 
2007, 1176, 206-216.
163. Narasimhan, S. J.Biol Chem. 1982, 257, 
10235-10242.
164. Wilson, J. R.; Williams, D.; Schachter, H. 
Biochem.Biophys.Res.Commun. 1976, 72, 
909-916.
165. Narimatsu, H.; Sinha, S.; Brew, K.; Okayama, 
H.; Qasba, P. K. Proc.Natl.Acad.Sci.U.S.A 
1986, 83, 4720-4724.
166. Paulson, J. C.; Prieels, J. P.; Glasgow, L. R.; 
Hill, R. L. J.Biol Chem. 1978, 253, 5617-5624.
167. Gasnier, F.; Baubichon-Cortay, H.; Louisot, 
P.; Gateau-Roesch, O. J.Biochem. 1991, 110, 
702-707.
168. Mechref, Y.; Novotny, M. V. Chem.Rev. 2002, 
102, 321-369.
169. Wuhrer, M.; Deelder, A. M.; Hokke, C. H. 
J.Chromatogr.B Analyt.Technol.Biomed.Life 
Sci. 2005, 825, 124-133.
170. Wang, X.; Emmett, M. R.; Marshall, A. G. 
Anal.Chem. 2010.
171. Wohlgemuth, J.; Karas, M.; Jiang, W.; 
Hendriks, R.; Andrecht, S. J.Sep.Sci. 2010, 33, 
880-890.
172. Wuhrer, M.; Koeleman, C. A.; Deelder, A. M. 
Anal.Chem. 2009, 81, 4422-4432.
173. Iskratsch, T.; Braun, A.; Paschinger, K.; 
Wilson, I. B. Anal.Biochem. 2009, 386, 133-
146.
174. Green, E. D.; Adelt, G.; Baenziger, J. U.; 
Wilson, S.; Van Halbeek, H. J.Biol Chem. 
1988, 263, 18253-18268.
175. Sergeant, K.; Pinheiro, C.; Hausman, J. F.; 
Ricardo, C. P.; Renaut, J. J.Proteome Res. 
2009, 8, 3182-3190.
176. Ruhaak, L. R.; Steenvoorden, E.; Koeleman, 
C. A.; Deelder, A. M.; Wuhrer, M. Proteomics. 
2010, 10, 2330-2336.
177. Rappsilber, J.; Mann, M.; Ishihama, Y. Nat.
Protoc. 2007, 2, 1896-1906.
178. Craft, D.; Doucette, A.; Li, L. J.Proteome Res. 
2002, 1, 537-547.
179. Hagglund, P.; Matthiesen, R.; Elortza, F.; 
Hojrup, P.; Roepstorff, P.; Jensen, O. N.; 
Bunkenborg, J. J.Proteome Res. 2007, 6, 3021-
3031.





181. Raju, T. S. Curr.Opin.Immunol. 2008, 20, 471-
478.
182. Carr, S. A.; Roberts, G. D. Anal.Biochem. 
1986, 157, 396-406.
183. Erdjument-Bromage, H.; Lui, M.; Lacomis, 
L.; Grewal, A.; Annan, R. S.; McNulty, D. E.; 
Carr, S. A.; Tempst, P. J.Chromatogr.A 1998, 
826, 167-181.
184. Li, N.; Shaw, A. R.; Zhang, N.; Mak, A.; Li, L. 
Proteomics. 2004, 4, 3156-3166.
185. Laroy, W.; Contreras, R.; Callewaert, N. Nat.
Protoc. 2006, 1, 397-405.
186. Yu, Y. Q.; Fournier, J.; Gilar, M.; Gebler, J. C. 
Anal.Chem. 2007, 79, 1731-1738.
187. Cohen, S. L.; Chait, B. T. Anal.Chem. 1996, 
68, 31-37.
188. Wohlgemuth, J.; Karas, M.; Eichhorn, T.; 
Hendriks, R.; Andrecht, S. Anal.Biochem. 
2009, 395, 178-188.
189. Van Droogenbroeck, B.; Cao, J.; Stadlmann, 
J.; Altmann, F.; Colanesi, S.; Hillmer, S.; 
Robinson, D. G.; Van Lerberge, E.; Terryn, 
N.; Van Montagu, M.; Liang, M.; Depicker, 
A.; De Jaeger, G. Proc.Natl.Acad.Sci.U.S.A 
2007, 104, 1430-1435.
190. Gabelica, V.; Schulz, E.; Karas, M. J.Mass 
Spectrom. 2004, 39, 579-593.
191. Harvey, D. J. Mass Spectrom.Rev. 1999, 18, 
349-450.
192. Harvey, D. J. Mass Spectrom.Rev. 2009, 28, 
273-361.
193. Kang, P.; Mechref, Y.; Klouckova, I.; Novotny, 
M. V. Rapid Commun.Mass Spectrom. 2005, 
19, 3421-3428.
194. Mechref, Y.; Kang, P.; Novotny, M. V. Methods 
Mol.Biol 2009, 534, 53-64.
195. Guillard, M.; Gloerich, J.; Wessels, H. J.; 
Morava, E.; Wevers, R. A.; Lefeber, D. J. 
Carbohydr.Res. 2009, 344, 1550-1557.
196. Garden, R. W.; Sweedler, J. V. Anal.Chem. 
2000, 72, 30-36.
197. Bouschen, Werner; Spengler, Bernhard 
International Journal of Mass Spectrometry 
2007, 266, 129-137.
198. Qiao, Hui; Piyadasa, Gamini; Spicer, Victor; 
Ens, Werner International Journal of Mass 
Spectrometry 2009, 281, 41-51.
199. Jaskolla, T. W.; Lehmann, W. D.; Karas, M. 
Proc.Natl.Acad.Sci.U.S.A 2008, 105, 12200-
12205.
200. Jaskolla, T.; Fuchs, B.; Karas, M.; Schiller, J. 
J.Am.Soc.Mass Spectrom. 2009, 20, 867-874.
201. Selman, M. H. J.; Hemayatkar, M.; Deelder, A. 
M.; Wuhrer, M. Anal.Chem. 2011, 83, 2492-
2499.
202. Oehlers, L. P.; Perez, A. N.; Walter, R. B. Rapid 
Commun.Mass Spectrom. 2005, 19, 752-758.
203. Ciucanu, Ionel; Kerek, Francisc Carbohydrate 
Research 1984, 131, 209-217.
204. Zauner, G.; Koeleman, C. A.; Deelder, A. M.; 
Wuhrer, M. Biochim.Biophys.Acta 2011.
205. Robbe, C.; Capon, C.; Flahaut, C.; Michalski, 
J. C. Electrophoresis 2003, 24, 611-621.
206. Leszyk, J. D. J.Biomol.Tech. 2010, 21, 81-91.
207. Harvey, David J.; Hunter, Ann P.; Bateman, 
Robert H.; Brown, Jeff; Critchley, Glen 
International Journal of Mass Spectrometry 
1999, 188, 131-146.
208. Nwosu, C. C.; Strum, J. S.; An, H. J.; Lebrilla, 
C. B. Anal.Chem. 2010, 82, 9654-9662.
209. Keller, Bernd O.; Li, Liang Journal of the 
American Society for Mass Spectrometry 
2000, 11, 88-93.
210. Smirnov, I. P.; Zhu, X.; Taylor, T.; Huang, Y.; 
Ross, P.; Papayanopoulos, I. A.; Martin, S. 
A.; Pappin, D. J. Anal.Chem. 2004, 76, 2958-
2965.
211. Guo, N.; Liu, Y.; Masuda, Y.; Kawagoe, M.; 
Ueno, Y.; Kameda, T.; Sugiyama, T. Clin.
Biochem. 2005, 38, 149-153.
212. Gutierrez, G.; Gentile, T.; Miranda, S.; 
Margni, R. A. Chem.Immunol.Allergy 2005, 
89, 158-168.
213. Umana, P.; Jean-Mairet, J.; Moudry, R.; 
Amstutz, H.; Bailey, J. E. Nat.Biotechnol. 
1999, 17, 176-180.
214. Davies, J.; Jiang, L.; Pan, L. Z.; LaBarre, M. 
J.; Anderson, D.; Reff, M. Biotechnol.Bioeng. 
2001, 74, 288-294.
215. Soonawala, D.; Rimmelzwaan, G. F.; Gelinck, 
L. B.; Visser, L. G.; Kroon, F. P. PLoS.ONE. 
2011, 6, e16496.
216. van Riet, E.; Retra, K.; Adegnika, A. A.; Jol-
van der Zijde CM; Uh, H. W.; Lell, B.; Issifou, 
S.; Kremsner, P. G.; Yazdanbakhsh, M.; van 
Tol, M. J.; Hartgers, F. C. Vaccine 2008, 26, 
3690-3695.
217. Selman, M. H. J.; Derks, R. J.; Bondt, A.; 
Palmblad, M.; Schoenmaker, B.; Koeleman, 
C. A.; van de Geijn, F. E.; Dolhain, R. J.; 
Deelder, A. M.; Wuhrer, M. J.of Proteomics. 
2011.
218. Mizuochi, T.; Hamako, J.; Titani, K. Arch.
Biochem.Biophys. 1987, 257, 387-394.
219. Mizuochi, T.; Hamako, J.; Nose, M.; Titani, K. 
J.Immunol. 1990, 145, 1794-1798.
220. Blomme, B.; Van Steenkiste, C.; Grassi, P.; 
Haslam, S. M.; Dell, A.; Callewaert, N.; Van 
Vlierberghe, H. Am.J Physiol Gastrointest.
Liver Physiol 2011, 300, G833-G842.
221. Parmentier, H. K.; De Vries, Reilingh G.; 
Lammers, A. Poult.Sci. 2008, 87, 918-926.
170
222. Welsh, R. M.; O‘Donnell, C. L.; Reed, D. J.; 
Rother, R. P. J.Virol. 1998, 72, 4650-4656.
223. Abdel-Motal, U. M.; Guay, H. M.; 
Wigglesworth, K.; Welsh, R. M.; Galili, U. 
J.Virol. 2007, 81, 9131-9141.
224. Hodoniczky, J.; Zheng, Y. Z.; James, D. C. 
Biotechnol.Prog. 2005, 21, 1644-1652.
225. Goulon, M.; Girard, O.; Grosbuis, S.; 
Desormeau, J. P.; Capponi, M. F. Nouv.Presse 
Med. 1972, 1, 3049-3050.
226. Ding, H.; Tsai, C.; Zhou, F.; Buchy, P.; Deubel, 
V.; Zhou, P. PLoS.ONE. 2011, 6, e17821.
227. Stanekova, Z.; Vareckova, E. Virol.J. 2010, 7, 
351.
228. Wrammert, J.; Koutsonanos, D.; Li, G. 
M.; Edupuganti, S.; Sui, J.; Morrissey, M.; 
McCausland, M.; Skountzou, I.; Hornig, M.; 
Lipkin, W. I.; Mehta, A.; Razavi, B.; Del Rio, 
C.; Zheng, N. Y.; Lee, J. H.; Huang, M.; Ali, Z.; 
Kaur, K.; Andrews, S.; Amara, R. R.; Wang, 
Y.; Das, S. R.; O‘Donnell, C. D.; Yewdell, J. W.; 
Subbarao, K.; Marasco, W. A.; Mulligan, M. J.; 
Compans, R.; Ahmed, R.; Wilson, P. C. J.Exp.
Med. 2011, 208, 181-193.
229. Jegerlehner, A.; Schmitz, N.; Storni, T.; 
Bachmann, M. F. J.Immunol. 2004, 172, 5598-
5605.
230. Huber, V. C.; McKeon, R. M.; Brackin, M. 
N.; Miller, L. A.; Keating, R.; Brown, S. A.; 
Makarova, N.; Perez, D. R.; Macdonald, G. 
H.; McCullers, J. A. Clin.Vaccine Immunol. 
2006, 13, 981-990.
231. Carragher, D. M.; Kaminski, D. A.; Moquin, 
A.; Hartson, L.; Randall, T. D. J.Immunol. 
2008, 181, 4168-4176.
232. Huber, V. C.; Lynch, J. M.; Bucher, D. J.; Le, J.; 
Metzger, D. W. J.Immunol. 2001, 166, 7381-
7388.
233. Vella, S.; Rocchi, G.; Resta, S.; Marcelli, M.; 
De Felici, A. J.Med.Virol. 1980, 6, 203-211.
234. Burton, D. R. Nat.Rev.Immunol. 2002, 2, 706-
713.
235. Buonaguro, F. M.; Tornesello, M. L.; 
Buonaguro, L. Expert.Opin.Biol Ther. 2011.
236. Pilkington, C.; Lefvert, A. K.; Rook, G. A. 
Autoimmunity 1995, 21, 131-135.
237. Lang, B.; Vincent, A. Curr.Opin.Pharmacol. 
2009, 9, 336-340.
238. Titulaer, M. J.; Verschuuren, J. J. 
Ann.N.Y.Acad.Sci. 2008, 1132, 129-134.
239. Niks, E. H.; Kuks, J. B.; Verschuuren, J. J. 
J.Neurol.Neurosurg.Psychiatry 2007, 78, 417-
418.
240. Titulaer, M. J.; Wirtz, P. W.; Kuks, J. B.; 
Schelhaas, H. J.; van der Kooi, A. J.; Faber, 
C. G.; van der Pol, W. L.; de Visser, M.; 
Sillevis Smitt, P. A.; Verschuuren, J. J. 
J.Neuroimmunol. 2008, 201-202, 153-158.
241. Lubin, J. H.; Colt, J. S.; Camann, D.; Davis, S.; 
Cerhan, J. R.; Severson, R. K.; Bernstein, L.; 
Hartge, P. Environ.Health Perspect. 2004, 112, 
1691-1696.
242. Uh, H. W.; Hartgers, F. C.; Yazdanbakhsh, M.; 
Houwing-Duistermaat, J. J. BMC.Immunol. 
2008, 9, 59.
243. Banda, N. K.; Wood, A. K.; Takahashi, K.; 
Levitt, B.; Rudd, P. M.; Royle, L.; Abrahams, 
J. L.; Stahl, G. L.; Holers, V. M.; Arend, W. P. 
Arthritis Rheum. 2008, 58, 3081-3089.
244. Parekh, R. B.; Dwek, R. A.; Rademacher, T. 
W. Br.J.Rheumatol. 1988, 27 Suppl 2, 162-169.
245. Rodgaard, A.; Nielsen, F. C.; Djurup, R.; 
Somnier, F.; Gammeltoft, S. Clin.Exp.
Immunol. 1987, 67, 82-88.
246. Niks, E. H.; van Leeuwen, Y.; Leite, M. I.; 
Dekker, F. W.; Wintzen, A. R.; Wirtz, P. W.; 
Vincent, A.; van Tol, M. J.; Jol-van der Zijde 
CM; Verschuuren, J. J. J.Neuroimmunol. 
2008, 195, 151-156.
247. Oosterhuis, H. J.; Limburg, P. C.; Hummel-
Tappel, E.; The, T. H. J.Neurol.Sci. 1983, 58, 
371-385.
248. Domon, B.; Costello, C. E. Biochemistry 1988, 
27, 1534-1543.
249. Sleat, D. E.; Wang, Y.; Sohar, I.; Lackland, H.; 
Li, Y.; Li, H.; Zheng, H.; Lobel, P. Mol.Cell 
Proteomics. 2006, 5, 1942-1956.
250. Go, E. P.; Rebecchi, K. R.; Dalpathado, D. S.; 
Bandu, M. L.; Zhang, Y.; Desaire, H. Anal.
Chem. 2007, 79, 1708-1713.
251. Deshpande, N.; Jensen, P. H.; Packer, N. H.; 






Immunoglobulins (Igs) represent an important part of the human immune system and 
can adapt to many different antigenic challenges. Structural variety of Igs is achieved 
by the expression of hypervariable regions which create the antigen binding site and 
define the antigen specificity and affinity. Moreover, multiple classes (i.e. IgM, IgD, 
IgG, IgA, IgE) and subclasses (e.g. IgG1-4) of immunoglobulins are present in humans, 
differing in temporal expression patterns as well as in function. IgG represents the most 
abundant antibody class in the human circulation, being present at a concentration 
of approximately 10 mg/ml. IgG consists of two heavy chains and two light chains. 
Parts of the heavy chains, together with the light chains, form two fragment antigen 
binding (Fab) moieties, whilst the remainders of the two heavy chains form the 
fragment crystallizable (Fc) moiety. Next to the enormous variety in the sequence of 
the antigen-binding region of plasma IgG, human IgGs vary in the N-glycan structure 
at the highly conserved N-glycosylation site asparagine 297 in the CH2 domain of 
each heavy polypeptide chain of the Fc part. This N-glycan is often core-fucosylated 
and varies in the number of antenna galactose residues resulting in the prominent 
glycoforms G0F (no galactose), G1F (1 galactose), and G2F (2 galactoses). A small part 
of the Fc N-glycans may carry a bisecting N-acetylglucosamine (GlcNAc). In addition, 
these glycans may contain a sialic acid residue attached to an antenna galactose. 
Fully galactosylated N-glycans are positioned between the Fc polypeptide chains, 
resulting in an open Fc conformation which is required for high affinity binding to Fcγ 
receptors. Small changes in the Fc glycosylation pattern can already have a profound 
influence on the interaction of the Fc portion with receptors modulating the anti- 
and pro-inflammatory properties of IgG. Over the past 30 years, many descriptive 
data regarding the biological and clinical role of IgG Fc N-glycosylation have been 
accumulated. The biological role of IgG Fc N-glycosylation and strategies to purify and 
analyze the Fc N-glycosylation are reviewed in Chapter 1. In addition, the importance 
of the glycosylation on therapeutic antibodies is described.
Mass spectrometry provides great opportunities for detailed structural characterization 
of protein glycosylation including protein identification, determination of site-specific 
glycosylation profiles, and structural characterization of glycans at the level of released 
glycans and glycopeptides. In Chapter 2 the development of a fast reversed phase (RP) 
nanoLC-MS system for IgG Fc N-glycosylation analysis is described. A robust system was 
obtained by coupling the fast nanoLC separation to the mass spectrometer by a sheath-
flow ESI sprayer. For each of the IgG subclasses the eight major glycoforms showed an 
interday analytical variation of below 5%. The method was successfully applied for fast 
and detailed IgG subclass-specific profiling of the Fc N-glycosylation for 26 women 
at several time points during pregnancy and after delivery, confirming the previous 
reported increase of IgG galactosylation during pregnancy. The technique additionally 
allowed sensitive and accurate determination of sialylated IgG glycopeptides, revealing 
increased levels of IgG sialylation during pregnancy.
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Compared to LC-MS, MALDI-MS analysis times are much shorter. For sensitive 
and detailed glycosylation analysis by MALDI-MS analysis, however, suitable sample 
preparation of glycopeptides is crucial as signals are easily suppressed by coexisting salts 
and peptides. Hydrophilic interaction liquid chromatography (HILIC) has been found to 
be very suitable for selective glycopeptide purification. In Chapter 3 the development of 
filter-free cotton wool HILIC solid-phase extraction (SPE) microtips for the purification 
of glycoconjugates is described. The reproducibility of pristine and reused tips was 
extensively evaluated, showing a low interday variability for the major IgG glycoforms. The 
cotton wool microtips showed a high capacity (at least 5 mg 2-AA labeled maltoheptaose 
per 500 mg cotton) and were successfully applied for the extraction and purification of 
glycopeptides and released glycans from complex samples.
In Chapter 4 of this thesis the potential of 96-well plate format purification 
strategies for reproducible high-throughput sample preparation and detailed MALDI 
analysis of IgG Fc N-glycosylation in the human circulation is described. It is shown 
that 96-well plate format IgG purification with protein A affinity chromatography 
combined to RP or HILIC SPE purification of the tryptic glycopeptides provided 
very reproducible and detailed subclass-specific IgG Fc N-glycosylation profiles with 
a low interday variability (below 5% for the six major IgG1 and IgG2 glycoforms). 
The occurrence of massive in-source and metastable decay for sialylated glycopeptides 
during MALDI-TOF-MS limited high resolution analysis to neutral glycopeptides 
only. By contrast, MALDI-FTICR-MS equipped with an intermediate pressure MALDI 
source proved to be very suited for fast and robust high resolution profiling of intact 
IgG Fc N-glycopeptides including sialylated glycopeptides. The suitability of Sepharose 
HILIC SPE and MALDI-FTICR-MS for IgG subclass-specific high-throughput Fc 
N-glycosylation profiling from human plasma was successfully shown for a cohort 
of 62 human samples, confirming the previously described age- and sex-related IgG 
glycosylation changes.
The choice of the MALDI matrix is crucial for minimizing desialylation of 
glycoconjugates by mass spectrometric in-source and metastable decay. For example, 
CHCA tends to lead to an almost complete loss of sialic acids, while the “colder” character 
of DHB often limits sialic acids loss, particularly in combination with negative-ion mode 
and/or linear-mode MALDI-TOF-MS. In MALDI sample preparation, DHB however 
tends to form large needle-like crystals. This macrocrystalline nature generally results 
in areas where certain analytes are highly concentrated, and in a very large spatial 
heterogeneity of mass spectra obtained from one sample spot. Moreover, MALDI-
TOF-MS of macrocrystalline sample preparations is known to result in mass spectra of 
rather low resolution and mass accuracy in linear oriented MALDI-TOF instruments. 
In Chapter 5 the potential of the microcrystalline 4-chloro-α-cyanocinnamic acid 
(Cl-CCA) matrix for MALDI-TOF-MS detection of labile sialylated glycoconjugates has 
been evaluated. The microcrystalline nature of the Cl-CCA matrix with homogeneous 




and mass accuracy. Both DHB and Cl-CCA allowed sensitive and reproducible negative 
ion mode MALDI-TOF-MS analysis of sialylated glycopeptides. The Cl-CCA matrix 
proved to be as effective as DHB in preventing sialic acid loss during MALDI-TOF-MS, 
which was illustrated by the analysis of sialylated N- and O-glycoconjugates.
Antibody effector functions are modulated by the attached Fc N-glycans. In 
response to specific stimuli, different glycosylation profiles can be obtained at the 
level of antigen-specific IgG in comparison to glycosylation at the level of total IgG. 
In Chapter 6 IgG Fc N-glycosylation changes induced by vaccination of 10 Caucasian 
adults and 10 African children were studied. While vaccination was found to have no 
effect on the glycosylation of total IgG, anti-vaccine IgG1 showed increased levels of 
galactosylation and sialylation and a decreased level of bisecting N-acetylglucosamine 
upon active immunization. The data indicate that the infectious agent will encounter 
IgGs with quite different glycosylation profiles depending on the vaccination time point 
which might influence the antibody effector functions relevant to immunity. However, 
it should be stressed that the regulatory aspects and functional implications of human 
IgG glycosylation features are still largely unknown, and that further research is needed.
Shifts in IgG Fc N-glycosylation features in well-defined antibody-mediated 
autoimmune diseases could provide valuable insights into which IgG Fc 
N-glycosylation features potentially influence antibody pathogenicity. In Chapter 7 
IgG Fc N-glycosylation changes have been evaluated for the neurological disorders 
Lambert-Eaton myasthenic syndrome (LEMS), and myasthenia gravis (MG). LEMS 
and MG patients showed lower levels of IgG2 galactosylation compared to controls. 
In addition, the level of IgG1 galactosylation in LEMS patients was lower compared 
to the controls. Interestingly, LEMS patients below 50 years showed elevated levels 
of bisecting N-acetylglucosamine on IgG1 and IgG2, demonstrating for the first 
time the link of changes in the level of bisecting N-acetylglucosamine with disease. 
However, the immunological relevance of the observed IgG glycosylation changes 
remains unclear and future longitudinal studies of total and autoantigen-specific IgG 
Fc N-glycosylation are required to reveal possible associations between disease severity 
and glycosylation features.
In this thesis novel approaches for fast, miniaturized and high-throughput analysis 
of IgG Fc N-glycosylation are presented, and the utility of these methods has been 
demonstrated for clinically relevant research questions. The limitations, strengths and 
perspectives of these techniques are discussed in Chapter 8.
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Samenvatting
Immunoglobulinen (Igs) vertegenwoordigen een belangrijk deel van het menselijk 
immuunsysteem en worden geproduceerd als reactie op lichaamsvreemde stoffen 
(antigenen) aanwezig op pathogenen zoals virussen en bacteriën. Doordat de Igs 
deze antigenen herkennen, kunnen pathogenen onschadelijk worden gemaakt. In het 
menselijk lichaam komen meerdere Ig klassen (i.e. IgM, IgD, IgG, IgA, IgE) en subklassen 
(e.g. IgG1-4) voor, waarvan IgG de hoogste concentratie heeft in de circulatie (ca. 10 mg/
ml bloed). IgG bestaat uit twee identieke lichte en twee identieke zware aminozuurketens 
die elk constante delen en een variabel deel bevatten. De lichte aminozuurketens vormen 
samen met het variabele deel en een constant deel van de zware aminozuurketens 
twee antigeen bindende (Fab) delen. De resterende constante delen van de zware 
aminozuurketens (CH2 en CH3) vormen het fragment crystallizable (Fc) gedeelte wat 
verantwoordelijk is voor de binding met de Fcγ receptoren op effector cellen. In het Fc 
gedeelte zit op de sterk geconserveerde N-glycosylerings site asparagine 297 in het CH2 
domein van beide zware aminozuurketens een suikerketen (N-glycaan). N-glycanen 
hebben een gemeenschappelijk bi-antennaire kern (chitobiose kern) en variëren in het 
aantal antenne galactoses. Een groot gedeelte van de N-glycanen heeft een fucose aan 
het met het asparagine residu verbonden N-acetylglucosamine. Een klein percentage 
van de N-glycanen heeft een siaalzuur aan de antenne galactose(s) en/of een additionele 
N-acetylglucosamine (bisecting N-acetylglucosamine). Doordat de suikerketens van 
volledig gegalactosyleerde N-glycanen naar elkaar toe wijzen ontstaat een open Fc 
structuur die noodzakelijk is voor een sterke binding met de Fcγ receptoren. Kleine 
veranderingen in de samenstelling van de Fc N-glycanen kunnen een grote invloed hebben 
op de binding met de Fcγ receptoren en kunnen hierdoor de anti- en pro-inflammatoire 
eigenschappen van IgG veranderen. In de laatste 30 jaar is veel onderzoek verricht naar de 
precieze biologische rol van IgG Fc N-glycosylering. In hoofdstuk 1 zijn de belangrijkste 
bevindingen en analyse technieken van de voornaamste studies samengevat. Tevens 
wordt het belang van de glycosylering van therapeutische antilichamen beschreven.
Een van de meest potentiële technieken voor de gedetailleerde structurele 
karakterisering van IgG Fc N-glycosylering is vloeistof chromatografie (LC) gekoppeld 
aan massaspectrometrie (MS). In hoofdstuk 2 van dit proefschrift is de ontwikkeling 
van een snelle reversed phase (RP) nanoLC-MS methode voor de analyse van IgG Fc 
N-glycosylering beschreven. Door de nanoLC te koppelen aan de MS met een “sheath-
flow” electrospray (ESI) sprayer is een robuust en gevoelig systeem verkregen. Voor 
de acht meest voorkomende Fc N-glycopeptiden van IgG1 en IgG2 was de inter-dag 
analytische variatie kleiner dan 5%. De methode is succesvol toegepast voor de analyse 
van een cohort van 26 zwangere vrouwen en de verkregen resultaten bevestigen de in 
de literatuur gerapporteerde verhoging in IgG galactosylering tijdens de zwangerschap. 
Daarnaast werd door de gevoelige meting van gesialyleerde glyopeptiden een verhoging 




In vergelijking met LC-MS zijn de analyse tijden met matrix-assisted laser desorptie 
ionisatie (MALDI) MS vele malen korter. Glycopeptide signalen kunnen echter 
gemakkelijk worden onderdrukt door andere moleculen in het mengsel zoals zouten 
en peptiden zonder glycanen. Voor een gevoelige en gedetailleerde MALDI-MS analyse 
is de monstervoorbereiding dan ook cruciaal. Door de hydrofiele eigenschappen van 
de N-glycanen kunnen glycopeptiden zeer specifiek worden gezuiverd met hydrofiele 
interactie vloeistof chromatografie (HILIC). In hoofdstuk 3 van dit proefschrift is 
de ontwikkeling van watten HILIC microtips voor de vaste fase extractie (SPE) van 
glycoconjugaten beschreven. De reproduceerbaarheid van nieuwe en hergebruikte 
microtips laat voor de meest voorkomende IgG Fc N-glycopeptiden een lage inter-dag 
analytische variatie zien. De watten microtips hebben een hoge capaciteit (minimaal 5 
mg 2-AA labeled maltoheptaose per 500 mg wat) en konden succesvol worden toegepast 
voor de extractie en zuivering van glycopeptiden en afgesplitste glycanen uit complexe 
mengsels.
In hoofdstuk 4 van dit proefschrift is de geschiktheid van RP (i.e. C18) en HILIC 
(i.e Sepharose, cellulose) SPE in 96-well plaat format beschreven voor de high-
throughput zuivering van IgG Fc N-glycopeptiden. Voor de zes meest voorkomende 
Fc N-glycopeptiden van IgG1 en IgG2 was de inter-dag analytische variatie van de 
monstervoorbereidingen kleiner dan 5%. De monsters zijn met zowel MALDI-TOF-
MS als intermediate pressure MALDI-FTICR-MS gemeten. Tijdens MALDI-TOF-
MS analyse vindt op grote schaal in-bron en metastabiel verval van gesialyleerde 
glycopeptiden plaats, waardoor het niet mogelijk is om deze met hoge resolutie te meten. 
De MALDI-FTICR-MS bleek echter uitermate geschikt voor de hoge resolutie analyse 
van de gesialyleerde en neutrale glycopeptiden. De Sepharose HILIC-SPE met MALDI-
FTICR-MS detectie is succesvol toegepast voor de analyse van IgG Fc N-glycopeptiden 
van 62 humane controle monsters. De verkregen resultaten bevestigen de leeftijd en 
geslacht gerelateerde IgG Fc N-glycosylerings veranderingen zoals beschreven in de 
literatuur.
De keuze van de MALDI matrix is cruciaal voor het minimaliseren van in-bron 
en metastabiel verval van gesialyleerde glycopeptiden. α-Cyano-4-hydroxycinnamic 
zuur (CHCA) als hete matrix leidt bijvoorbeeld tot een vrijwel volledig verlies van de 
siaalzuren. Dit kan worden beperkt door gebruikt te maken van een koude matrix zoals 
2,5-dihydroxybenzoëzuur (DHB). Tijdens de standaard MALDI monstervoorbereiding 
heeft DHB echter de neiging om grote naaldachtige kristallen te vormen. Deze 
eigenschap resulteert vaak in sweet spots (lokale plaatsen in het kristal die rijk aan 
monster zijn) en in een relatief lage resolutie en massa nauwkeurigheid met lineair 
georiënteerde MALDI-TOF-MS instrumenten. In hoofdstuk 5 is de potentie van de 
microkristallijne matrix 3-(4-chloor-fenyl)-2-cyano-acrylzuur (Cl-CCA) geëvalueerd 
voor de MALDI-TOF-MS analyse van gesialyleerde glycoconjugaten. De zeer homogene 
ruimtelijke verdeling van de Cl-CCA microkristallen resulteerde in een hoge shot-to-
shot reproduceerbaarheid met een goede resolutie en massa nauwkeurigheid voor de 
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IgG glycopeptiden. Met zowel DHB als Cl-CCA was een gevoelige en reproduceerbare 
negatieve ion mode MALDI-TOF-MS analyse van gesialyleerde glycopeptiden 
mogelijk. De Cl-CCA matrix bleek even efficiënt voor het minimaliseren van siaalzuur 
verlies als de DHB matrix, wat is geïllustreerd aan de hand van de analyse van N- en 
O-glycoconjugaten.
IgG effector functies worden beïnvloed door de Fc N-glycosylering. Tijdens stimuli 
kunnen de IgG Fc N-glycoprofielen op totaal IgG niveau verschillen ten opzichte 
van de IgG Fc N-glycoprofielen op antigeen-specifiek niveau. In hoofdstuk 6 zijn 
de veranderingen in Fc N-glycosylering van totaal IgG en antigeen-specifiek IgG 
onderzocht voor en na vaccinatie van 10 Kaukasische volwassenen en 10 Afrikaanse 
kinderen. 
Terwijl er bij vaccinatie geen effect zichtbaar was voor de Fc N-glycosylering op totaal 
IgG niveau, was bij anti-vaccin specifiek IgG1 de galactosylering en sialylering verhoogd 
en de hoeveelheid bisecting N-acetylglucosamine verlaagd. De resultaten tonen aan dat 
afhankelijk van het vaccinatie tijdstip een ziekteverwekker IgGs zal tegenkomen met 
zeer verschillende Fc N-glycoprofielen die een rol kunnen spelen bij antilichaam effector 
functies en immuniteit. Verder onderzoek is noodzakelijk om de regulerende aspecten en 
functionele implicaties van IgG Fc N-glycosylering op te helderen.
Verschuivingen van IgG Fc N-glycosylerings profielen in goed gedefinieerde auto-
immuunziekten waarbij antilichamen een belangrijke rol spelen kunnen waardevolle 
inzichten bieden in welke glycosylerings kenmerken de antilichaam pathogeniciteit 
kunnen beïnvloeden. In hoofdstuk 7 zijn IgG Fc N-glycosylerings veranderingen 
bestudeerd bij de neurologische aandoeningen Lambert-Eaton myasthenic syndroom 
(LEMS) en myasthenia gravis (MG). Ten opzichte van de onaangedane controles was 
de IgG2 galactosylering in LEMS en MG patiënten lager. Bij LEMS patiënten werd 
tevens een lagere IgG1 galactosylering waargenomen dan die bij de controlegroep en 
was het niveau van de IgG1 en IgG2 bisecting N-acetylglucosamine voor patiënten 
onder de 50 jaar hoger. De immunologische relevantie van de waargenomen IgG 
glycosylerings veranderingen is echter nog onduidelijk. Om eventuele associaties van 
Fc N-glycosylering met de ernst van de ziekte op te helderen is longitudinaal onderzoek 
waarbij gekeken wordt naar totaal en autoantigeen-specifieke IgG noodzakelijk.
In dit proefschrift worden nieuwe methoden gepresenteerd voor snelle, 
geminiaturiseerde en high-throughput analyse van IgG Fc N-glycosylering. Verder 
wordt het nut van deze methoden aangetoond aan de hand van klinisch relevante 
onderzoeksvragen. De beperkingen, sterke kanten en perspectieven van deze methoden 





2-AA  2-aminobenzoic acid 
3-AA  3-aminobenzoic acid 
2-AB  2-aminobenzamide 
AChR  postsynaptic muscle nicotinic acetylcholine receptors 
ACN  acetonitrile 
ADCC  antibody-dependent cellular cytotoxicity 
ANOVA  analysis of variance 
APTS  8-aminopyrene-1, 3, 6-trisulphonate 
BSA  bovine serum albumin
CDC  complement-dependent cytotoxicity
CHCA  α-cyano-4-hydroxycinnamic acid 
CID  collision induced dissociation
CIEX  cation exchange 
Cl-CCA  3-(4-chloro-phenyl)-2-cyano-acrylic acid), 4-chloro-α-  
  cyanocinnamic acid
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing  
  Non-integrin
DHB  dihydroxybenzoic acid 
DSS  disease severity scores 
DTT  dithiothreitol 
ESI  electrospray ionization 
FA  formic acid 
Fab  fragment antigen binding 
Fc  fragment cristallizable 
Flu  fluorescence detection
FTICR  Fourier transform ion cyclotron resonance 
Fuc  fucose 
Gal  galactose
GlcNAc  N-acetyl glucosamine 
Glu-C  endoproteinase Glu-C and V8 protease 
GnF  biantennary N-glycan with n galactoses and a core fucose 
GnF Sn  biantennary N-glycan with n galactoses, a core fucose and n sialic acids
GnF NSn  biantennary N-glycan with n galactoses, a core fucose, an N-acetyl  
  glucosamine and n sialic acids
Hex  hexose
HexNAc  N-acetylhexosamine 
HILIC  hydrophilic interaction liquid chromatography 
IgG  immunoglobulin G 
IPA  isopropanol.  
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IVIg  intravenous immunoglobulin 
LEMS  Lambert-Eaton myasthenic syndrome 
LIF  laser-induced fluorescence 
LOD  limit of detection
Lys-C  lysylendopeptidase 
m/z  mass over charge ratio
mAb  monoclonal antibody 
MALDI  matrix assisted laser desorption 
MG  myasthenia gravis 
MS  mass spectrometry 
MuSK  muscle-specific kinase 
NANA  N-acetyl neuraminic acid 
NeuGc   N-glycolylneuraminic acid  
NP-40  nonidet P-40
OVA  ovalbumin 
PA  propionic acid 
PBS  phosphate buffered saline
PGC  porous graphitic carbon 
PMP  1-phenyl-3-methyl-5-pyrazolone
PNGase F N-glycosidase F  
QIT  quadrupole ion trap
RA  rheumatoid arthritis 
RCA-I  ricinus communis agglutinin-I 
RP  reversed phase 
RSD  relative standard deviation 
RT  room temperature
S/N  signal to noise ratio
SA  sialic acid
SDS  sodium dodecyl sulfate 
SNA  Sambucus nigra agglutinin
SPE  solid phase extraction 
STD  standard deviation 
TAT  total analysis time 
TFA  trifluoroacetic acid 
TOF  time of flight 
TPCK  tosyl phenylalanyl chloromethyl ketone 
VGCC  voltage-gated calcium channels 





Het meest gelezen en besproken onderdeel van een proefschrift is toch wel het 
dankwoord. Nu lijkt het eenvoudig om al die mensen die hebben bijgedragen aan dit 
boekje bij naam te bedanken voor hun hulp en gezelligheid, maar de kans dat hierbij 
iemand wordt vergeten ligt natuurlijk op de loer. Gelukkig ben ik een gemakkelijke 
prater en heb ik mij van jongs af aan aangeleerd om mezelf voor dergelijke situaties in 
te dekken. Dus u allen van wie ik de naam hier niet noem maar die dit wel verdienen, 
mijn oprechte excuses daarvoor en bedankt voor al jullie hulp en inzet. Goed nu wil 
ik beginnen met een persoon die vanaf december 2007 de rode draad is geweest in 
mijn promotie. Als hoofd van de glycoproteomics en mijn copromotor is het niet altijd 
even eenvoudig geweest. Al die verschillende karakters en stuk voor stuk eigenwijs 
zoals het een onderzoeker betaamt. Zelf noem ik het vasthoudend en is in mijn ogen 
een van de belangrijkste eigenschappen die een onderzoeker gedreven en gemotiveerd 
houd. Manfred al onze discussies hebben sterk bijgedragen aan de kwaliteit van 
mijn onderzoek. Al vanaf de eerste dag had ik het gevoel dat we een gouden team 
vormden en ik ben dan ook enorm trots op ons resultaat. Hiervoor bedankt! Onze 
afdelingsprofessor en mijn promotor mag natuurlijk ook niet ontbreken in dit 
dankwoord. André ik voel mij bevoorrecht dat ik ondanks het in scene zetten van uw 
ontvoering nog steeds bij u mag promoveren. Ik ben u dankbaar voor de nagenoeg 
onbeperkte mogelijkheden binnen de afdeling Parasitologie en vond de discussies met 
u erg informatief en gezellig. During my first year I spend a lot of time in searching for 
solutions to allow high resolution analysis of intact sialylated glycopeptides by MALDI. 
This solution we found in the intermediate pressure MALDI source of the FT-ICR-
MS. Liam thank you for your knowledge and help with the FT which helped me a lot 
and resulted in a very nice joint publication. I hope that we can continue this fruitful 
cooperation in the future to. During my research I encountered the problem that more 
data was generated than I could manually process. Magnus thus sometimes hard to 
get, your scripts successfully allowed automated processing of my large datasets which 
helped me tremendously with the data handling. Thank you for that! Gedurende de 
laatste 4 jaar ben ik regelmatig tegen HPLC en MS problemen aangelopen die niet altijd 
even eenvoudig waren op te lossen. Carolien, Rico, Bart en Hans jullie wil ik bedanken 
voor alle hierbij geboden hulp en discussies. Het genereren van een grote data set is een 
ding. Er waardevolle informatie uit halen het andere. Voor alle hulp bij de statistische 
analyse wil ik daarom Ronny Wolterbeek bedanken. Een belangrijk onderdeel wat 
erg heeft bijgedragen aan mijn werkplezier in Leiden was het regelmatig terugkerend 
interdisciplinair werkoverleg. Rawi en alle andere regelmatig aanschuivende collega’s 
met koffie humor hiervoor bedankt. Gerhild you I would like to thank for your energy, 
collegiality and the nice atmosphere you generate in our office. Albert hoewel ik niet 
erg blij was met de halvering van mijn bureau is jouw aanvulling in onze kamer een 
aangename verversing. Carolin you I would like to thank for helping me in my early 
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PhD stage with keeping my presentations short and to the point. Marco jou wil ik 
bedanken voor al je hulp met het oplossen van sofware en computer problemen. 
Moniek, wil ik bedanken voor al haar hulp met van alles en nog wat en natuurlijk 
die la vol M&M’s en chocola. Cees, Arjen, Renee, Crina, Niels, Mahdi, Nicole, en 
Leonardo wil ik bedanken voor de gezelligheid op onze werkkamer. Mijn oud collega’s 
uit Utrecht mogen zeker niet ontbreken in dit dankwoord, want van hen heb ik geleerd 
dat het drinken van koffie onderzoek naar een heel ander niveau kan tillen. Verder 
wil ik alle coauteurs bedanken voor hun betrokkenheid binnen mijn onderzoek. Al 
mijn overige collega’s mag ik natuurlijk ook niet vergeten want ook zij hebben mijn 
promotie tot een succesvolle en gezellige periode gemaakt. Dus Emanuela, Caroline, 
Yoann, Bas, Jantine, Paul, Oleg, Oleg, Jean-Marc, Rob, Simone, Tiziana, Alex, Yuri, 
Axel, Emrys, Aswin, Evelyne, Dorien, Rene, Angela, Sibel, Alexandra, Irina, Katja, 
Katja, Ralf, Hannah, Linda, Linda, Dieuwke, Yvonne, Jannetje, Jai, Jingwen, Alwin, 
Hermelijn, Jacob, Anouk, Luciën, Aga en Hans bedankt. Maria en Ron wil ik bedanken 
voor hun immunologische inbreng binnen mijn onderzoek. Ron jou wil ik tevens 
bedanken voor je goede en heerlijk nuchtere adviezen. Gedurende mijn promotie heb 
ik het voorrecht gehad om een aantal studenten te mogen begeleiden tijdens hun stage 
bij de glycoproteomics. Sanne, Luke, Lisette, Ewoud, Marcus en Antoinette bedankt en 
succes in jullie toekomst. Bart Jacobs wil ik graag bedanken voor onze samenwerking 
en het sturen van Willem-Jan en Juliette. Twee goede studenten met een overweldigend 
en overwaaiend enthousiasme. From Roche Diagnostics I would like to thank Dietmar 
Reusch, Niklas Engler, Markus Haberger and Christine Jung whom provided a valuable 
and successful cooperation. Promoveren doe je niet alleen en naast de steun en hulp 
van je collega’s is een begrijpende en behulpzame thuis situatie erg belangrijk. Mijn 
vrouw Berina wil ik dan ook in het bijzonder bedanken dat ze altijd voor me klaar 
staat. Dit laatste jaar ben ik niet de meest aanspreekbare persoon geweest als er thuis 
iets moest worden geregeld. Onvermoeibaar heb je mij zo veel mogelijk uit handen 
genomen en mij gesteund met de laatste lootjes. Jouw rust en ondernemendheid 
brachten mij ontspanning en plezier. Zelf heb je ook in dit schuitje gezeten en dat heeft 
mij bruikbare tips en tricks opgeleverd. Ook hiervoor wil ik je bedanken. Als laatste 
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